Characterization of the genetic architecture of dilated cardiomyopathy using families and cohorts by Mazzarotto, Francesco
1 
 
Characterization of the genetic architecture 
of dilated cardiomyopathy using families and 
cohorts 
 
Submitted to Imperial College London 
for the degree of Doctor of Philosophy 
 
by 
 
Francesco Mazzarotto 
M.Sc. 
 
Cardiovascular Genetics and Genomics 
NIHR Royal Brompton Cardiovascular Biomedical Research Unit 
Imperial College - Faculty of Medicine 
 
 
December 2015 
  
2 
 
Declaration of originality 
I, Francesco Mazzarotto, declare that this thesis is my own work and has not been submitted in any 
form for another degree or diploma at any university or other institute of tertiary education. Any 
contribution of others to the work described is duly acknowledged, and all else accordingly 
referenced. 
  
3 
 
Copyright declaration 
The copyright of this thesis rests with the author and is made available under a Creative Commons 
Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or 
transmit the thesis on the condition that they attribute it, that they do not use it for commercial 
purposes and that they do not alter, transform or build upon it. For any reuse or distribution, 
researchers must make clear to others the licence terms of this work. 
  
4 
 
Abstract 
Cardiomyopathies are the leading cause of heart transplantation in the developed world, and 
dilated cardiomyopathy accounts for an important proportion of all heart failure cases in large 
clinical trials. In spite of a strong genetic basis for dilated cardiomyopathy being demonstrated 
widely in the past two decades, 60% of familial cases remain unexplained. Dilated cardiomyopathy 
is characterized by marked genetic heterogeneity, with more than 60 individual genes reported to 
cause the disease, yet only one (TTN) explaining more than 10% of cases.  
Here, high-throughput sequencing data, advanced imaging techniques and bioinformatics analyses 
were used to dissect the genetic architecture of dilated cardiomyopathy, by measuring the 
contribution of single genes and multi-genic variation on disease risk and severity, and performing 
gene and variant discovery in affected families. 
Burden testing (using bespoke software developed in the R programming language for this study) 
and regression modelling were used to examine the genetic determinants of disease by comparing 
a cohort of disease cases (n=332) to ethnically matched, phenotypically characterised healthy 
controls (n=319). This produced a measure of the contribution of each gene to dilated 
cardiomyopathy, taking into account the background variation rate in the general population. 
Analyses of multi-genic interactions were also performed, and having detected the signature of 
additive effects of variation in multiple genes on both disease likelihood and severity, further 
analyses were performed to identify specific gene-gene interactions in causing dilated 
cardiomyopathy.  
Subsequently, variant prioritisation strategies were developed to identify, from whole-exome 
sequencing data, possible genetic causes of an unexplained and very severe form of early-onset 
dilated cardiomyopathy segregating in a family. This led to the identification of new candidate 
genes, which might contribute towards a genetic diagnosis in the analysed family and to new 
insights into the pathogenesis of dilated cardiomyopathy. Preparatory work in developing variant 
prioritisation pipelines from whole-exome sequencing data had been performed earlier, on families 
affected with various inherited arrhythmia syndromes. 
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GATK Genome Analysis Toolkit 
Gb Gigabase, unit indicating a sequence of 1 billion nucleotides 
GO Gene Ontology 
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GWAS Genome-wide association study 
Hardy-Weinberg Principle stating that both allele and genotype frequencies in a 
Equilibrium randomly-mating population remain constant – and remain in this 
equilibrium across generations – unless a disturbing influence is introduced 
HAVANA Human And Vertebrate ANalysis and Annotation 
HCM Hypertrophic cardiomyopathy 
Het/Hom Heterozygous to homozygous ratio 
Heteroduplex A DNA molecule with mismatched constitutive strands 
HF Heart failure 
HGMD Human Gene Mutation Database 
HVOL Healthy volunteers 
IBD Identity-by-descent. Term indicating two alleles that are identical copies of 
the same allele from some earlier generation 
ICC Inherited cardiac condition 
ICD Implantable cardiac defibrillator 
Kb Kilobase, unit indicating a sequence of 1000 nucleotides 
LA Left-atrial 
LD Linkage disequilibrium. The non-random association between two or more 
alleles such that certain combinations of alleles are more likely to occur 
together than just by chance. 
LGE Late gadolinium enhancement, a technique to detect scar tissue (present, 
for example, as a consequence of myocardial infarction), based on 
differences in the volume of distribution of gadolinium. 
LRT Likelihood Ratio Test 
LRG Locus Reference Genomic 
LV Left-ventricular 
LVAD Left-ventricular assist device 
LVEDV Left-ventricular end-diastolic volume 
LVEF Left-ventricular ejection fraction, a measure of myocardial contractility. It 
corresponds to the fraction of the blood contained in the ventricle at the 
end of the diastole that is expelled during the systole  
LVNC Left-ventricular non-compaction 
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LVWT Left-ventricular wall thickness 
MAD Median absolute deviation 
MAF Minor allele frequency 
Mb Megabase, unit indicating a sequence of 1 million nucleotides 
MD Muscular dystrophy 
MGD Mouse Genome Database, hosted by Mouse Genome Informatics at Jackson 
Laboratories 
mtDNA Mitochondrial DNA 
NGS Next-generation sequencing 
NHLBI National Heart, Lung and Blood Institute 
Nominal p-value P obtained prior to correcting for multiple testing 
Ns/S Non-synonymous to synonymous ratio 
OMIM Online Mendelian Inheritance in Man 
Paralog Two genes in the same species are paralogs if they originated from a 
duplication event within a genome, and the evolved new functions, related 
to the original one. 
PCA Principal Component Analysis 
PCR Polymerase chain reaction 
Phred-scaled score Score based on the logarithmic (base 10) relation to the error probability 
(e.g. 10 = 1 in 10 chances of error (90% accuracy); 20 = 1 in 100 chances of 
error (99% accuracy)) 
Positional cloning Method for identifying a gene causing a phenotype based solely on its 
chromosomal position. Positional cloning, involving the process of 
chromosome walking, has been widely used starting from pre-defined 
candidate regions (identified, for example through linkage studies). 
RA Right-atrial 
RCM Restrictive cardiomyopathy 
rCRS Revised Cambridge Reference Sequence 
RFLP Restriction fragment length polymorphism 
SAET SOLiD Accuracy Enhancement Tool 
Sanger method DNA-sequencing method based on the incorporation and detection of 
labelled dideoxynucleotides. 
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Sarcomere The repeating contractile unit of a myofibril, delimited by the Z bands 
SD Standard deviation 
SNV Single nucleotide variant 
STDEP Arrhythmogenic phenotype characterized by an abnormal depression of the 
ST segment of the ECG, observed in one of the families analysed in Chapter 4 
Ti/Tv Transition to transversion ratio 
TTNnt TTN-non-truncating variants 
TTNtv TTN-truncating variants 
VCF Variant Call Format 
WGS Whole-genome sequencing 
WHO World Health Organization 
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1 Introduction 
1.1 Cardiovascular disease and cardiomyopathy  
According to the World Health Organization (WHO), 17.5 million individuals died of cardiovascular 
disease (CVD) in 2012 alone, making CVD the number one cause of morbidity and mortality globally, 
and accounting for 31% of all deaths worldwide (1). Among the main contributors to this public 
health problem is heart failure (HF), which is generally described as a progressive loss of the ability 
of the heart to pump blood in an efficient manner and has an estimated prevalence of ~23 million 
worldwide (approximately 0.3-0.4%) (2), with peaks of 1-2% in the Western world (3). HF itself is a 
final common stage of several forms of CVD such as cardiomyopathies, hypertension and ischemic 
or valvular heart disease.  
Cardiomyopathies are diseases of the myocardium, characterised by abnormal wall thickness, 
chamber size and/or contractility, in the absence of congenital heart disease (developmental or 
structural anomalies), valve disease, hypertension or coronary artery disease sufficient to cause the 
observed global systolic impairment (4). The classification of primary cardiomyopathies – those not 
caused by a different pre- or co- existing condition – has been repeatedly revised over the past 
decades, but a generally accepted approach divides them into 5 descriptive categories: dilated 
(DCM), hypertrophic (HCM), restrictive (RCM), arrhythmogenic right-ventricular cardiomyopathy 
(ARVC), and left-ventricular non-compaction (LVNC) (5,6). Cardiomyopathies are the underlying 
heart disease in three quarters of young adults undergoing heart transplantation (7), and DCM, the 
primary focus of the work described in this thesis, is the commonest form of cardiomyopathy. 
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1.2 Overview of dilated cardiomyopathy 
1.2.1 Definition and clinical characteristics 
The main morphological characteristics of DCM are an abnormal enlargement of the left ventricular 
(LV) chamber and thinning of the LV wall (Figure 1.1). The clinical definition of DCM, following 
internationally accepted guidelines, is based on a combination of cardiac morphological and 
functional parameters, and a patient is diagnosed with DCM if presenting with fractional 
shortening (FS) <25% and/or left-ventricular ejection fraction (LVEF) <45%, 
and LV end-diastolic diameter >117% of the predicted value after correction for age and body 
surface area (BSA) (8). Diagnosis is most commonly made using either two-dimensional 
echocardiography or, increasingly, cardiac magnetic resonance imaging (CMR). DCM can remain 
latent for decades due to incomplete penetrance or activation of compensatory mechanisms aimed 
at maintaining normal contractility which, eventually, become unsustainable (9). When homeostatic 
responses fail, overt disease often presents with symptoms of heart failure (either with congestive 
features and/or reduction of the cardiac output), arrhythmic disease or thromboembolic disease, 
such as stroke. Treatment is generally pharmacological, and more severe cases may require the 
implantation of a pacemaker, an implantable cardiac defibrillator (ICD) or a LV assist device (LVAD). 
However, cardiac transplantation remains the only definitive treatment for HF or DCM refractory to 
device or medical therapy. 
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Figure 1.1 - Longitudinal section showing the morphology of a normal heart (on the left) and a heart affected with dilated 
cardiomyopathy (on the right) [Adapted from Hershberger et al, 2013]. 
 
1.2.2 Epidemiology of DCM 
Formal estimates of prevalence and incidence of DCM date back to the 1980s, when a study 
conducted in Olmstead County (Minnesota, USA) between 1975 and 1984 reported a prevalence of 
approximately 1 in 2,700 individuals, and an incidence of 6 per 100,000 person-years (10). However, 
the same study underestimated by approximately 10-fold the prevalence for HCM, as demonstrated 
about 10 years later (11), and, on the basis of this and other observations, Hershberger et al. revised 
in 2013 the estimated prevalence of DCM to ~1 in 250 individuals, and estimated DCM to be the 
underlying cause of up to 1 in 6 HF cases in USA (12). DCM can affect individuals of any ethnic 
background, any gender and any age, but is more common in blacks than in whites (13), in men than 
in women (14), and tends to manifest in adults between 30 and 60 years of age (15). 
1.2.3 Aetiology 
The cause of DCM is often unknown, and its aetiology is complex and heterogeneous. In general, 
DCM can be acquired (or “secondary”) – either as a result of prolonged environmental insults or as 
a consequence of a known medical condition – or inherited. External insults that can lead to DCM 
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include abuse of certain drugs (e.g. cocaine) and alcohol, as well as exposure to toxins (e.g. cobalt) 
and chemotherapeutic treatments (e.g. anthracyclines), while medical conditions that can 
secondarily cause DCM include many infectious diseases (e.g. diphtheria, Chagas disease and HIV), 
muscular dystrophies and coronary artery disease (CAD). In the latter case, DCM is referred to as 
“ischemic DCM” whenever caused by myocardial ischemia and infarction related to CAD. Table 1.1 
gives an overview of the factors that can cause acquired DCM.  
The work described in this thesis focuses on genetic forms of DCM. It is estimated that from 20 to 
50% of all idiopathic DCM cases, by definition without a clearly identified primary cause, could have 
a genetic basis (referred to with “familial DCM”) (16), with the variability of estimates due to 
differences in how family members were screened, and also to the discovery of new genes 
associated with DCM over time. The term “primary” was coined before the advent of widespread 
genetic testing, and now generally encompasses both familial cases of the disease, as well as purely 
unexplained cases. 
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Table 1.1 - Overview and examples of factors that may cause secondary DCM 
CAUSAL FACTOR EXAMPLES 
Connective tissue diseases Dermatomyositis, Marfan syndrome** 
Infectious agents Bacterial (Brucellosis, Dyptheria), fungal, 
parasitic (Chagas disease, schistosomiasis), 
viral (AIDS, varicella) 
Inflammatory/infiltrative conditions Hypersensitivity myocarditis, 
Haemochromatosis, Kawasaki disease 
Metabolic abnormalities Electrolyte disturbances, endocrine 
abnormalities, nutritional deficiencies 
Neuromuscular diseases Muscular dystrophies, Friedrich ataxia 
Pregnancy * 
Tachyarrhythmia 
Toxins Alcohol, amphetamines, chemotherapeutic 
drugs, cobalt, lead, mercury 
* recent work demonstrated pregnancy-caused DCM (peripartum cardiomyopathy, PPCM) to share a genetic cause with 
primary DCM, suggesting that at least some cases currently considered as secondary DCM might be better classified as 
primary genetic cardiomyopathies (17). 
**Although this is a very rare event, DCM in absence of severe valve dysfunction can be a feature of Marfan syndrome 
(18), due to poorly understood effects of Marfan variants on cardiac myocyte function. 
1.2.4 Genetic background 
Early studies of the genetic causes of cardiomyopathies led to the understanding that, while HCM is 
caused by sarcomere dysfunction, DCM is a disease due to underlying cytoskeletal abnormalities 
(19). It soon became clear that this was an overly simplistic hypothesis, as research conducted 
subsequently demonstrated how DCM could arise from mutations in genes encoding components 
of virtually every pathway and structure of the cardiac myocyte, ranging from cytoskeletal, 
nucleoskeletal, sarcomeric, desmosomal and mitochondrial proteins to ionic channels, transcription 
cofactors and RNA splicing machinery. More than 60 genes have been at least putatively associated 
with DCM to date (Table 1.2), several of which explaining <1% of familial cases with only a few 
accounting for 3-5%, rendering DCM the most genetically heterogeneous cardiomyopathy (20,21). 
A pronounced genetic overlap with other cardiomyopathies (especially HCM), neuromuscular and 
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cardiac diseases gradually emerged (12,22), posing the challenge of understanding how variation in 
the same gene can lead to different disease pathways. The shared genetic background between 
DCM and other cardiomyopathies is also underlined by the genes for which genetic testing is 
available, many of which are present in panels for different cardiomyopathies (23), as displayed in 
Figure 1.2, and by studies emphasizing the importance of using broad pan-cardiomyopathy gene 
panels for genetic screening in the clinical setting (24).  
Disease-causing variation is generally represented by rare or private mutations altering the amino-
acid composition of proteins, by either substituting functionally or structurally important residues, 
truncating the full-length protein product or altering splicing patterns.  
Protein-truncating variants in the TTN gene (TTNtv), encoding the giant sarcomeric protein titin, 
have been reported to account for up to 25% of familial DCM cases (25), and as such are the 
commonest genetic causation underlying DCM. Recent work performed by our group in 
collaboration with others demonstrated a length-dependent disease mechanism, showing the 
disease-causing potential of TTNtv to be associated with the position of the variant along the 
protein, with the level of exon usage and with the protein isoform truncated by the variant (26), 
explaining also why some TTNtv-carriers do not develop disease. Among other genes considered of 
primary importance for DCM, although responsible for smaller proportions of cases (≤5%) are, for 
example, LMNA and MYH7. LMNA encodes the nuclear protein lamin A/C, and it is often associated 
with DCM accompanied or preceded by conduction system disease or arrhythmias, with the disease 
mechanism still unclear (15). MYH7 instead encodes the protein forming the bulk of the thick 
filament in cardiac muscle (myosin heavy chain beta), and is perhaps the most prominent example 
of genetic overlap between cardiomyopathies, being among the top contributor genes for both 
familial DCM and HCM.    
In HCM, variation in MYH7 and MYBPC3 accounts for approximately 80% of familial cases (27), and 
in ARVC variants in PKP2, DSP and DSG2 explain 40-50% of all disease cases (28), emphasizing the 
highly diversified genetic background of DCM.  
Several studies suggested familial DCM to be inherited in an autosomal dominant pattern in about 
90% of kindreds, with marked age-dependent penetrance and variable expressivity (29–31), while 
small proportions of kindreds show autosomal recessive (1-2%) or X-linked (5-10%) inheritance (32). 
Nonetheless, the spectrum of genetic causes of DCM ranges from highly penetrant, mono-genic 
syndromes at one end to multi-genic disease, caused by an additive effect of more common, less 
penetrant genetic variants at the opposite end, with the vast majority of studies and diagnostic 
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strategies focusing on the former of the two. The investigation of the role of multi-gene variation in 
causing DCM is one of the prominent and most innovative features of the work described in this 
thesis. 
 
 
Figure 1.2 – Example of genes associated in literature with DCM, HCM and/or ARVC. 
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Table 1.2 - Known and putative DCM genes, their protein product, location/function within the cell, PubMed ID of the first report of association 
to DCM, publication year of first report, number of publications reporting an association to DCM, number of variants reported to be associated 
to DCM in HGMD Professional v2013.4, alongside how many had functional evidence supporting the association. Colour-coding of gene cells 
represents the strength of evidence of association to DCM. For most of the genes I retrieved this last information from the PanelApp by the 
Genomics England consortium [https://bioinfo.extge.co.uk/crowdsourcing/PanelApp/]. Gene panels for a variety of diseases have been 
established using four different sources (Radboud University Medical Center, Illumina Trugenome Predisposition Screen, Emory Genetics 
Laboratory and UKGTN), and the colour of each gene represents the level of confidence for the gene-DCM association (RED=high confidence, 
ORANGE=medium confidence, YELLOW=low confidence). Not all genes with literature reports of associations to DCM are included in the DCM 
panel built through the PanelApp tool. For genes not included, I looked for the most supportive type of evidence of association to DCM using 
PubMed, and colour-coded genes accordingly (BROWN=evidence based on frequency of variation in cases/controls, PINK=evidence based on co-
segregation of disease and variants in family pedigrees, GREY=evidence based on in vitro/in vivo functional data, in absence of frequency 
information in humans).  
GENE 
SYMBOL 
ENCODED PROTEIN 
LOCATION/ 
FUNCTION 
DCM 
ASSOC. 
PUBMED 
ID 
YEAR 
N. 
DCM 
PUBL. 
REP. 
N. 
DCM 
VARS. 
HGMD 
N. DCM 
VARS. HGMD 
WITH 
FUNCTIONAL 
EVIDENCE 
ABCC9 
ATP-binding cassette 
C9 
Ion channel 15034580 2004 2 2 0 
ACTC1 Cardiac Actin Sarcomere 9563954 1998 8 5 2 
ACTN2 Actinin, alpha 2 Z-disk 14567970 2003 3 5 0 
ALMS1 Alstrom syndrome1 
Cytoskeleton/ 
centrosome/cilia 
15689433 2005 5 0 0 
ANKRD1 
Ankyrin repeat protein 
1 
Transcription factor 19525294 2009 3 8 1 
BAG3 
BCL2-associated 
athanogene 3 
Chaperone 
regulator 
21353195 2011 8 18 0 
CASQ2 Calsequestrin 2 
Endoplasmic 
reticulum/Ca2+ 
binding 
24503780 2014 1 0 0 
CAV3 Caveolin-3 Plasma membrane 19773168 2009 1 0 0 
CRYAB Alpha B crystallin Z-disk 16483541 2006 6 2 2 
CSRP3 
Cys and gly-rich 
protein 3 
Z-disk 12507422 2002 8 4 1 
CTF1 Cardiotrophin 1 Cytokine 11058912 2000 1 1 0 
DES Desmin Desmosome 10430757 1999 11 11 1 
DMD Dystrophin 
Dystrophin assoc. 
protein complex 
8789442 1996 16 13 1 
DNAJC19 HSP40 Homolog, C19 
Mitochondrial 
membrane 
16055927 2006 3 2 0 
DSC2 Desmocollin 2 Desmosome 23570452 2010 2 2 0 
DSG2 Desmoglein 2 Desmosome 18678517 2008 3 3 0 
DSP Desmoplakin Desmosome 11063735 2000 10 10 0 
EMD Emerin Nuclear envelope 23785128 2013 2 1 0 
EYA4 Eyes absent 4 Transcription factor 15735644 2005 2 0 0 
FHL2 
Four and half LIM 
protein 2 
Z-disk 17416352 2007 1 0 0 
FKRP Fukutin-related protein Golgi/glycosyl 15833432 2005 2 0 0 
FKTN Fukutin Golgi/glycosyl 17036286 2006 3 3 0 
FLT1 
Fms-related tyrosine 
kinase 1 
Kinase 16715312 2006 1 1 0 
FOXD4 Forkhead box D4 Transcription factor 17273782 2007 1 1 0 
FXN Frataxin 
Mitochondrial Fe 
chaperone 
26219880 2016 1 0 0 
GATA4 GATA binding prot. 4 Transcription factor 24041700 2013 3 1 0 
HFE 
Hemochromatosis 
gene 
Fe transport 11040018 2000 2 0 0 
ILK Integrin-linked kinase Kinase 17646580 2007 2 2 0 
JUP Plakoglobin Desmosome 21859740 2011 1 1 0 
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GENE 
SYMBOL 
ENCODED PROTEIN 
LOCATION/ 
FUNCTION 
DCM 
ASSOC. 
PUBMED 
ID 
YEAR 
N. 
DCM 
PUBL. 
REP. 
N. 
DCM 
VARS. 
HGMD 
N. DCM 
VARS. HGMD 
WITH 
FUNCTIONAL 
EVIDENCE 
LAMA2 Laminin alpha2 Extra cellular matrix 18700894 2008 2 2 0 
LAMA4 Laminin alpha4 Extra cellular matrix 17646580 2007 2 2 0 
LAMP2 
Lysosome-Associated 
Membrane Protein 2 
Lysosome 23785128 2013 1 1 0 
LDB3 Cypher/ZASP Z-disk 14662268 2003 10 11 3 
LMNA Lamin A/C Nuclear envelope 10580070 1999 92 119 27 
MYBPC3 
Myosin-binding protein 
C3 
Sarcomere 12379228 2002 15 58 0 
MYH6 
Alpha myosin heavy 
chain 
Sarcomere 15998695 2005 5 9 1 
MYH7 
Alpha myosin heavy 
chain 7 
Sarcomere 11106718 2000 37 94 4 
MYL2 
Myosin regulatory light 
chain 2 
Sarcomere 25825243 2015 1 0 0 
MYPN Myopalladin Z-disk 18006477 2008 4 11 0 
NEXN Nexilin Z-disk 19881492 2009 2 3 0 
NFKB1 NF-Kappa B1 Transcription factor 19480714 2009 2 0 0 
PDLIM3 
PDZ/LIM domain 
protein 3 
Z-disk 17254821 2007 1 1 0 
PKP2 Plakophilin 2 Desmosome 23570452 2010 2 3 0 
PLEC1 Plectin-1 Inter filament 20016501 2010 1 0 0 
PLN Phospholamban Ca2+ cycling 12610310 2003 12 6 3 
PSEN1 Presenilin 1 
Membrane 
protein/protease 
17186461 2006 1 1 0 
PSEN2 Presenilin 2 
Membrane 
protein/protease 
17186461 2006 2 2 0 
RAF1 Raf-1 proto-oncogene Kinase 24777450 2014 1 0 0 
RBM20 
RNA-Binding motif 
protein 20 
RNA binding 19712804 2009 8 17 6 
SCN5A 
Voltage gated Na 
channel V alpha 
Ion channel 15671429 2005 18 16 4 
SDHA 
Succinate 
dehydrogenase 
Mitochondrial 20551992 2010 1 0 0 
SGCB Beta-Sarcoglycan 
Dystrophin 
associated protein 
complex 
23349452 2013 1 1 0 
SGCD Delta-Sarcoglycan 
Dystrophin 
associated protein 
complex 
10974018 2000 6 2 1 
SOD2 Superoxide dismutase 
Mitochondrial 
matrix 
10425186 1999 1 0 0 
SYNE1 Nesprin-1 Nuclear envelope 19944109 2010 1 1 0 
SYNM Desmulin Z-disk 16715312 2006 1 1 0 
TAZ Tafazzin Mitochondrial 20474083 2010 3 2 0 
TBX20 T-box 20 Transcription factor 26118961 2015 1 0 0 
TCAP Titin-cap Z-disk 12507422 2002 5 6 0 
TMPO Thymopoietin Nuclear envelope 16247757 2005 2 1 0 
TNNC1 Troponin C Sarcomere 15542288 2004 15 7 5 
TNNI3 Troponin I Cardiac sarcomere 15070570 2004 15 11 2 
TNNT2 Troponin T Cardiac sarcomere 11106718 2000 38 30 10 
TPM1 Tropomyosin, alpha1 Sarcomere 11273725 2001 17 14 3 
TTN Titin Sarcomere 10051295 1999 13 79 0 
TXNRD2 Thioredoxin reductase Mitochondrial 21247928 2011 1 2 0 
VCL (meta)Vinculin Z-disk 11815424 2002 4 6 0 
ZBTB17 
Zinc finger and BTB 
domain-containing 
protein 17 
Transcription factor 23570452 2013 2 0 0 
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1.3 Previously published studies on genetic variation in DCM using 
targeted gene panels 
Since a large portion of the work I performed on DCM relates to the investigation of the 
genetic architecture underlying disease using cases and controls sequenced on a targeted 
gene panel, I searched in the literature, by means of PubMed and Google searches, for studies 
analysing genetic variation in DCM using targeted gene sequencing approaches. All the 10 
studies of this kind that I detected were performed in the last decade, targeting between 1 
and 84 genes, and on DCM cohorts ranging from 105 to 766 patients. With one exception (as 
explained later in the paragraph), in none of the studies in question investigators looked at 
the cumulative frequency of disease variants in controls, and control cohorts were used only 
to genotype specific variants observed in cases. This represented a limitation of these studies, 
since reported frequencies of putatively pathogenic variation in any given gene did not take 
into account background variation frequencies in healthy subjects. 
Hershberger and colleagues pioneered this type of study in the context of DCM, producing, 
between 2006 and 2010 at least four studies of genetic variation in patients, using the same 
cohort of approximately 320 cases (the number varied slightly depending on the genes 
analysed, with approximately 58% of cases with family history of DCM) and using external 
controls to exclude single variants observed in healthy subjects as being pathogenic. The first 
of these studies (33), performed in 2006, consisted in evaluating sequence variation in 315 
DCM patients in the presenilin genes (PSEN1 and the highly homologous PSEN2). Two 
missense variants (one in PSEN1 observed in a single family, and one in PSEN2, observed in 2 
families), both segregating with DCM and absent in 413 controls were identified, with the 
variant in PSEN1 associated with complete penetrance and a more severe phenotype, 
resulting in the necessity of cardiac transplantation. The three probands carrying the variants 
were screened for variants in six previously known DCM genes (LMNA, MYH7, TNNT2, SCN5A, 
CSRP3 and PLN) but no potentially disease-causing variants were found. Following a very 
similar approach, Parks et al. (group led by Hershberger) produced in 2008 an analogous work 
on LMNA on 324 patients (34). Variants were considered possibly disease causing if they 
predicted a change in a conserved amino-acid or caused a protein truncation, and were 
absent in controls (n=150). Variants were instead considered likely pathogenic if, besides 
meeting the above criteria, were also segregating with disease in multiple affected individuals 
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in a family, or were identified in multiple unrelated probands, or were previously reported as 
causative of DCM in literature. Eighteen likely pathogenic variants, (of which 14 not reported 
in literature) were found in 19 subjects (5.9% of DCM cases), although 6 were characterized 
by incomplete co-segregation with disease in families. In these cases, the proband and one 
genotype-negative, phenotype-positive family member were screened for variants in other 
known DCM genes (MYH7, TNNT2, SCN5A, TCAP, LDB3 and CSRP3) but no likely pathogenic 
variants were found. One of the proposed explanations for these phenotype-positive, LMNA-
negative subjects in the kindreds was that of variants in additional DCM genes, hypothesizing 
the possibility of multi-genic variation underlying DCM. Two further studies performed 
following the same framework were published in 2008 (35) and 2010 (36). In the former, 
investigators screened 313 patients (from the same cohort used in previous studies) for 
disease variants in the six genes analysed in the kindreds showing incomplete segregation of 
LMNA variants (MYH7, TNNT2, SCN5A, TCAP, LDB3 and CSRP3). In this study the control 
cohort consisted in 253 external samples, alongside 169 internal African-American samples 
used to evaluate variants found in African-American DCM patients. Of the six genes examined, 
the most commonly altered by rare variants considered likely pathogenic variants was MYH7 
(4.2% of DCM cases), followed by TNNT2 (2.9%) and SCN5A (1.6%). The remaining three genes 
were characterized by frequencies of variation considered likely or possibly disease causing 
<1%. In the latter study from 2010, 312 DCM patients were screened for variation in 5 other 
genes, all encoding sarcomeric proteins (MYBPC3, MYH6, TPM1, TNNC1 and TNNI3) (36). The 
same controls used in the previous study were used. In this case, the gene most frequently 
carrying likely or possibly pathogenic variation was MYBPC3 (variants in 4.2% of DCM 
samples), followed by MYH6 (3.2%), TPM1 (1.9%), TNNC1 (1.3%) and TNNI3 (0.6%). Authors 
thus reported to have established approximately 27% of the putative genetic cause of DCM 
in the analysed cohort, evaluating variation in the 14 genes screened across the four studies 
performed by the group between 2006 and 2010, with LMNA being the most often mutated 
gene in disease (5.9% of DCM cases).In 2011, Millat et al. (37) screened 105 unrelated DCM 
patients (61% with family history), of which most - differently from the cohort analysed by 
the Hershberger group - were also phenotyped with CMR. Sequencing was performed on 4 
genes previously considered by Hershberger and colleagues (LMNA, MYH7, TNNI3 and 
TNNT2), beside a highly conserved region in exon 9 of RBM20. A cohort of 200 ethnically 
matched controls, beside publicly accessible data from Phase 1 of the 1000 Genomes Project 
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was used to ascertain the absence, in healthy subjects, of the variants detected in patients. 
Criteria for classifying detected variation as possibly or likely disease-causing were the same 
used by the Hershberger group, with the difference in considering any protein-truncating 
variant likely pathogenic per se. The authors reported the two most frequent genes involved 
in mutation-positive index patients were LMNA (8.6% of DCM cases, thus confirming it, at the 
time, as top contributor gene to DCM) and TNNT2 (4.6%), followed by MYH7 (3.8%), TNNI3 
(1%) and the highly conserved region of RBM20 (1%). The authors did not detect any 
genotype-phenotype association, besides LMNA variants being associated to arrhythmogenic 
features, as expected. 
In the following year (2012), Lakdawala et al. analysed variation in up to 10 genes in 264 DCM 
patients, with 70% of the patients tested for all 10 genes (38). Screening for disease variants 
was organized in two tiers, with sarcomeric genes (MYH7, TNNT2, TPM1, MYBPC3 and TNNI3) 
belonging to “tier 1” and the rest of the genes (LMNA, ACTC1, PLN, TAZ and LDB3) belonging 
to “tier 2”, which would be analysed only if no variants were found in “tier 1” genes. Four 
hundred controls (200 African-Americans and 200 Caucasians) were used to define the clinical 
relevance of variants (with the absence in controls being one of the requirements for a variant 
to be considered clinically relevant). In this study, variants were classified in 7 categories of 
different clinical significance, based on observations relating to frequency in controls, 
conservation, linkage and segregation data, literature reports, functional studies and in silico 
predictions for the variant effect). MYH7 was the most prevalently variant gene in this case 
(6.6% of DCM patients carrying a putative disease variant), followed by LMNA (5.3%). A 
modest role of MYBPC3 in DCM was hypothesized, with <1% of DCM patients carrying a 
mutation in this gene. The authors highlighted how this discrepancy with previous studies, 
reporting frequent variation in MYBPC3 in DCM, might have been due to the inappropriate 
inclusion of variants previously demonstrated to cause HCM as a cause of primary DCM. To 
support this hypothesis, Lakdawala et al. suggested that it is unlikely that an individual variant 
can cause both DCM and HCM, given the considerable difference in histopathology between 
the two cardiomyopathies and the different consequences on sarcomere biophysical 
properties (39).Later in 2012, Herman et al. published a report detailing the sequencing of 
TTN in 312 DCM patients, alongside 231 HCM patients and 249 controls (25). Protein-
truncating variants in TTN were identified in up to 25% of DCM patients, a significantly higher 
proportion than either of the other two cohorts (1% in HCM, 3% in controls). Strong co-
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segregation with disease in families was also documented, thus relegating LMNA as top 
contributor gene to the burden of DCM. A further analysis reporting a more detailed 
dissection of the cardiac effects of TTN truncations, integrating genetic data with RNA and 
protein analysis of human heart tissues, was developed by our group while this work was 
produced, and recently published (26). More than 5200 individuals across the spectrum of 
cardiac physiology were included for analysis, encompassing DCM patients, deeply 
phenotyped healthy controls and large cohorts, representative of the general population. 
These two published studies on TTN were, among those that I detected, the only ones 
reporting the background frequency of the analysed genetic variation in healthy controls. 
In 2013, van Spaendonck-Swartz and colleagues analysed variation in 418 DCM patients, in 
up to 22 genes (with a mean of 6 genes per sample), not including TTN (40). Variants were 
classified in 3 categories, on the basis of in silico predictions, frequency in ESP, co-segregation 
in families and functional analysis/phenotype data. Surprisingly, the gene harbouring most 
pathogenic variants was PLN (14% of DCM patients), followed by LMNA (5%) and MYH7 (2%). 
The striking prevalence of a single pathogenic PLN variant (p.Arg14del) was the result of a 
founder effect, specifically present in the Dutch population analysed. Also this study did not 
find MYBPC3 to contribute consistently to the burden of DCM (1 of approximately 160 
patients sequenced on MYBPC3 carried a variant of unknown clinical significance).The role of 
MYBPC3 was further investigated by Pugh et al. in 2014 (24), who screened 766 DCM patients 
for pathogenic variation on gene panels of different compositions (from 5 to 46 genes) and 
classified variants in 5 categories of clinical significance. In this case, only 0.3% of patients 
carried one of the three variants detected in MYBPC3, all classified as of “unknown 
significance – favour pathogenic”. Notably, also in other 23 genes, including MYH6, no likely 
pathogenic variants were detected. This study confirmed TTN as largest contributor (14% of 
DCM patients, with the great difference compared to the frequency reported by Herman et 
al. probably due to inherently different characteristics of the DCM cohort), followed by LMNA 
(4.1%) and MYH7 (3.4%). DSP, an ARVC gene, ranked fourth with variants in 2.4% of DCM 
patients, and on the basis of this observation authors highlighted the importance of pan-
cardiomyopathy gene panels, while stating that, increasing the number of tested genes from 
5 to 46, they observed a 3-fold increase in sensitivity, but accompanied by a 10-fold increase 
in inconclusive results (patients with variants of unknown clinical significance).The final study 
of this kind that was found through the search described here was published in 2014 by Haas 
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et al. (41), who screened 639 DCM patients on 84 genes. Also in this case variants were 
classified in 5 categories of pathogenicity, based on observations relating to frequency in ESP, 
reports in HGMD, predicted effect in silico, and presence of the variant in dbSNP. The authors 
found 46% of the DCM patients to carry a known disease mutation (reported in HGMD) absent 
in ESP. However, when considering only DCM-causing variants by excluding those reported in 
HGMD to cause other cardiomyopathies, a known mutation was found in 16% of patients. 
Furthermore, considering known disease (not only DCM) mutations reported in HGMD, the 
most frequently affected gene was PKP2, an ARVC gene, with more than 40 variants 
identified, all reported to cause ARVC in HGMD. Interestingly, MYBPC3 ranked second in 
terms of known disease variants (with approximately 40), with the vast majority being 
associated to HCM in HGMD. Authors believed these as indications of a marked overlap in 
terms of genetic causes between DCM and other cardiomyopathies. Taking into consideration 
the whole set of studies performed on genetic variation in DCM using targeted gene panels 
that I describe above, it became evident that, while they were concordant with regards to 
some findings (e.g. prevalence of likely pathogenic variants in LMNA), they were highly 
discordant with regards to others (this is particularly evident in the case of MYBPC3). While 
this could be due, for example, to different parameters used in different studies to categorize 
variants’ clinical significance, the presence of a comprehensively sequenced control cohort 
(characterizing only the studies performed on TTN truncations by Herman et al. in 2012 and 
Roberts et al. in 2014) would allow the direct measurement of the background rate of the 
same categories of variants analysed in patients in healthy subjects, thus providing more 
precise estimates of the contribution of variation in each gene to DCM. In the case of the work 
reported in Chapter 2 of this thesis, a comprehensively sequenced and carefully phenotyped 
cohort of healthy controls was available. This control arm not only provided the chance of 
estimating the background rate of variation in healthy subjects in several genes and by variant 
class, but also gave the possibility of analysing the contribution of variation simultaneously 
occurring in multiple genes on disease risk and severity in DCM, which was previously 
unexplored in literature. 
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1.4 Detection of genetic variants 
1.4.1 Technologies enabling variant detection 
A wide variety of technologies allow the detection of genetic variants, regardless of their 
disease-causing potential and ranging from single nucleotide alterations to large structural 
changes such as duplication, loss or rearrangement of entire chromosomes. A classic 
distinction is made in literature between cytogenetic and molecular methodologies to detect 
or identify genetic variants. The former generally encompass methods primarily aimed at the 
detection of large chromosomal aberrations, while the latter include techniques to detect 
smaller variants, down to single nucleotide variants (SNVs). However, technical advances in 
the last decades have greatly increased the resolution of cytogenetic methods, making them 
suitable for explorations beyond the simple chromosomal status of a genome, thus blurring 
the border between the two categories (42). For this reason, I prefer to divide methods for 
variant detection into those requiring prior knowledge about the variant that is investigated, 
and those allowing the detection – and in some cases also the characterisation – of variants 
at previously unknown variant sites. 
1.4.1.1 Methods requiring prior knowledge about the investigated variation 
Several methodologies detect variants at known sites. Among the most classic techniques 
used for detecting large chromosomal anomalies one example is fluorescence in situ 
hybridization (FISH). In its typical setting, FISH is adopted to determine the presence or 
absence of a specific DNA sequence on a cytological target, by hybridizing fluorescently-
labelled DNA to metaphase chromosomes or interphase nucleus. The bound fluorescent 
probe is then visualized using ultra-violet light to identify its chromosomal location and 
quantify its presence to detect duplication, fusion, deletion or translocation of a gene or a 
chromosomal segment (43).  
As far as methods characterised by higher resolution are concerned, there is a wide variety of 
techniques allowing the detection of variants down to point mutations. These range from 
cheap, low-throughput techniques such as allele-specific PCR (AS-PCR) (44), which can be 
used as rapid screening methods to confirm the presence of a specific variant, to high-
throughput technologies such as DNA microarrays, allowing variant detection on a much 
larger scale and finding their application in several fields (genotyping, forensic analysis, 
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detecting variant sites between different ethnic groups etc.). In the context of genomic 
research and in particular with regards to variant- and gene-discovery studies, the inability of 
microarrays to detect variants at unknown sites caused a progressive replacement of 
microarrays with next-generation sequencing (NGS) technologies (Paragraph 1.4.1.3) in 
recent years, after their prices became comparable (45). Microarrays are, still commonly used 
in other areas (e.g. forensics) and are particularly useful for copy number variant analysis in 
clinical laboratories. 
1.4.1.2 Methods allowing to detect unknown variants 
Also within methods allowing the detection of unknown variants there is a notably wide range 
of choice in terms of cost and throughput. Conventional karyotyping – done by arresting cell 
division during metaphase and isolating, staining and examining compacted chromosomes – 
is the most classic cytogenetic method to detect large chromosomal anomalies (such as 
aneuploidies) without prior knowledge about the investigated aberrations. For smaller 
variants, restriction fragment length polymorphism (RFLP) allows variant detection based on 
the principle of restriction enzymes cleaving DNA sequences at different positions, depending 
the presence of variants in restriction sites (46), while array CGH allows comparative genome-
wide analysis of two samples, enabling the detection of allelic imbalances down to resolutions 
in the order of kilobases  (Kb) (47). 
Techniques allowing variant detection at high resolution and higher throughput, with no need 
of prior knowledge about the variant site are, for example high resolution melt (HRM) (48) 
and denaturing high performance liquid chromatography (DHPLC) (49). In HRM, DNA 
sequences are discriminated on the basis of their behaviour during thermal denaturation, 
which depends on their sequence, length, GC content, and strand complementarity. DHPLC is 
instead based on the formation of DNA heteroduplexes between a wild-type and a 
variant sequence through hybridization, after heating and cooling of PCR products. Partially 
denatured PCR amplicons are separated by reverse-phase chromatography, and UV light or 
fluorescence are used for detection.  
In spite of the great enhancements these techniques and several others have undergone after 
their invention, NGS represents the group of technologies that caused an unprecedented 
transformation of genetic research in the last years. NGS technologies are in fact the only 
ones simultaneously allowing variant detection and characterization, also for variation at 
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novel variant sites, in a high-throughput fashion and now at costs that render the routine 
application of NGS affordable for many genomics laboratories. All the data on which the work 
herein described is based have been produced with NGS, and for this reason, they deserve to 
be described separately in Paragraph 1.4.1.3. 
1.4.1.3 Direct DNA sequencing technologies  
The ability to sequence DNA undoubtedly represents one of the most important 
achievements of scientific research and technological development in the past century. DNA 
sequencing is nowadays a mainstay of biological research, and, more recently, the importance 
of adopting sequencing technologies in healthcare has been widely recognized by 
governments, strategists and researchers at the highest levels. In the United Kingdom, the 
Human Genomics Strategy Group of the Department of Health was established with the aim 
of “monitoring advances in genetic and genomic research, both basic and translational” and 
to “develop […] a vision for genomics in the National Health Service (NHS)”, and states that 
“The potential of this [NGS-based genomic medicine] for the NHS is considerable. It already 
means that we are able to diagnose diseases and detect variants far more precisely and 
quickly, tailor treatments both to the exact variant and to reflect a person’s wider genetic 
make-up, and better identify those at higher risk genetically of inherited disease and a range 
of common chronic conditions.” (50). 
In 1977, Sanger and collaborators published a milestone paper presenting the DNA 
sequencing technique that would become and remain the gold standard for more than 2 
decades (51). The Sanger method was subsequently automated, and this technological 
advance enabled the publication of the first, complete sequence of a human genome in the 
context of the Human Genome Project (International Human Genome Consortium 2004). This 
proved that human whole-genome sequencing (WGS) was achievable, but at a cost and 
timescale rendering large-scale DNA sequencing impossible to be used on a routine basis. 
However, the achievements obtained by “first-generation” sequencing methods in the 
context of the Human Genome Project and parallel private efforts, together with the inherent 
limitations of such methods catalysed impressively fast-paced technological advances in the 
field, leading to the arrival of massively parallel NGS technologies, although automated 
Sanger sequencing continues to be used as a complementary technology to sequence small 
regions, regions difficult to target (e.g. those at high GC content) and to validate NGS findings. 
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The development of NGS has followed several paths in terms of physicochemical principles 
underlying the DNA sequencing procedure, but with the common aim of providing faster, 
cheaper and accurate sequencing enabling its routine usage in research and healthcare. The 
transition from first-generation to next-generation technologies has been ground-breaking, 
with a throughput increased by at least 5 orders of magnitude and a cost dropped from 100 
million USD in 2001 to about 5,000 USD in 2014 for a whole human genome (53). NGS 
technologies are now often classified in second-, third- and even fourth-generation (54,55), 
with an objective difficulty in defining what constitutes a new generation, given the very rapid 
time scale on which advances are being made.  The term NGS, originally indicating second-
generation systems, is nowadays used to refer to all high-throughput, massively parallel 
sequencing systems, widespread throughout research labs and clinics all over the world. The 
market of second-generation platforms is largely dominated by a few manufacturing 
companies, such as Illumina (HiSeq, MiSeq and NextSeq platforms; www.illumina.com), Life 
Technologies (SOLiD, Ion PGM and Ion Torrent platforms, www.lifetechnologies.com), and 
Roche/454 (GS Junior and GS FLX platforms, www.454.com), with the main discerning 
features among different systems being in template preparation, sequencing chemistry 
(despite being all based on sequencing-by-synthesis) and imaging techniques (56). These 
technologies are steadily improving their performance, with general trends towards longer 
read lengths meaning more accurate mapping (challenged by the inverse proportionality 
between read length and throughput, newest systems now operate in the range 150-700bp), 
lower error rates, shorter run times and smaller benchtop sequencers. However, one of the 
drawbacks by which all second-generation systems are characterized is the PCR-amplification 
step that can introduce artefactual sequence variation. Some manufacturers, such as Pacific 
Biosciences (www.pacificbiosciences.com) have partially overcome this limitation by 
developing systems for which PCR is not needed, like the recently commercialized PacBio RS 
II platform. While being based on much longer reads (>3 kb), this technology still relies on a 
template replication system, where, in a highly parallelized fashion, a single molecule of DNA 
polymerase synthesizes a single molecule of DNA, positioning it somehow between second- 
and third- generation technologies. Nanopore-based sequencing systems, such as those 
manufactured by Oxford Nanopore Technology (www.nanoporetech.com), are instead fully 
classifiable as third-generation systems, being based on the direct reading of individual DNA 
molecules and not using enzymatic replication. They point towards long read lengths (>2 kb) 
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but still face challenging issues such as a high native error rate (57).  Fourth-generation 
methods are still largely experimental, and aim at a fully contextualized, in situ sequencing 
technology (58), which would prove particularly useful for example in studying cancers, where 
neighbouring cells often do not share the same genome. 
1.4.2 Variant identification after next-generation sequencing 
The output of a NGS DNA sequencing run consists in millions to billions of raw reads, of which 
the sequence is saved in text files. These often correspond to huge amounts of informatics 
data that need to be quality-assessed, processed and analysed downstream. A widely 
accepted file format for NGS raw data is FASTQ (59), which incorporates read sequences as 
well as a variety of read-specific and base-specific quality scores. A broad range of informatics 
tools have been developed to assess the quality and to filter raw NGS data, such as FASTQC 
(60), allowing the exclusion of low-quality bases – usually found at the ends of the reads – 
and low-quality reads from further analysis. 
1.4.2.1 Read mapping 
After raw data quality control and pre-processing, reads still represent a much longer DNA 
molecule in a highly fragmented state, and the original sequence needs to be reconstructed 
for enabling downstream analysis. This can be accomplished in two ways – either aligning 
reads to a known reference sequence or assembling them de novo. Both approaches present 
limitations, the most prominent being the very high computational complexity for de novo 
assembly and the difficulty to align within repetitive regions or in regions that don’t exist in 
the reference genome – usually because of gaps in the reference sequence or insertions, 
deletions or structural variants in the genome being analysed – for read mapping. However, 
de novo assembly is needed to construct the reference sequence of any organism with an 
unknown genome.  For this reason, de novo assemblies are often reported for bacterial 
genomes, given the paucity of sequence information for some bacterial species (61,62). Once 
a reference sequence is defined, read mapping is generally the preferred approach. Many 
different tools have been developed for read mapping, based on a variety of underlying 
alignment algorithms and optimized for different read lengths, sequencing technologies and 
analytical needs (63), with popular examples including BWA (64) and Bowtie2 (65). 
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1.4.2.2 Post-mapping quality control 
After mapping reads to the reference genome, a three-step post-alignment processing, 
consisting in removal of duplicate reads, indel realignment and base quality score 
recalibration, is performed to improve the quality of downstream variant calling (66,67). 
Duplicate reads are most likely artefactual products of PCR, and are removed or marked with 
tools like Picard (68) and SAMtools (69), and the proportion of reads discarded from further 
analysis can vary greatly depending on the number of PCR cycles performed before 
sequencing. As already mentioned, one of the drawbacks of mapping reads to a reference 
sequence is the difficulty to align those containing insertions or deletions. For this reason, 
realignment is performed locally in regions containing indels, and most of popular algorithms 
developed for this purpose – such as IndelRealigner from the Genome Analysis Toolkit (GATK) 
(70) – use a mixture of local de novo assembly and pure local realignment to the reference 
genome to achieve improved mapping in these difficult regions. The last post-alignment 
quality control concerns the base-specific quality scores assigned by the sequencer and 
indicated in the FASTQ files. Such scores are often biased and inaccurate (71,72), and can be 
adjusted with softwares such as BaseRecalibrator from GATK. Score-recalibrating softwares 
take into account covariation among, for example, different reads, lanes and machine cycles 
to output a corrected score for bases that show an artificial covariate trend. However, local 
indel realignment and base quality score recalibration were recently suggested to have an 
important effect only on low-coverage samples (73). 
1.4.2.3 Variant calling 
The last step leading to a final list of variants observed in the samples that have been 
sequenced is variant calling, which is based on the detection of differences between the 
aligned sequences of the analysed samples and a reference sequence. 
It can be performed with software – such as UnifiedGenotyper and HaplotypeCaller by the 
GATK suite – which take into account several information from the whole upstream analysis 
to infer definitively the most likely nucleotide at each base position. The final output for a 
given base depends on a variety of parameters, such as read depth, base quality, mapping 
quality, ratio between reference and variant reads and many more. A widely accepted output 
for the variant calling process is the Variant Call Format (VCF) file (Figure 1.3), which lists all 
positions at which the allele in the analysed genome is different from the reference sequence, 
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indicating also a variety of quality scores. Variant calling can generally be performed in a 
multi-sample or single-sample fashion, each with different advantages and limitations. 
Compared to single-sample, multi-sample calling additionally takes into account information 
from the same genomic position across other samples, with the aim of reducing the rate of 
false-positive calls, and it is usually recommended when the sample set is coherent (e.g. all 
cases or all controls, same ethnicity etc.). However, even when samples analysed together 
are heterogeneous, a variant that does not pass quality filters in a single sample may be 
identified if the same variant is seen in other individuals, effectively raising the probability of 
borderline-quality variants to represent true positives. 
 
 
 
Figure 1.3 - Example rows of a multi-sample VCF file. Each row represents a genetic variant. CHROM=chromosome, 
POS=genomic position, ID=variant ID from dbSNP, REF=reference allele, ALT=variant allele, QUAL=phred-scaled quality score, 
FILTER=passed/failed quality filters of the variant calling software, INFO=various quality/annotation information about the 
variant (modified to [….] here for space purposes), FORMAT=key to interpret sample columns, 20FM00417 and 
20FT00420=two sample columns with genotype and read depth/quality information. 
1.4.2.4 Detection of copy number variants and structural variants 
Although the terms “copy number variant” (CNV) and “structural variant” are often used 
interchangeably, CNV conventionally indicates deletions or duplications of DNA segments 
greater than 1 Kb and less than 5 megabases (Mb) (74), whereas “structural variant” is 
generally used to indicate variation (also including inversions and other complex 
rearrangements) involving larger genomic regions. Independently of the arbitrary boundary 
between the two definitions (I will refer to these variants as a unique class with the term 
CNV), all types of CNVs – also those shorter than 1 Kb and longer than 5 Mb – can theoretically 
be detected from NGS data, but their identification is often not straightforward, and it 
requires different analytical approaches than for smaller variants, such as SNVs or short 
indels. It is estimated that approximately 12% of the human genome is subject to CNVs (75), 
and, although not always having negative effects on human health, CNVs are pervasive and 
can contribute to disease-causing processes.  
Several methods to detect CNVs from NGS data have been developed, mainly relying on 4 
different strategies: paired-end mapping, split read, read depth and de novo assembly, with 
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some methods combining multiple strategies (76). Paired-end mapping and split-read 
approaches rely on the abnormal mapping position of reads to a reference sequence in case 
of a large variant being present. The former strategy identifies CNVs from discordantly 
mapped paired-reads whose distances are significantly different from the average insert size, 
while the latter exploits read pairs where one read uniquely aligns to the reference while the 
other fails to map or only partially maps. Read depth-based methods have recently become a 
major approach mainly due to the accumulation of high-coverage NGS data, and they use the 
depth of coverage to identify regions affected by CNVs, and can detect the exact copy number 
beside their simple presence. De novo assembly strategies are based on reconstructing the 
DNA sequence from overlapping reads, not using any reference sequence. After the assembly, 
the sequence is aligned to a reference and regions with discordant copy numbers are 
identified. Each of the 4 strategies presents advantages and limitations (of which examples 
are given in Table 1.3), and none of them can comprehensively detect all types of CNVs.   
However, irrespective of the methodology of choice, whole-exome sequencing (WES) or any 
targeted sequencing methodology (described in Paragraph 1.6.2.2) per se pose some issues 
with regards to the efficient detection of CNVs, as opposed to a full-coverage approach like 
WGS. The limited genome coverage (1-2% for WES) implies that the full spectrum of CNVs 
may not be completely characterized (for example, break points may be missed if outside 
coding regions), and in addition many large CNVs and cross-chromosomal rearrangements 
may not be detected. Furthermore, any type of targeted sequencing (including WES) relies on 
a capture method upstream, and variable capture efficiency in different genomic regions can 
be problematic for read depth-based approaches. 
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Table 1.3 - Examples of advantages and disadvantages for each of the 4 analytical approaches to detect CNVs from NGS 
data 
STRATEGY ADVANTAGES DISADVANTAGES 
Paired-end mapping 
Can identify mobile element 
insertions/deletions and tandem 
duplications 
Not applicable to events larger 
than the average insert size of the 
library 
Split-read 
Identifies precise start/end 
positions 
Depends on read length and work 
only for unique regions 
Read depth 
Detects exact copy number, 
suitable for large insertions and 
CNVs in complex regions 
If without ≥1 control samples, it 
has to rely on depth distribution 
of a single sample (often very 
noisy for targeted sequencing), 
confounded by variable capture 
efficiency 
De novo assembly Unbiased for novel CNVs 
Requires a minimum read depth 
and it is computationally heavily 
demanding  
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1.5 Characterization of genetic variants 
1.5.1 Variant and gene annotation 
With the large number of variants identified by NGS experiments, it is extremely important 
that such genetic variation is made biologically interpretable. This ultimately comes down to 
categorizing each variant with supportive information regarding, for example, its genomic 
context, functional effect, frequency in the ethnically matched population and disease-
causing potential. A broad variety of databases store relevant information and several tools 
have been developed to combine annotations from different sources. The vast majority of the 
databases form a complex continuum of data exchange, with many relying to at least some 
degree upon others for their information.  Annotation of a given genetic variant often needs 
to span different – yet related – contexts to allow an exhaustive biological interpretation, 
ranging from the molecular to the clinical perspective.   
1.5.1.1 Sources of annotation information 
Genome browsers such as Ensembl (77) are of vital importance for contextualizing variation 
with respect to the genome, genes and gene structures, providing graphical interfaces and a 
number of tools for the visualisation of the reference sequence at the base-pair resolution, 
and integrating the content of different sequence and gene annotations databases. An 
example of the latter is Gene Ontology (GO) (78), which aims at standardising the 
representation of genes and gene product attributes across species and different sources of 
information. GO is organised in a species-independent manner, and it is made of three 
ontologies (structured controlled vocabularies) describing gene products in terms of their 
associated biological processes, molecular functions and cellular localization. The GO 
ontology is structured as a directed acyclic graph, where each term has defined relationships 
to one or more terms in the same domain. Terms are organized hierarchically such that higher 
level terms are more general and thus are assigned to more gene products. One of the most 
common analyses that make use of GO is enrichment, which allows to assign biologically 
relevant attributes to groups of genes that emerge from experiments or analyses. Sequence 
databases like RefSeq (79) instead store data about naturally existing genomic DNA, transcript 
and protein sequences, often with the primary aim of providing a stable, non-redundant, 
unambiguous and well-annotated reference dataset.  
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Several efforts, some based on manual curation, are constantly being made to address the 
problematic ambiguity commonly caused by automatic annotation pipelines based on slightly 
different workflows, coordinate systems or data formats in different databases. An example 
is the establishment of the Locus Reference Genomic records (LRG) (80) for reference 
sequences, aimed at providing a standardized, version-independent and fixed format useful 
also for reporting disease-relevant genetic variation. Manual annotation efforts are also being 
made with regards, for example, to human transcripts as well as those of the most often used 
model organisms (mouse, rat, zebrafish, pig), for which Ensembl shows not only automatic 
annotations produced by the Ensembl genebuild pipeline, but also manual ones produced by 
the Human And Vertebrate ANalysis and Annotation (HAVANA) team. Another significant 
effort aiming at a standardized, high-quality and stable protein-coding region annotation is 
that of the Consensus Coding Sequence (CCDS) Project (81), which maintains a dataset of 
protein-coding regions identically annotated by the participating groups between the 
reference human and mouse genome assemblies. CCDS tracks such annotations with a stable 
ID, and ensures that they are consistently represented by the National Center for 
Biotechnology Information (NCBI) (82), Ensembl (77) and University of California Santa Cruz 
(UCSC) (83) genome browsers. 
Many databases have also been established to facilitate human disease studies. The Online 
Mendelian Inheritance in Man (OMIM) (www.omim.org) importantly provides known 
relationships between human genes and diseases, while ClinVar (84) and the Human Gene 
Mutation Database (HGMD) (85) collect associations between specific variants and disease, 
with the corresponding supporting evidence. Another example is dbNSFP (86), a database 
collecting functional prediction and annotation information of all potential protein-altering 
SNVs in the human genome.  
1.5.1.2 1.4.1.2 Types of annotation information  
All the databases mentioned in the previous paragraph often gather the different types of 
annotation information computed by third-party software or stored in other repositories. 
These information encompass an extremely wide range of features, ranging from the 
predicted effect that a variant has on the transcript(s) and encoded protein(s), to in silico 
functional or pathogenicity predictors, the frequency of a variant in the general population, 
and measures of the evolutionary conservation of the residue altered by a SNV.  
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Several indices, such as GERP++ (87), PhastCons (88) and PhyloP (89) measure the degree of 
evolutionary conservation of single nucleotides, mostly through algorithms taking into 
account the number of substitutions occurred along evolution, inferred from multiple-
sequence alignments. Similarly, different methodologies have been proposed to score human 
genes on the basis of their overall intolerance to variation in humans, such as the Residual 
Variation Intolerance Score (RVIS) (90), extrapolated from the discrepancy between the 
expected and the observed amount of functional variation in each gene in human cohorts. In 
silico predictors of the effect of DNA variants  – such as SIFT (91) and Polyphen-2 (92) – can 
provide a useful contribution in characterizing a variant, by predicting whether the 
corresponding amino-acid alteration is likely to impair the protein function or cause disease. 
Although the output of such predictors can be similar, the underlying algorithms may rely on 
radically different pieces of information, ranging from the evolutionary conservation of the 
altered residue to the physicochemical consequences caused by its modification. Another 
fundamentally important piece of information regarding genomic variants in the context of 
human studies is their frequency in the general population, often strongly indicative of the 
variant’s disease-causing potential in humans. All the work described in this thesis focused 
primarily on rare variants, defined by the frequencies observed in publicly available cohorts, 
discussed in Paragraph 1.5.2. 
Popular tools such as SnpEff (93) and EnsemblVEP (94) were specifically developed to render 
the annotation of sequence variants straightforward, by retrieving or integrating these and 
many other information for example from the databases and repositories mentioned in the 
previous paragraph. Given the extremely vast variability of available tools and resources, 
those used in the context of this work will be described and discussed in the relevant chapters.  
1.5.2 Publicly available reference populations 
Exceptional efforts have been and are being made to make sequencing data of large reference 
cohorts accessible to the public. These are undoubtedly resources of great importance, for 
example, to allow comparison of variants’ frequencies in disease cases and in the general 
population, and therefore to make inferences about the disease-causing potential of specific 
variants or categories of variation. Populations from phase 1 of the 1000 Genomes Project 
((95) and http://www.1000genomes.org/) and cohorts brought together by the National 
Heart, Lung and Blood Institute (NHLBI) GO Exome Sequencing Project (ESP) 
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(http://evs.gs.washington.edu) and the Exome Aggregation Consortium (ExAC) ((96) and 
http://exac.broadinstitute.org) have been used throughout this project as a proxy for general 
population and to gather allele frequencies for variants of interest. 
1.5.2.1 1000 Genomes Project 
The 1000 Genomes Project (1KGP) includes several populations from around the world, 
grouped in Native Americans, Africans, Asians and Europeans on the basis of their coarse 
ethnic background. The initial phase of the 1KGP was called ‘pilot project’, and split in 3 
studies: the low-coverage WGS of 179 individuals from 4 populations, the high-coverage WGS 
of two family trios and WES of 679 individuals from 7 populations (97). The subsequent main 
project is instead divided in phase 1, 2 and 3 including 1092, approximately 1,700 and 2,500 
samples, respectively, and with improved methodologies between phases 1 and 2 with 
regards, for example, to multi-allelic sites. Phase 3 data, besides including new African 
samples also comprise individuals from South Asian populations. Samples of the 1KGP are 
mostly anonymous with no associated clinical or phenotype data, and the aim of 1KGP is to 
discover virtually all variants present in >1% of the studied populations. 
1.5.2.2 NHLBI GO Exome Sequencing Project 
The Exome Sequencing Project (ESP) is an enormous medical sequencing project funded by 
the NHLBI, encompassing 18 well-phenotyped populations in the United States, totalling up 
to more than 200,000 individuals. Currently, exome variant data for 4,300 European-
Americans and 2,203 African-American individuals are publicly accessible. The 6,503 
unrelated samples have been selected to contain controls, individuals with extreme low-
density lipoprotein and blood pressure values, and patients affected with heart and lung 
diseases. No phenotype information about any particular individual is released, and the goal 
of ESP is releasing frequency counts of specific variants regardless of the carriers’ phenotypes. 
1.5.2.3 Exome Aggregation Consortium 
The ExAC is another very large, more recently launched effort, aimed at aggregating, 
harmonizing and summarizing exome sequencing data from several large-scale sequencing 
project – including samples from 1KGP and ESP – and make them publicly accessible. 
Harmonization of data is achieved through re-processing all the raw data and jointly 
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performing variant calling for all projects included in the final aggregate dataset. In total, ExAC 
provides data spanning 60,706 unrelated and not necessarily healthy individuals of different 
ethnic backgrounds. Individuals are mostly from cohorts gathered for studies of complex 
(non-Mendelian) diseases, and compared with the general population they are likely to be 
depleted of severe Mendelian diseases that would be recognized at study recruitment. No 
individual information is available, but frequency counts for any particular variant are broken 
down for 7 separate ethnic groups (Non-Finnish Europeans, Finnish, African, Latinos, East 
Asians, South Asians, Others). ExAC data were released in October 2014. 
  
49 
 
1.6 Strategies to identify genetic causes of disease 
1.6.1 Classification of diseases with a genetic causal component 
Traditionally, disorders with a genetic causal component have been classified as either 
Mendelian or complex diseases, with the former following inheritance patterns in families 
reflecting the presence of a one or two (in case of dominant or recessive inheritance, 
respectively) variants of large effect, and the latter being the ultimate result of several 
variants of small effect in combination with environmental factors and lifestyle habits. 
Decades of genetic research have largely highlighted the very simplistic nature of this 
classification, with many diseases occurring along the whole causality spectrum from mono-
genic to complex, if not even entirely environmental. Likewise, a substantial proportion of 
genes has been observed to be involved in both Mendelian and complex disorders (98), and 
co-morbidity between the two classes of genetic diseases has been demonstrated (for 
example, between Marfan syndrome and complex neuropsychiatric disorders such as autism 
and depression) highlighting how variants contributing to each complex disease are enriched 
in genes implicated in a unique set of Mendelian conditions (99). More recently, shared 
genetic contributions to congenital heart disease, neurodevelopmental disabilities and extra-
cardiac congenital anomalies were demonstrated (100), further substantiating the hypothesis 
of an overlapping genetic basis between Mendelian and complex diseases. 
As described in Paragraph 1.2.3, DCM is an example of such overlap between Mendelian and 
complex disorders, since a phenotype of cardiac dilatation and reduced contractility can be 
caused by genetic variation, by environmental exposures or by an interplay of the two. This 
work focused on the genetic causes of DCM, treating it primarily as a Mendelian condition 
and concentrating on rare variation, and beginning to explore and dissect the oligo-genic 
aetiology that might be behind a proportion of disease cases. 
1.6.2 Sequencing strategies and their rationale 
1.6.2.1 Whole-genome sequencing 
Deep whole-genome sequencing (WGS) undoubtedly represents the most comprehensive 
approach for studying disease-causing genetic variation, but its application is still hampered 
by the high cost and computational demand required for a large-scale application. The clear 
advantages of such an exhaustive strategy are the opportunity to detect all variants, whether 
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in coding or in non-coding regions, and the fact of not depending on a target capture method 
to select a genomic region of interest. An increasing number of research groups used WGS in 
recent years to identify genes or variants responsible for disease (101–103). While the cost of 
WGS per se is rapidly decreasing, the other main challenge posed by WGS is the need to have 
computational resources suited to store, handle and analyse terabytes of data. Furthermore, 
in the case of non-coding variants being prioritised as disease-causing, less resources are 
generally available for annotation and less is known about their biological consequences.  
However, a less costly alternative to deep WGS is low-depth WGS, which can rely on 
linkage disequilibrium (LD)-based methodologies to improve the quality of variant 
detection and estimated genotypes. These methodologies can help overcome the higher 
genotyping error rates of low-depth WGS when it comes to common variation, due to the 
higher power provided by many individuals carrying the same allele (e.g. in the identification 
of common polymorphisms used, for example, as markers of ethnicity), but they are not 
suitable in the context of rare variant detection, as they would be blind towards a de novo 
variant and any private variant would most likely be treated as a genotyping error. 
1.6.2.2 Targeted-region sequencing 
The observation that protein-coding regions of the genome, although constituting about 1% 
of the human genetic makeup, harbour approximately 85% of variants with large effect on 
disease traits (104) underpins the rationale for whole-exome sequencing (WES). In other 
words, WES – which generally targets the ~30 million bases of the consensus coding sequence 
from the CCDS project (105) – represents a very powerful strategy for elucidating the genetic 
basis of rare and common diseases at a lower cost and lighter computational burden 
compared to WGS. An intrinsic weakness of WES lies in the assumption at the basis of its 
rationale: approximately 15% of disease variants of large effect on disease traits lie outside 
coding regions, therefore they would be missed by any approach based on WES. The main 
technical weaknesses of WES lie instead in the dependence on a PCR amplification step and 
on an exon capture method, with the capture efficiency being potentially variable for 
different exons (106). This latter drawback has been recently highlighted by comparative 
studies demonstrating how WGS was more powerful than WES in detecting exome variation 
(107). Anyhow, WES has contributed to the identification of causal genes in more than 100 
Mendelian diseases as to May 2012 (108), and whilst the cost of WGS decreases to levels 
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allowing its routine adoption, WES has rapidly become the first-line approach for presumed 
mono-genic disorders (109) and remains an extremely valid strategy for the identification of 
disease genes and variants. 
The same workflow of WES can be applied to sequence particular genomic regions of interest, 
such as exons of a targeted panel of genes. Targeted gene sequencing is commonly desirable 
for diagnostic purposes or genetic screening in the clinical setting, providing a cost-effective 
way to sequence, for example, susceptibility genes for a given disease. The main technical 
drawbacks of this strategy are the same as for WES, and this approach by definition is limited 
to pre-defined gene sets, making it unsuitable for unbiased disease gene discovery studies. 
Both WES and targeted-region sequencing will feature extensively in this work. 
1.6.3 Population-based analytical approaches 
Population-based strategies to identify disease-causing variants usually rely on large groups 
of unrelated individuals and consist in either comparing a cohort of cases to one of controls 
when the object of study is a binary outcome (e.g. disease vs no disease), or on the analysis 
of a single group of individuals in case of a continuous trait being analysed (e.g. blood 
pressure, height etc.). In both settings the aim is investigating whether genetic variation is 
associated with the analysed disease or trait, and several analytical approaches can be 
adopted. 
1.6.3.1 Single-variant tests and genome-wide association studies 
Single-variant tests consist in testing each variant of interest individually for association with 
the disease or trait in question. The most popular approach based on single-variant testing is 
perhaps represented by genome-wide association studies (GWASs), which have been 
adopted extensively in the last decade to dissect the genetic architecture of complex diseases 
and quantitative traits. In a GWAS, hundreds or thousands of individuals are typically 
genotyped over up to 2 million common SNV sites (often SNVs with minor allele frequency 
(MAF) ≥ 5%). Each single variant is then tested individually for statistical association with the 
disease or trait, checking if allele frequencies significantly differ in cases and controls or 
correlate with the measured trait. The underpinning hypothesis of a disease GWAS is that 
common disorders are driven by multiple common variants of small effect, but importantly 
increasing disease susceptibility when acting together. Disease-causing variants are usually 
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not identified directly, but genomic locations linked to them may be detected, and more 
finely-tuned downstream analyses can be adopted to dig out the actual risk alleles potentially 
present. More than 10,000 common variant disease associations have been found through 
GWAS (110), but common alleles often impart very modest effects and seem to explain only 
a small fraction of the heritability of complex phenotypes (111). Possible explanations for this 
include potentially inflated heritability estimates (112), difficulties in identifying downstream 
causative variants in non-coding regions and the actual lack of power of GWAS in detecting 
association to rare alleles. Especially this last observation has led, in recent years, to the 
establishment of a “rare variant-common disease” hypothesis (113), stating that multiple rare 
alleles may drive susceptibility to common diseases. The rapidly increasing success rate of 
NGS studies in elucidating genetic bases of disease particularly when caused by rare variants 
is however accompanied by a continued use of GWAS to unveil the genetics underlying 
complex phenotypes, suggesting that “rare variant-common disease” and “common variant-
common disease” are likely not mutually exclusive hypotheses (114), and indeed strong 
supportive arguments exist for both theories (115).  
The “rare variant-common disease” hypothesis has been investigated by several studies in 
the last decade. On one hand, it became clear that there are rare and low-frequency variants 
with large effects on complex diseases or traits, but on the other hand it is also evident, that 
the number of cases where this applies is small. An example is given by the protective effect 
of two low-frequency missense variants in PCSK9 against CAD (116), although this probably 
represents the exception rather than the rule. Also other studies found significant effects of 
rare variants on complex diseases, but these rare variants were only explaining very small 
proportions of the missing heritability for the traits in question. Examples include variants in 
APOA5 and LDLR being associated with increased risk of MI, but explaining only 0.08-0.17% 
and 0.13-0.32% of the phenotypic variance, respectively (117), and variants in SLC12A3, 
SLC12A1 and KCNJ1 contributing to blood pressure variation, with variants in each of the three 
genes explaining <0.17% of the phenotype variance. This said, while an effect of rare variants 
on complex traits is clearly present, the general success of such studies in explaining the 
missing heritability has, thus far, been remarkably low. A number of challenges need to be 
overcome in order to reach clearer answers with regards to the contribution of rare variants 
on complex traits: larger sample sizes are needed, new statistical methods to test association 
between functionally related groups of variants should be developed, the contribution of rare 
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non-coding genetic variation on human phenotypical variation should be explored, and, since 
rare variants are mostly population-specific, the improvement of methods to correct for 
population stratification will be important (118).  
Whichever approach one chooses to adopt, regardless of Mendelian or complex diseases 
being studied, rare variants are much more numerous than common variants, thus more 
stringent significance levels might be necessary, further reducing power. One approach to 
address this issue is to combine together information about rare variants in a region, rather 
than testing single variants, as explained in the next paragraph. 
1.6.3.2 Region-based aggregation tests 
Rather than testing each variant individually, aggregation tests collapse information about 
genetic variation in a pre-defined region – such as one or more genes – thereby increasing 
power when multiple variants in the region are associated with a given disease or trait, and 
resulting ideal in analysing rare variation. Several such methods have been developed, based 
on different assumptions about the underlying genetic model, with the actual power 
depending inevitably on the true disease model. 
Classic burden tests, such as the cohort allelic sum test (CAST) (119), represent the simplest 
aggregating strategy, by collapsing information about variation in a genomic region into a 
score, and then testing its association with disease. Other tests like the one proposed by 
Madsen and Browning (120) weight such score on the basis, for example, of the MAF of 
variants and can be ideal if one wants to test variants at different frequencies simultaneously. 
Both classic burden tests and weighted tests assume that all targeted variants have the same 
direction and size of effect, but on the other hand they are probably the most widely used 
and the most versatile testing strategies. Adaptive burden tests such as the estimated 
regression coefficient test (EREC) (121) avoid assumptions on the direction of effect and are 
often characterized by a two-step procedure, where the direction of effect of each variant is 
estimated in different ways, and the association between variation and disease is tested 
afterwards. While being more powerful than simpler testing strategies in case of mixed 
directions of effect or variants influencing a disease or a trait, limitations of these approaches 
can be the instability of estimates on the effect of very rare variants (as in the case of EREC) 
or the computational complexity of other methods using permutations to overcome this 
problem.  
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Several and more complex alternatives to burden tests exist, ranging from variance-
component tests – such as the sequence kernel association test (SKAT) (122) – to tests based 
on Bayesian frameworks, which don’t collapse the region-based information into a single 
statistics. The former evaluates differences between cases and controls in the distribution of 
scores assigned to single variants in the region, but like other tests of the same category is 
less powerful than burden tests if most variants are causal and effects are in the same 
direction (123). A representative of the latter is instead the EC test (124), which is conversely 
powerful if only a small proportion of variants are causal, assuming that only one variant in 
the region is disease-causing. 
1.6.4 Family-based analytical approaches  
Family-based strategies can prove particularly attractive for studying rare mono-genic 
disease-causing variation, as they allow multiple copies of rare variants to be sampled and are 
extremely useful for studying de novo mutations (125), and they represent the “classic” model 
for Mendelian gene discovery. Furthermore, without family information it is often difficult to 
predict the mode of inheritance of the disease in question. Several family-based analytical 
strategies have been developed, many of which are depending on prior observations on the 
disease inheritance pattern observed in the pedigree. 
1.6.4.1 Techniques based on genetic markers 
Traditionally, the identification of causative variants in families with multiple affected 
individuals relied on linkage analysis followed by genetic screening of the candidate region. 
Parametric linkage analysis consists in genotyping affected family members over known 
genetic markers, with the degree of co-segregation of the disease phenotype and one or more 
marker alleles being used to infer the location of the causative gene. Subsequently, more 
finely-tuned genetic screening techniques such as positional cloning have frequently 
been adopted to narrow down the candidate region, and have been successful in identifying 
unequivocally the causative gene or variants (126–128). Traditional linkage studies proved 
very useful to reveal rare risk alleles typically responsible of Mendelian diseases, but have 
been often unsuccessful for complex disorders especially due to low resolution and lack of 
power in identifying more common variants of modest effects, and to the lack of large and 
genetically informative families (129). Non-parametric linkage strategies were however 
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developed to study disorders with unclear segregation patterns and complex diseases, 
without requiring the specification of an inheritance model, which is often problematic to 
define for non-Mendelian diseases. A widely used method belonging to this category of 
analyses has been that of affected sib-pairs (ASP), which consists in studying identity-
by-descent (IBD) sharing between two siblings in multiple sib-pairs affected with the 
disease of interest. The underlying hypothesis is that, in the vicinity of a locus influencing risk 
of disease, affected sibling pairs as a group should share more alleles by IBD than expected 
by chance. However, the success of ASP studies on complex diseases has been greatly limited 
by several aspects: for example, the widespread usage of genetic models with a single disease 
susceptibility locus (with the number of actual risk loci often unknown and likely multiple), 
the assumption of allele frequencies at this locus to be in Hardy-Weinberg 
equilibrium, in unselected random mating populations, and the assumption of high 
penetrance for the causative variants. These assumptions were not only likely to be violated 
for complex diseases, thus greatly lowering the power of such approaches, but also hard to 
verify. 
Nonetheless, IBD-based methods can be applied also at the population level (130). The 
underlying rationale is that even seemingly unrelated individuals share some segments by IBD 
from a more or less recent common ancestor, and IBD sharing between affected individuals 
will be higher in segments harbouring risk alleles (131). With NGS technologies now being 
widespread and accessible for most laboratories in terms of cost, in spite of their limitations 
(related, for example, to the presence of phenocopies (132)) IBD-based methodologies can 
be usefully coupled with sequencing to identify disease variants. IBD-based methods can be 
used in the first place, to allow the identification of important genes or gene pathways, which 
can then become candidates for NGS in much larger samples of individuals with the pertinent 
disease or trait (133).  
1.6.4.2 Techniques based on the direct identification of functional variants 
The advent of high-throughput sequencing technologies provided the possibility of reading 
DNA at base-pair resolution over large genomic regions. This, whilst representing an 
unprecedented opportunity to understand the genetic basis of familial diseases and identify 
the disease-causing variants with a single sequencing experiment, also shifted the main 
difficulty from the ability to detect genetic variation in a cost- and time-efficient manner, to 
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the interpretation and filtering huge numbers of candidate variants. The prioritisation process 
in case of a disease segregating with a Mendelian pattern inevitably depends on prior 
observations on the inheritance model and assumptions about the penetrance of the causal 
variant. Several tools such as KGGSeq (134) and VAAST (135) have been developed for 
automatic filtering and prioritisation of variants on the basis of segregation, predicted 
pathogenicity, frequency in the population and other features. For disorders likely to be 
mono-genic, prioritisation pipelines generally assume the causal variant to be unique in 
patients or at least very rare in the general population, located within the protein-coding 
regions of the genome and altering the amino-acid composition of the protein encoded by 
the gene harbouring the variant. After this initial prioritisation and the elimination of variants 
characterized by poor quality scores, in a whole-exome study still 150-500 private candidate 
variants are typically shortlisted as potential pathogenic mutations, and several strategies 
have been adopted to further prioritise causal variation (136). Exhaustive genomic and 
functional characterization through a detailed annotation process, beside statistical 
assessment, are then of key importance for evaluating the potential implication in disease of 
the final candidates.  
With the cost of sequencing rapidly declining, the expectation is that deep WGS will soon 
become the technology of choice for investigating all genetic diseases. However, it is worth 
stressing how whole-genome data are affected by the problem of the “narrative potential” of 
the human genome, with many variants among the enormous amount of candidate causal 
mutations providing a persuasive story about how they may influence the trait (137). 
Therefore, coupling classic linkage analysis – formally taking into account phenocopy rates 
and reduced penetrance in computing LOD scores - with NGS-based filtering approaches can 
be a successful strategy to identify disease-causing variants in families, especially for variants 
associated with a complex trait with high penetrance (138). Under this framework, linkage 
analysis can be performed in the first place, as done by Marikkannu et al. in the context of 
breast cancer (139), followed by NGS in order to subsequently prioritise variants focusing in 
the genomic regions surrounding linkage peaks. Generally, WES has been coupled with 
linkage (for example in associating rare variants to phenotypic traits such as hearing 
impairment (140), familial goitres (141) and hypertension (142)) rather than custom targeted 
sequencing targeting only the peaks, as off-the-shelf NGS solutions are often more cost-
effective than designing and implementing a custom product. In the future, with its reduction 
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in cost, WGS will likely replace WES also in this kind of studies. When adopting a filtering 
approach on a family affected with a Mendelian disease (as I did on families affected with 
DCM (Chapter 3) and arrhythmia syndromes (Chapter 4)), the filtering strategy is conceptually 
based on the identification of rare variants shared by multiple affected family members. Given 
the low likelihood of multiple individuals sharing the same rare variant independently, such 
variants are most likely harboured by genomic regions identical-by-descent (which would 
therefore be the same regions characterised by high LOD scores in a classic linkage analysis), 
thus in cases of monogenic familial diseases caused by rare and highly penetrant variation, 
filtering approaches are often sufficiently powerful to identify pathogenic variation per se, as 
upstream linkage analysis would likely identify the same genomic regions harbouring the 
variants filtered from WES data alone.  
1.6.5 Forward and reverse genetics approaches 
Approaches to identify disease-causing variation can be classified in forward-genetics and 
reverse-genetics strategies. There is notable confusion in literature, with contrasting 
definitions, about what forward and reverse approaches are. For the sake of clarity, I have 
chosen to follow the definition stating that forward approaches are founded on a “genotype-
first” principle, in which case detailed phenotyping is performed once the presence of, for 
example, a certain variant is ascertained. Conversely, reverse approaches operate in a 
“phenotype-first” fashion – where samples with a phenotype of interest are selected in the 
first place and the underlying genetic causes are investigated afterwards. In the context of my 
work, both the population-based and the family-based analytical strategies described in 
Paragraphs 1.6.3 and 1.6.4 fall within the reverse approaches, inevitably requiring a very 
careful prior selection of the subjects of study in terms of phenotypical characterization.  
Forward genetics also encompasses all genetic screens consisting, for example, in the 
introduction of a genetic mutation or in the disruption of gene functionality in cells (143,144) 
or on animal models (145,146), in order to observe how the phenotype is influenced by the 
mutation(s) of interest or by the disruption of the activity of a gene. Such approaches are 
widely used as strategies to support and confirm original results, as discussed in the following 
paragraph (1.6.6). Specific mutations can be introduced using techniques such as site-directed 
mutagenesis, while the functionality of a gene can be disrupted with knock-out experiments 
based, for example, using homologous recombination or gene silencing through RNA 
58 
 
interference. Recently developed techniques based on the use of programmable nucleases, 
such as CRISPR-Cas9 can be used to disrupt gene function, insert specific mutations, or even 
insert new genes (gene knock-in) at specific sites in a genome (147).  
The constantly increasing availability of large amounts of sequencing data is gradually 
enabling the application of forward genetic screens also in new model organisms (without the 
need for a reference sequence) and in the context of complex genetic backgrounds (148). An 
era of forward genetics approaches involving humans has already started, with studies based 
on the identification of patients harbouring variants and the characterization of their clinical 
and physiological consequences (149). The potential of these genotype-first strategies in 
humans is apparent, for example, in elucidating the genetic background and the 
heterogeneity of complex disorders (150). 
1.6.6 Strategies to substantiate the genetic causes of a phenotype 
Broadly speaking, strategies to confirm original results of an association between genetic 
variation and a disease can fall into two categories: those based on the concept of 
reproducibility, and those based on experimental evidence. 
Once an association between a given phenotype – such as a disease – and a genetic variable 
has been detected, the investigator should collect as much supporting evidence as possible, 
to augment further the potential link between the phenotype and the observed genetic 
variation. This comprises validation of the sequencing data if not previously performed, 
thorough annotation (as discussed in Paragraph 1.5.1), evidence from previously published 
reports in literature, and information regarding variants with similar predicted effects in the 
same gene or in genes with similar functions (paralogs, for example).   
However, a genotype-phenotype association can be detected by chance, with no true cause-
effect relationship, and therefore be a false positive. For this reason, the scientific community 
often emphasizes the need for result confirmation, and problems to confirm results, even 
those obtained with very stringent quality controls and with plenty of supporting evidence, 
are rather common.  
A failed confirmation of results might first hint at a false positive result in the original findings, 
but on the other hand, may be due to chance itself and to a false-negative finding in the 
confirmation analysis, or also be caused by differences between the discovery and the 
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confirmation cohorts. On the other hand, also a successful confirmation of original results 
does not give absolute certainty of the observed association to be true.  
1.6.6.1 Strategies based on reproducibility 
Strategies based on reproducibility aim fundamentally at a duplication of the original result. 
There is a certain degree of confusion with regards to the usage of terms in this context. Kӧnig 
proposed some years ago a distinction for the terms “replication” and “validation”, in which 
the former refers to a result confirmation attempted using other samples from the same 
original population, while the latter describes the usage of external confirmation samples 
(151).  
Using samples from the same original population presents the advantage of a reduction of 
systematic differences to a minimum, since the confirmation samples are generally obtained 
with the same techniques, following the same protocols applied by the same investigators as 
for the discovery samples. On the other hand, when cohort dimensions are limited, sub-
setting the original sample set for later performing replication can pose the issue of a further 
reduction in statistical power to detect associations, which can be particularly important 
especially for rare variant studies, such as the work described in chapter 2.  
The alternative scenario of a validation, attempted on samples from a different population, 
inevitably implies some differences with respect to the discovery cohorts, in terms of ethnic 
background, definition of the phenotype and sampling or recruitment strategies. However, a 
confirmation of results in spite of modified influencing factors might reflect a stronger 
association between the genetic variable and the phenotype of interest. 
1.6.6.2 Strategies based on experimental evidence 
Experimental evidence that can contribute to support for gene implication in disease 
comprise several categories, starting from the demonstration that the normal gene function 
is consistent with the known biology of the disease process. However, strategies relying on 
experimental evidence are often aimed at showing how the disruption of the candidate gene 
or the presence of the candidate variant in a model system or organism results in a phenotype 
that recapitulates the relevant pathology in humans, and is unlikely to occur when disrupting 
a random gene. Whether particular cell lines or animal models will be most appropriate 
depends on the study hypothesis and on what the investigator attempts to demonstrate: cell 
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cultures may be inappropriate for disorders affecting complex organ systems, but on the 
other hand animal models are often not well-suited for validating human-specific aspects of 
biology (152). In the context of DCM, examples of animal models that faithfully recapitulate 
aspects of the human patho-physiology include zebrafish (153), mice, hamsters, pigs and dogs 
(154). Differently from mammals, zebrafish can live up to two weeks with a non-contractile 
heart, and thus allows mechanistic studies of homozygote mutants for loss-of-function 
genetic variants, as it has been done also in the context of TTN truncating variants (155). 
Furthermore, zebrafish is a model of particular interest for studies on heart muscle 
regeneration, given its marked ability to regenerate its heart after injury (156).  
Smaller animals possess the general advantages of being cheaper to keep, easier to house 
and handle and to be characterized by short life cycles, while large ones provide the main 
advantage of being more similar to humans in terms of organ size, and their responses to 
some treatments are more reliable predictors than those observed in reduced-size models.  
However, it must be always taken into account that what is observed in an animal model does 
not necessarily reflect what we, as human geneticists, investigate in humans. From this 
perspective, even the animals with the most similar physiological characteristics to humans, 
such as monkeys, must always be considered as proxies (at most) to the human patho-
physiology. Taking this into consideration, the most powerful confirmation strategy to 
substantiate a genetic variable-disease association probably remains an independent 
observation of the association in other humans, in a group large enough to yield high 
statistical power and strong statistical significance. 
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1.7 Aims of thesis 
1) To investigate the genetic architecture underlying DCM by: 
a) Comparing the frequency of potentially disease-causing genetic variation in 
DCM cases and healthy and population controls in putative DCM genes 
b) Investigating the presence of an additive effect of variants in multiple genes 
on DCM risk 
c) Surveying whether specific di-genic interactions are associated with DCM risk 
d) Analysing the effects of potentially disease-causing genetic variation on DCM 
severity 
2) To identify putative causative genes and variants in a family with unexplained DCM 
using WES 
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2 Overview of the genetic architecture of DCM through a 
population-level case-control analysis 
2.1 Introduction 
In recent years, several studies have improved our understanding of the genetic basis of DCM. 
These studies include family-based approaches including linkage analysis and/or WES 
(157,158), GWAS in large cohorts (159,160), and gene-panel resequencing efforts (5-90 
genes) in affected individuals (Table 2.1). Major limitations of the latter approach is the 
absence of a well-characterized control group, to enable robust assessment of the 
background rate of genetic variation in healthy individuals (previous studies used publicly 
accessible reference cohorts as control populations, enabling the investigators to assess only 
the frequency of individual variants, but not the total background frequency of variants in a 
given gene, for example), and the lack of analyses aimed at better understanding the effects 
of multi-genic variation in DCM. The latter point was made also by Golbus et al., highlighting 
how the frequency of potentially disease-causing variants in susceptibility genes for 
cardiomyopathies is much higher than would be expected based on the disease prevalence, 
raising the possibility that many variants causing disease only if in combination with each 
other (161), or that some variants are not-disease causing at all.  
A few studies of cardiomyopathies have explored the effect of multiple variant genes on 
disease penetrance and/or expressivity, notably in the study of HCM (162–164). With regards 
to DCM, I have found only one report in which an assessment of multi-genic effects was 
performed, but on a small cohort and focused on a specific combination of genes (165). This 
disparity between HCM and DCM may be explained, in part, by the less pronounced genetic 
heterogeneity of hypertrophic cardiomyopathy, where 2 sarcomeric genes (MYH7 and 
MYBPC3) cause up to 70% of disease cases, and the total number of genes associated with 
disease is lower than for DCM (166). 
To overcome the limitations of previous studies, in this chapter I investigate the genetic 
architecture of DCM by comparing rare, protein-altering variation (MAF ≤ 0.1%) in 64 putative 
cardiomyopathy genes in a large DCM cohort, alongside ethnically matched, carefully 
phenotyped healthy volunteers (HVOLs) sequenced on the same platform. I explore the 
contribution of each gene to DCM, estimate the likelihood that variation in single genes is 
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pathogenic, develop multi-genic models of DCM risk and severity and survey whether specific 
di-genic interactions play an important role in DCM. The decision to prioritise variants with 
MAF≤ 0.1% derives from the assumption of full penetrance for the filtered variation, taking 
into account that individuals in the ESP are not all healthy and some may be DCM cases. I 
considered 0.1% as a conservative upper-bound as a result of the following estimation: given 
the estimated prevalence of DCM (1 in 250, which corresponds to one pathogenic variant in 
500 chromosomes, assuming dominant monogenic inheritance and full penetrance), and 
considered that the gene most commonly involved (TTN) explains up to 25% of cases, this 
implies that 1 in 1000 in the general population is affected with DCM due to variation in TTN. 
Given that a single variant is very unlikely to represent the unique pathogenic variation 
responsible for DCM in a whole gene, and given that the estimated prevalence of 1 in 250 also 
includes cases of non-genetic origin, 0.1% represents an inclusive upper-bound, and variants 
at higher frequencies in the general population would not be expected to be highly penetrant 
pathogenic mutations. 
Table 2.1 - Previously published studies on genetic variation in DCM using targeted gene panels. With the exception of the 
study by Herman at al from 2012, while controls were used to assess the rarity of specific candidate variants identified in 
case cohorts, none of these studies included a comprehensively sequenced control arm suitable to assess the background 
rate of rare variation in the population. 
YEAR STUDY/IES CASE 
COHORT SIZE 
N. OF GENES 
2006 
2008 
2008 
2010 
Li et al., Am J Hum Gen (33) 
Parks et al., Am H J (34) 
Hershberger et al., Clin Transl Sci (35) 
Hershberger et al., Circ Card Gen (36) 
315 
324 
313 
312 
2 
1 
6 
5 
2011 Millat et al., Eur J Med Genet (37) 105 5 
2012 Lakdawala et al., J Card Fail (38) 264 10 
2012 Herman et al., N Engl J Med (25) 312 1 
2013 Van Spaendonck-Zwarts et al., Eur J Heart Fail (40) 418 22 
2014 Pugh et al., 2014 (24) 766 46 
2014 Haas et al., 2014 (41) 639 84 
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2.2 Study design overview 
The study described in this chapter was conceived as a case-control analysis, aimed at 
identifying the genetic determinants of DCM and its overall genetic architecture by comparing 
sequencing data of disease cases and healthy controls. The study plan was to: 
1) Use burden testing to compare the frequency of potentially disease-causing variation 
in cases and controls in putative DCM genes, so to estimate the contribution of each 
gene to DCM 
2) Use regression models to investigate the presence of a multi-genic effect in DCM and, 
if detected, investigate whether particular gene-gene interactions are associated with 
disease 
3) Investigate the effects of genetic variation on the cardiac morphology and function of 
DCM patients 
A more detailed description of the study design, and a schematic representation 
delineating the process of selection of samples and genes for the various analyses that I 
performed in this study is represented in Figure 2.1.
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Figure 2.1 -Overview of the study design and selection process of samples and genes analysed in the various steps of the study. Prosp = 
prospectives, Retro = retrospectives. ICC4, ICC5 and ICC6 indicate three different technical iterations of the targeted gene panel on which samples 
were sequenced. The subdivision of DCM patients and the iterations of the gene panel are described in detail in Paragraph 2.3. 
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2.3 Materials and methods 
2.3.1 Discovery cohorts 
Thousands of patients affected with a variety of CVD as well as healthy volunteers (HVOL) 
have been recruited via advertisement at the MRC Clinical Science Centre in London and 
through the Royal Brompton and Harefield NHS Trust (RBHT) cardiovascular Biomedical 
Research Centre (cBRU). As far as DCM patients are concerned, they can be essentially divided 
in two cohorts: one consisting in prospectively recruited, unselected patients, and one with 
individuals affected with end-stage DCM, recruited retrospectively from a tissue bank. 
2.3.1.1 Prospectively recruited unselected DCM patients 
The RBHT biobank prospectively collects, processes and stores specimens, with the associated 
clinical data, consented for donation to research by patients undergoing treatment at the 
Trust. From July 2001 to August 2012, patients referred to the RBHT CMR unit for evaluation 
of a possible diagnosis of DCM and who agreed to provide samples for biobanking were 
prospectively recruited at the National Institute for Health Research cBRU, RBHT and Imperial 
College London (n=386). These patients were referred from centres across the South of 
England. CMR scan and evaluation were performed by two independent Level 3 accredited 
CMR cardiologists. A diagnosis of DCM was confirmed and evaluated against published CMR 
criteria, stating that, to be classified as DCM case, a patient needed to present with LVEF > 2 
SD below and with left-ventricular end-diastolic volume (LVEDV) > 2 SD above the mean 
normalised for age and sex (167,168). Normalised means were derived from a study 
performed in 2006 (168) undertaken at the RBHT CMR, using the same scanners as for cohorts 
analysed in this study. Results of the study from 2006 suggested that interpretation of LV 
parameters in borderline cases (e.g. early cardiomyopathy) should be referred to age, sex and 
BSA normalised values in order to determine whether there is abnormality. Following this, all 
cases given a diagnosis of DCM but not meeting strict CMR criteria were re-evaluated and 
passed to a Level 3 accredited CMR cardiologist to confirm exclusion or inclusion in the DCM 
cohort based on clinical history and supportive CMR characteristics. Borderline LVEDV (>1.5-
2 SD above mean for age and sex) and LVEF (>1.5-2 SD below mean for age and sex) were 
considered supportive CMR characteristics in presence of supporting echocardiographic 
and/or clinical evidence. 55 of the 386 prospective DCM cases were included on the basis of 
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this rationale. No patients had clinical symptoms or signs suggesting active myocarditis or 
CMR evidence of infiltrative disease. Whenever serial scans were available, the first diagnostic 
scan was used. Coronary angiography was not performed in patients with a low likelihood of 
myocardial ischemia based on non-invasive testing or on clinical profiling of the patient (e.g. 
a young family member of a patient with known DCM). In some patients in whom angiography 
was performed, bystander CAD was detected, defined as significant CAD but evaluated as 
insufficient to cause a secondary DCM phenotype (< 2 affected segments with late 
gadolinium enhancement (LGE) < 25% on CMR). Information regarding the presence 
of risk factors for non-ischemic DCM were collected, (e.g. history of myocarditis and alcohol 
excess). A family history of a minimum of 3 generations was taken with direct query for DCM, 
other cardiomyopathies, skeletal myopathy or dystrophy and sudden cardiac death. 
Electrocardiographic data collected included conduction disease, atrial fibrillation, sustained 
or non-sustained ventricular tachycardia and ventricular fibrillation. Patients’ clinical data 
were obtained by questionnaire at the time of enrolment and from clinical records. A copy of 
the questionnaire (same as for HVOL) given to the recruited DCM patients is included in the 
thesis appendix (Paragraph 6.1). 
2.3.1.2 Retrospective end-stage DCM patients 
All end-stage DCM patients who were referred for implantation of a left-ventricular assist 
device or for cardiac transplantation at the RBHT between 1993 and 2011 were prospectively 
enrolled in a tissue bank. For a total of 155 subjects peripheral blood was available for DNA 
analysis. For this cohort, diagnosis of non-ischemic DCM was confirmed from patients’ clinical 
records, but detailed clinical data were not available. 
2.3.1.3 Healthy volunteers 
Healthy adult volunteers (age range 18-72) were prospectively recruited via advertisement at 
the MRC Clinical Science Centre, Imperial College London. Participants with previously 
documented cardiovascular disease, hypertension, hypercholesterolemia or diabetes were 
excluded. Females were excluded if pregnant or breastfeeding, but were eligible if taking oral 
contraceptives. Standard published safety indications to magnetic resonance imaging were 
applied, with a scanner weight limit of 100 kg. Normal cardiac morphology and function and 
function was confirmed by CMR in all HVOL samples by a Level 3 accredited CMR cardiologist 
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and phenotypic data were used as a baseline against which to compare the morphology of 
the DCM cohort. A copy of the questionnaire (same as for DCM patients) given to the 
recruited HVOL is included in the thesis appendix (Paragraph 6.1).  
2.3.1.4 Samples selected for study 
Of the sequenced samples available in the group’s in-house database at the time of study 
design (n=541 DCM, of which 386 prospectively recruited and 155 end-stage DCM from the 
tissue biobank; and n=420 HVOL), I originally selected all those sequenced using the same 
capture technology and the same sequencing platform, in order to reduce potential bias 
caused by the usage of different capture or sequencing methods. Following this rationale, I 
selected 505 DCM patients (Mean±SD1: 54±16 years old, 74.3% males, 85.7% Caucasians) and 
420 HVOL (45±13 years old, 54.3% females, 76.7% Caucasians) all sequenced on a targeted 
gene capture panel encompassing 204 genes implicated in inherited cardiac conditions (ICC) 
(for a total target size of approximately 2 Mb) using a SOLiD 5500xl platform (DNA extraction, 
library preparation and sequencing details in Paragraph 2.3.3). Genes targeted by the ICC 
panel were chosen before the development of this work on the basis of reported associations 
of disease-causing variants with relevant ICCs identified in HGMD Professional. Three 
technical iterations of the 204-genes panel were implemented during the years in which 
sequencing occurred, and while all the three panel versions were used within the DCM cohort, 
only the two most recent versions were adopted to sequence HVOL samples (details in 
Paragraph 2.3.3.3). The 505 DCM cases were composed of 386 from the prospectively 
recruited unselected DCM patients (n=386, 58±14 years old, 72.3% males, 86.5% Caucasians) 
and 119 from the retrospective, end-stage DCM cohort (n=119, 40±16 years old, 80.7% males, 
83.2% Caucasians). Results for categorical variables for the 386 prospective are displayed in 
Table 2.2 (ethnicity and gender data were available also for the 119 retrospectives and the 
420 HVOL). While this work was being produced, the ICC genes panel was redesigned and 
optimised to a newer version encompassing 174 genes. Details regarding its development 
have been published in early 2016 (169).
                                                     
1 Whenever I use the notation X±X, I indicate mean ± standard deviation. 
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Table 2.2 -Results for categorical variables in the cohorts selected for study. 
VARIABLE N WITH DATA CLASS: N PERCENTAGE 
Family history of DCM 311 46 14.8% 
History of myocarditis 298 14 4.7% 
History of alcohol excess 318 44 13.8% 
History of chemotherapy 295 15 5.1% 
History of iron overload 314 5 1.6% 
Conduction disease 306 96 31.4% 
Peripartum 332 8 2.4% 
Bystander CAD 367 25 6.8% 
Self-reported 
ethnicity (DCM Prospectives) 
386 
Caucasian: 334 86.5% 
Asian/Subcontinent: 20 5.2% 
Afrocaribbean: 13 3.4% 
Other: 10 2.6% 
African: 5 1.3% 
Chinese: 3 0.8% 
Mixed: 1 0.3% 
Self-reported  
ethnicity (DCM Retrospectives) 
119 
Caucasian: 99 83.2% 
Asian/Subcontinent: 9 7.6% 
African: 3 2.5% 
Unknown: 3 2.5% 
Afrocaribbean: 2 1.7% 
Other: 2 1.7% 
Self-reported 
ethnicity (DCM TOTAL) 
505 
Caucasian: 433 85.7% 
Asian/Subcontinent: 29 5.7% 
Afrocaribbean: 15 3.0% 
Other: 12 2.4% 
African: 8 1.6% 
Chinese: 3 0.6% 
Unknown: 3 0.6% 
Mixed: 1 0.2% 
Sex (DCM Prospectives) 386 
Males: 279 72.3% 
Females: 107 27.7% 
Sex (DCM Retrospectives) 119 
Males: 96 80.7% 
Females: 23 19.3% 
Sex (DCM TOTAL) 505 
Males: 375 74.3% 
Females: 130 25.7% 
Self-reported ethnicity (HVOL) 420 
Caucasian: 322 76.7% 
Asian/Subcontinent: 47 11.2% 
Afrocaribbean: 13 3.1% 
African: 12 2.9% 
Chinese: 9 2.1% 
Other: 8 1.9% 
Mixed: 7 1.7% 
Japanese: 2 0.5% 
Sex (HVOL) 420 
Males: 228 54.3% 
Females: 192 45.7% 
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2.3.2 CMR phenotyping 
2.3.2.1 CMR phenotyping of prospectively recruited DCM subjects 
CMR for the prospectively recruited DCM patients was performed using a Siemens Sonata 1.5 
T or Avanto 1.5 T (Erlangen, Germany). Cine images were acquired using a steady-state free-
precession sequence in standard 2-, 3- and 4-chamber long-axis views (TE (echo time) / TR 
(repetition time) 1.6/3.2 ms, flip angle 60°), followed by sequential 8 mm short-axis slices (2 
mm gap) from the atrio-ventricular ring to the apex. Ventricular volumes and functionality 
were measured for both left and right ventricles using standard techniques (170). Left-atrial 
(LA) area and length were recorded manually from 2-chamber and 4-chamber images. LA 
volume was calculated using the biplane area-length method (171). Maximum wall thickness 
was measured in the short axis, and additionally mean wall thickness was measured at mid-
ventricular (papillary muscle) level in the septum and lateral wall. LA, LV and right-ventricular 
volumes, wall thicknesses and LV mass were indexed to BSA. Image analysis was performed 
using semi-automated software (CMRtools, Cardiovascular Imaging Solutions, London, United 
Kingdom). LGE images were acquired 10 min after the intravenous injection of gadolinium-
DTPA (Schering, Berlin, Germany; 0.1 mmol/kg) in identical short-axis planes using an 
inversion-recovery gradient echo sequence, and LGE was considered to be present only when 
the area of signal enhancement could be seen in both phase-swapped images and in a cross-
cut long-axis image, as previously described in literature (172). 
2.3.2.2 CMR phenotyping of healthy volunteers 
CMR studies for HVOL were performed using a 1.5 T Philips Achieva system (Best, 
Netherlands). Cine images were acquired using a balanced-steady-state free-precession 
sequence in standard 2-, 3- and 4-chamber long-axis views (TE/TR 1.5/3.0 ms, flip angle 60°), 
followed by sequential 8 mm short-axis slices (2 mm gap) from the atrio-ventricular ring to 
the apex. LGE was not assessed. Ventricular volumes were measured and indexed as 
described in Paragraph 2.3.2.1 for the DCM cohort. Anteroseptal and inferoseptal wall 
thickness were measured, while LA volumes were not. 
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2.3.3 DNA extraction, preparation and sequencing 
2.3.3.1 DNA extraction and quality control 
Samples from the prospectively recruited DCM patients were prepared at the BRU genetics 
laboratory using an automated DNA extraction platform (EZ1 Advanced XL, Qiagen). DNA was 
extracted from whole blood (2x350 µl) following the manufacturer’s instructions (EZ1 DSP 
DNA Blood Kit). DNA from the retrospective DCM patients was obtained from the Royal 
Brompton and Harefield Transplant Unit Tissue Typing laboratory archive. Healthy volunteer 
samples were prepared by the Hammersmith Hospital Haematology Laboratory, that is 
equipped with an automated DNA extraction platform (QIAcube, Qiagen). DNA was extracted 
from whole blood as per manufacturer’s instructions. 
Quantity and quality of the DNA were assessed by nanodrop (Thermo Scientific). Samples 
were aliquoted into stock solutions and diluted preparations were stored in 96-well plates at 
-80 °C. A 260/280 ratio of >1.7 was considered acceptable for these samples. Quantity and 
quality of the DNA were re-assessed by agarose gel electrophoresis and/or fluorometry 
(Qubit, Life Technologies). 3 µg of genomic DNA were diluted in 120 µl of low TE buffer and 
sheared using the Covaris E System. 
2.3.3.2 DNA library preparation 
SureSelect SOLiD XT (Agilent) kits were adopted to construct DNA libraries using the Bravo 
Automated Liquid Handling Platform (Agilent) following the manufacturer’s protocol. Before 
and after hybridisation libraries were visualized on the Bioanalyser (Agilent) using the HS DNA 
Assays following the manufacturer’s protocol. Libraries’s hybridisation was performed with 
custom designed SureSelect capture libraries at 60 °C for 24 hours, captured with 
streptavidin-coated magnetic beads (Invitrogen Dynabeads) and amplified with 12 PCR cycles 
with indexing primers. Libraries were quantified using qPCR and pooled in equimolar amounts 
before template bead preparation using 500 pg of input library, using an automated SOLiD 
ePCR EZBead station. Template beads were enriched using standard protocols and loaded 
onto a sequencing slide. Sequencing run analysis reports were generated with the SOLiD 
Experiment Tracking System software. 
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2.3.3.3 Targeted gene panel sequencing assays 
SureSelect (Agilent Technologies) custom hybridisation capture probes were adopted to 
capture 204 genes implicated in different ICCs (encompassing, for example, 
cardiomyopathies, channelopathies, ischaemic heart disease and aortopathies). RNA baits 
were designed using the eArray platform set up by Agilent 
(https://earray.chem.agilent.com/earray/). Standard eArray parameters were used, apart 
from increased bait tiling across the target (five-fold). 
Three technical iterations of the targeted gene sequencing assay were used to sequence the 
204 ICC genes in DCM patients. The first assay (called ICC4) was characterized by some regions 
captured consistently poorly across samples (including whole genes such as BAG3 and TAZ). 
In collaboration with Agilent, our group redesigned the whole assay to redistribute sequence 
depth by removing some strict eArray bait design settings such as repeat masking, and by 
manually optimising bait design for poorly performing regions. Agilent developed algorithms 
for this (details not shared with our group), increasing the number of baits in poorly 
performing regions, and reducing it in regions performing well. Additionally, updates to 
SureSelect library preparation kits were introduced by Agilent, mainly shifting from blunt-
ended ligations in the original library preparation protocol used for ICC4, to more efficient 3’-
deoxyadenosine overhang ligations in the optimised protocol.  More efficient adaptor ligation 
resulted in higher library yields, which therefore reduced the number of PCR amplification 
cycles required. Reducing the number of amplification cycles increased the proportion of 
unique reads in the library, and therefore reduced the number of duplicate reads which 
needed to be discarded. The optimised assay (called ICC5) was the result of all these 
improvements.  
In order to bring target capture of samples already sequenced using ICC4 in line with 
subsequent samples sequenced using the ICC5, a “top-up” assay was produced. The design of 
this assay was simply those additional baits by which ICC5 differed from the original ICC4, and 
all samples sequenced on the original ICC4 assay were sequenced with the top-up assay. 
Sequencing reads for the original ICC4 assay and the top-up assay were merged prior to 
mapping to the reference genome, and variants calling was performed again (whit the term 
ICC4 I refer, from this point onwards, to the sequencing assay comprising the original ICC4 
sequencing reads merged with the top-up reads).  
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A third iteration of the panel, called ICC6, consisted in a slightly optimised version of ICC5, 
with additional baits designed to further improve capture in regions with sub-optimal 
coverage. Table 2.3 shows the number of samples in the DCM and HVOL cohorts sequenced 
on the three different version of the assay. 
Table 2.3 - Overview and breakdown of the cohorts in terms of ICC targeted gene assay version used for sequencing. 
COHORT ICC4 (N) ICC5 (N) ICC6 (N) TOTAL 
DCM Prospectives 317 69 0 386 
DCM Retrospectives 0 48 71 119 
DCM total 317 117 71 505 
HVOL 0 155 265 420 
TOTAL 317 272 336 925 
 
The metric that I adopted to measure and confront the sequencing quality on a gene-by-gene 
and on a sample-by-sample basis is the percentage of callable bases. This percentage, referred 
to also with the term “callability” was computed with the CallableLoci Walker tool from GATK 
v2.8-1. A base is considered “callable” by the algorithm under default parameters when 
covered by ≥4 reads, with phred-scaled scores ≥10 for mapping quality and ≥20 for 
base quality. I chose callability to compare sequencing quality on different assay versions, in 
different samples and in different genes as, for any given position, it collapses information 
regarding read depth, confidence of the alignment to the reference genome and quality of 
the base itself on the sequence reads covering the position. The assessment of the sequencing 
quality and subsequent data filtering on a gene-by-gene and sample-by-sample basis are 
discussed in Paragraph 2.3.6. 
2.3.3.4 Next-generation sequencing platform and variant calling 
All the 925 samples originally selected for inclusion in the study had been sequenced on a 
SOLiD 5500xl platform (Life Technologies), and underwent the same post-sequencing data 
processing pipelines. The SOLiD 5500xl generates up to 150 Gb of sequence data (75bp 
forward read length, 35bp reverse read length). 
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Reads were de-multiplexed and aligned to the Hg19 (GRCh37) human genome reference, in 
colour space, using the “Targeted re-sequencing” pipeline of the Lifescope Genomic Analysis 
software. SOLiD Accuracy Enhancement Tool (SAET) was used to improve colour call accuracy 
prior to mapping. Variants were called with Lifescope v2.5.1 (173), using the “diBayes” 
algorithm to find SNVs, and “smallindel” to call indels with the default parameters. Variants, 
in form of VCF files, were annotated using Ensembl VEP (API v75_37) (94) and the Human 
Gene Mutation Database (HGMD Professional v2013.4) (85).  
2.3.4 Replication cohorts 
2.3.4.1 DCM patients 
DCM cases used for replication analyses (n=386) were all sequenced at the Max Delbruck 
Center for Molecular Medicine in Berlin, Germany on a targeted gene panel encompassing 
DCM genes (n=11, details regarding which other genes were targeted by the panel apart from 
TTN and RBM20 were not analysed by our group). Targeted sequencing data for the two genes 
of interest for the replication analysis I performed (TTN and RBM20) were obtained from 
collaborators in the format of BAM files for all the 386 unrelated DCM cases, from four DCM 
cohorts (recruited in Berlin n=200, Amsterdam n=90, Heidelberg n=73 and Boston n=23). The 
bioinformatics team at the RBHT BRU reverted BAM files to FASTQ files using the command 
“bam2fastq” from bamUtil (http://genome.sph.umich.edu/wiki/BamUtil), and re-performed 
alignment and variant calling using the same software tools that had been used for replication 
HVOL samples (Paragraph 2.3.4.2), in order to maximise comparability between replication 
cases and controls. Alignment to the hg19 reference genome had been performed with BWA 
v0.7.12 (64) and variant calling was performed using GATK Haplotype Caller v3.3-0. Complete 
age and sex information were available for a subset of these samples (n=362, 51±13 years old, 
72.7% males, >90% Caucasians). All the 386 samples were sequenced on a targeted gene 
panel for cardiomyopathy genes on an Illumina MiSeq platform producing 150 bases-long 
paired-end reads, following capture with Nextera 37Mb Rapid Capture Exome kit.  
2.3.4.2 Controls 
Replication HVOL samples (n=514, unrelated, 42±13 years old, 53.5% females, 76.6% 
Caucasians) were recruited at the MRC-CSC during this study. Recruitment was performed as 
explained in Paragraph 2.3.1.3 for discovery controls. Replication HVOL were sequenced with 
75 
 
WES, with sequencing outsourced to Edinburgh Genomics, University of Edinburgh 
(https://genomics.ed.ac.uk/). The whole-exomes of the 514 HVOL samples were sequenced 
using an Illumina HiSeq 2500 platform following target capture with Nextera 37Mb Rapid 
Capture Exome kit (174), producing 135 bases-long paired-end reads. Reads were de-
multiplexed (allowing zero mismatches) with HiSeq Control software (175) and reads quality 
checked using FastQC v.0.10.1 (60). Low quality (<20) reads/bases were trimmed using 
PrinSeq v0.20.4 (176) and the good quality reads were aligned into hg19 reference using BWA 
v0.7.9 (64). Marking duplicate reads, local realignment around known indels and base quality 
score recalibration were performed in Picard v1.115 (68) & GATK v3.1-1 (70). Alignment 
summary metrics, callability and coverage report were calculated using Picard, Samtools 
v0.1.18 (69), Bedtools v2.11.2 (177) and in house perl scripts. A subset file was created 
(ontarget), based on reads mapping quality >8 and use this “ontarget” file to make consistent 
variant calls in GATK HaplotypeCaller. Bases covered by at least 4 reads with a mapping quality 
≥10 and base quality ≥20 were denoted as “callable”, i.e. adequately covered for variant 
calling with recommended GATK parameters. Variants were functionally annotated using the 
Ensembl VEP v75_37 (94) and HGMD Professional version 2014.1 (85) to predict the effect of 
variant in protein function. Table 2.4 shows an overview of the sequencing targets, platforms 
and software tools used on discovery and replication cohorts. 
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Table 2.4 -Overview of sequencing targets, platforms, read aligners and variant callers used on discovery and replication 
cases and controls. Systematic Sanger confirmation of variants detected by NGS was performed only for TTN truncating 
variants in discovery cohorts, in the context of the study on TTNtv (25,26) performed by the group while this work was 
produced. 
 COHORT 
N 
SAMPLES 
NGS 
TARGET 
NGS 
PLATFORM 
ALIGNER 
VARIANT 
CALLER 
DISCOVERY 
COHORTS 
DCM 332 
Panel of 204 
ICC genes (3 
iterations) 
SOLiD 
5500xl 
Lifescope 
Genome 
Analysis 
Software 
Lifescope 
v2.5.1 
HVOL 319 
Panel of 204 
ICC genes (2 
iterations) 
SOLiD 
5500xl 
Lifescope 
Genome 
Analysis 
Software 
Lifescope 
v2.5.1 
REPLICATION 
COHORTS 
DCM 386 
Panel of 11 
DCM genes 
Illumina 
MiSeq 
BWA 
v0.7.12 
GATK HC 
v3.3-0 
HVOL 514 WES 
Illumina 
HiSeq 
2500 
BWA v0.7.9 
GATK HC 
v3.1.1 
 
2.3.5 Selection of relevant cardiomyopathy genes 
I selected for study 71 genes (of the 204 targeted by the ICC genes panel developed by our 
laboratory) on the basis of ≥1 reported pathogenic protein-altering variants for any 
cardiomyopathy (DCM, HCM, ARVC and LVNC) in HGMD (Professional version 2013.4) 
(Paragraph 2.3.5). Of the 71 genes (shown in Table 2.5), 5 were discarded prior to any analysis 
due to the recurrence rate of the reportedly pathogenic variant in ESP/1KG (I allowed a 
maximum of 1 observation, retaining this a conservative approach towards possible DCM 
cases included in ESP and potential sequencing errors), and 2 were discarded later on, on the 
basis of extensive quality control on the sequencing quality in cohorts (Paragraph 2.3.6), 
bringing the total amount of analysed genes to 64.  
  
77 
 
Table 2.5 - Genes originally selected for the study. All genes with 1 variant associated with any cardiomyopathy in HGMD are 
listed, and for each gene the first disease association with a cardiomyopathy is shown, along with the corresponding 
publication. Rows in italic represent genes for which all associated variants were recurrent in ESP/1KGP (>1 observation) and 
have been therefore excluded from the study. Genes in brackets have been discarded from analysis following extensive quality 
control on the sequencing quality in cohorts (Paragraph 2.3.6). AC=Allele count, CM=Cardiomyopathy. 
GENE CM-ASSOCIATED 
VARIANTS IN HGMD 
OF WHICH NOVEL 
OR PRIVATE 
(AC≤1 IN ESP/1KGP) 
ASSOCIATED CM CM 
ASSOCIATION 
PUBMED ID 
PUBLICATION 
YEAR 
MYH7 468 458 HCM 2811944 1989 
MYBPC3 490 455 HCM 1975599 1990 
PKP2 172 152 ARVC 15489853 2004 
LMNA 126 126 DCM 10580070 1999 
TTN 102 95 DCM 10051295 1999 
DSP 105 90 DCM 11063735 2000 
TNNT2 87 83 HCM 8205619 1994 
DSG2 80 67 ARVC 16505173 2006 
TNNI3 56 54 HCM 9241277 1997 
DSC2 45 36 ARVC 17033975 2006 
TPM1 36 35 HCM 8205619 1994 
ACTC1 21 21 DCM 9563954 1998 
BAG3 18 16 DCM 21353195 2011 
MYL3 18 16 HCM 8673105 1996 
RBM20 17 15 DCM 19712804 2009 
MYPN 18 14 DCM 18006477 2008 
TNNC1 14 14 HCM 11385718 2001 
MYL2 16 13 HCM 8673105 1996 
SCN5A 16 13 DCM 15671429 2005 
JUP 14 13 ARVC 10902626 2000 
DES 15 12 DCM 10430757 1999 
DMD 15 12 DCM 8789442 1996 
TCAP 13 10 DCM 12507422 2002 
CSRP3 15 9 DCM 12507422 2002 
ACTN2 9 8 DCM 14567970 2003 
TAZ 9 8 LVNC 9382097 1997 
PRKAG2 8 8 HCM 11371514 2001 
MYH6 12 7 HCM 11815426 2002 
VCL 8 7 DCM 11815424 2002 
LDB3 11 6 DCM 14662268 2003 
PLN 6 6 DCM 12610310 2003 
RYR2 6 6 ARVC 11159936 2001 
ANKRD1 11 4 DCM 19525294 2009 
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GENE CM-ASSOCIATED 
VARIANTS IN HGMD 
OF WHICH NOVEL 
OR PRIVATE 
(AC≤1 IN ESP/1KGP) 
ASSOCIATED CM CM 
ASSOCIATION 
PUBMED ID 
PUBLICATION 
YEAR 
TMEM43 9 4 ARVC 18313022 2008 
JPH2 5 4 HCM 17476457 2007 
NEXN 5 4 DCM 19881492 2009 
FKTN 4 4 DCM 17036286 2006 
(GAA) 4 3 HCM 22555271 2012 
LAMA2 4 3 DCM 18700894 2008 
SGCD 3 3 DCM 10974018 2000 
SOS1 3 2 HCM 22589294 2012 
ABCC9 2 2 DCM 15034580 2004 
DNAJC19 2 2 DCM 16055927 2006 
ILK 2 2 DCM 17646580 2007 
LAMA4 2 2 DCM 17646580 2007 
PDLIM3 2 2 DCM 17254821 2007 
RAF1 2 2 HCM 17603483 2007 
CRYAB 3 1 DCM 16483541 2006 
MYOZ2 3 1 HCM 17347475 2007 
TRIM63 3 1 HCM 22821932 2012 
CALR3 2 1 HCM 17655857 2007 
CASQ2 2 1 HCM 17655857 2007 
LAMP2 2 1 HCM 21896538 2011 
CAV3 1 1 HCM 14672715 2004 
CTF1 1 1 DCM 11058912 2000 
DTNA 1 1 LVNC 11238270 2001 
EMD 1 1 DCM 23785128 2013 
(FOXD4) 1 1 DCM 17273782 2007 
FXN 1 1 HCM 15936968 2005 
GATA4 1 1 DCM 24041700 2013 
GLA 1 1 HCM 22336178 2012 
PTPN11 1 1 HCM 22555271 2012 
SDHA 1 1 DCM 20551992 2012 
SYNE1 1 1 DCM 19944109 2010 
SYNM 1 1 DCM 16715312 2006 
TP63 1 1 ARVC 18603493 2008 
MYLK2 2 0 HCM 11733062 2001 
PSEN2 2 0 DCM 17186461 2006 
PSEN1 1 0 DCM 17186461 2006 
SGCB 1 0 DCM 23349452 2013 
TMPO 1 0 DCM 16247757 2005 
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2.3.6 Data quality control and filtering 
Following the selection of 925 samples and 66 genes, I performed different types of data 
quality control and filtering that reduced overall sample and gene numbers. The processes of 
quality control and data filtering, prior to the main analysis on the genetics of DCM, are 
described in this section. Results of the main analysis, performed after the filtering of certain 
genes and samples of sub-optimal sequencing quality are described in Paragraph 2.4. 
2.3.6.1 Analysis on the comparability of the sequencing assay versions 
Since both cohorts had been sequenced on a mixture of different iterations of the 204-gene 
sequencing assay, with different proportions of cases and controls sequenced with each single 
panel version (as outlined in Table 2.3), I used gene callability to establish, in the first place, 
inter-assay variability in terms of gene-by-gene sequencing quality across ICC4, ICC5 and ICC6 
panel iterations. Considering the average callability of each gene across the three assays, ICC5 
and ICC6 showed similarly higher and homogeneous sequencing quality compared to ICC4 
(Figure 2.2). The variability in callability of each of the 66 genes between ICC4 and ICC5, and 
between ICC5 and ICC6 assay versions are shown in Figure 2.3 and Figure 2.4 respectively. 
Table 2.6 instead shows summarising figures of callability changes of the 66 genes selected 
for the study between the three versions of the sequencing assay. 
The analysis of intra-gene variability among different samples revealed how the generally sub-
optimal quality of sequencing data from the ICC4 assay was due to a heterogeneous 
sequencing quality between different samples, rather than all samples having a lower quality. 
Indeed, for several genes, a subset of samples sequenced on ICC4 showed callability values 
comparable to those observed on ICC5 and ICC6, while the rest was characterized by lower 
values.  Considering all samples (n=317 on ICC4, n=272 on ICC5 and n=336 on ICC6), on 
average each of the 66 genes was characterized by a median absolute deviation (MAD) in 
callability of 0.8% on ICC5 and ICC6, and 1.9% on ICC4. MAD is a measure of dispersion robust 
to outliers, and the fact that ICC4 samples were characterized by a MAD more than 2-fold 
greater than those of ICC5 and ICC6 reflected how the inter-sample variability in terms of 
sequencing quality was considerably higher in ICC4.  
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Figure 2.2 - Boxplot showing the mean callability of single genes considering samples sequenced on ICC4 (green, n=317), ICC5 
(blue, n=272) and ICC6 (red, n=336) sequencing panel versions. The plot shows how the overall sequencing quality was very 
similar (also for outlier genes) between ICC5 and ICC6 panel versions, while being generally lower in samples sequenced on 
using ICC4. Different colours are used for facilitating the reader in following the changes of single genes across the three 
panel versions.  
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Table 2.6 - Summarising figures for callability value changes between the different iterations of the sequencing assay. 
 BETWEEN ICC4 AND ICC5 BETWEEN ICC5 AND ICC6 
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SMALLEST CHANGE 0.2% ABCC9 99.8% 100.0% 0.0% 
CALR3, 
CASQ2, 
CAV3, 
CRYAB, 
CSRP3, 
DTNA, 
GLA, 
MYL2, 
MYL3, 
MYOZ2, 
PLN, 
RAF1, 
SGCD, 
TNNC1, 
TNNT2  
100.0% 100.0% 
LARGEST INCREASE 23.6% TCAP 76.2% 99.9% 4.7% JPH2 56.9% 61.7% 
LARGEST DECREASE -5.5% FOXD4 68.0% 62.5% -2.0% FOXD4 62.5% 60.5% 
AVERAGE ABSOLUTE 
GENE CHANGE (± SD) 
6.8 ±4.1 % 0.4 ± 0.8 % 
NUMBER OF GENES 
THAT INCREASED 
/DECREASED 
64 / 2 33 / 33 
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Figure 2.3 - Mean callability of each gene (n=66) sequenced on ICC4 (mean on 317 samples) and ICC5 (mean on 272 samples). The first panel on the left shows the whole set of 66 genes, while the three other panels 
are iteratively zoomed in on callability ranges with higher density of genes (ranges 80-100%, 90-100% and 95-100%). Lines represent the change in callability of each gene between the two assay versions, different 
colours are used to ease the reader in following each gene’s change. Each gene’s change is shown only once, in the panel with the highest resolution among those including both callability values (on ICC4 and ICC5) 
for the gene.  
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Figure 2.4 - Mean callability of each gene (n=66) sequenced on ICC5 (mean on 272 samples) and ICC6 (mean on 336 samples). The first panel on the left shows the whole set of 66 genes, while the two other panels 
are iteratively zoomed in on callability ranges with higher density of genes (ranges 95-100% and 99-100%). Lines represent the change in callability of each gene between the two assay versions, different colours 
are used to ease the reader in following each gene’s change. Each gene’s change is shown only once, in the panel with the highest resolution among those including both callability values (on ICC5 and ICC6) for the 
gene.   
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Figure 2.6 shows inter-sample callability values for LMNA, MYBPC3, MYH7 (three of the most 
prevalent DCM genes in literature) and TTN (reported to cause up to 25% of familial cases). 
For a subset of the 66 genes (e.g. TTN, values displayed in Figure 2.6) the overall sequencing 
quality of ICC4 samples was already comparable to that characterizing samples sequenced on 
ICC5 and ICC6 (despite the presence of some outliers with very low percentages of callable 
bases), while for others (e.g. LMNA, values displayed in Figure 2.6) the overall sequencing 
quality of ICC4 samples was markedly variable – and lower, on average – compared to ICC5 
and ICC6 samples. Having the ICC4 assay version been used uniquely in DCM cases and not in 
HVOL, this translated into a systematic difference, for at least a subset of the genes, between 
cases and controls. The average absolute callability difference between the two cohorts over 
the 66 genes was 3.5% (average SD 16.9% in DCM, 7.7% in HVOL), with 17 genes showing a 
difference between DCM and HVOL >5%.  
Table 2.7 summarises the difference between the 505 DCM cases and the 420 controls 
originally selected in terms of overall sequencing quality over single genes. The evident 
difference between some genes in terms of average callability and inter-sample variability is 
due to inherently different characteristics of gene sequences, among which the percentage 
of GC content, which previous studies demonstrated to be significantly and negatively 
associated with exome sequencing coverage (178). Figure 2.5 shows the significantly different 
(p = 0.016) GC percentages of the top 5 genes and the bottom 5 genes (among the 66 selected 
for the study) in terms of average callability computed over all the 925 samples.
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Table 2.7 -  Summarizing figures in terms of percent callability computed on the 505 DCM and 420 HVOL originally selected for the study. Some 
figures are not shown as they are implicit: The gene characterized by the lowest mean callability in HVOL is CTF1, as displayed for DCM. 
 VALUE (%) GENE VALUE IN 
DCM (%) 
VALUE IN 
HVOL (%) 
Smallest difference in mean callability 
between DCM and HVOL 
0.1 DES 77.7 77.6 
Largest difference (higher mean in DCM) 11.1 FOXD4 65.7 54.6 
Largest difference (higher mean in HVOLs) 13.9 TCAP 84.9 98.8 
Least homogenous callability in DCM 
(largest standard deviation) 
27.0 TCAP 27.0 8.5 
Least homogenous callability in HVOL 
(largest standard deviation) 
13.0 FOXD4 20.7 13.0 
Most homogenous callability in DCM 
(smallest standard deviation) 
0.7 ABCC9 0.7 7.7 
Most homogenous callability in HVOL 
(smallest standard deviation) 
4.1 CTF1 7.0 4.1 
Lowest mean callability in DCM 26.4 CTF1 26.4 25.0 
Highest mean callability in DCM 99.8 ABCC9 99.8 99.3 
Highest mean callability in HVOL 99.5 PLN 97.4 99.5 
 
 
 
Figure 2.5 - GC percentage (computed on the CCDS of the Ensembl canonical transcript) of the top 5 (green bars) and bottom 5 (red bars) genes 
in terms of average callability over the whole set of 925 samples. GC percentages of the two groups were significantly different (Mann-Whitney 
U test p=0.016)
86 
 
 
Figure 2.6 – Inter-sample callability distributions for four of the most representative DCM genes in literature. Distributions 
are shown separately for samples sequenced on ICC4, ICC5 and ICC6; and divided by cases and controls. The boxplots are 
superimposed to beeswarm plots to show medians and quartiles of distributions.   
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At this point, given the different degrees of overall sequencing quality in the different genes, 
and the systematic imbalance between cases and controls due to the ICC4 assay version being 
used only in the DCM cohort, I was faced with three different options:  
1) Discard genes with significantly different sequencing quality between the two cohorts, 
in order to keep as many samples as possible and maximize statistical power. 
2) Discard samples needed to render each gene’s sequencing quality not significantly 
different between cases and controls, to maximize the number of genes included in 
the study. 
3) Look for a compromise between the two previous strategies, by excluding samples at 
generally lower sequencing quality, attempting not to reduce cohort sizes excessively, 
and excluding genes where sequencing quality was not comparable if not by excluding 
many samples. 
I discarded the first option for two reasons: in the first place, one of the main objectives of 
this study was to assess the effect of multi-genic variation on disease risk and severity, 
therefore discarding several genes would have hampered the possibility of efficiently 
surveying this aspect. Comparing the distributions of callability values between the 505 cases 
and the 420 controls with Mann-Whitney U test, 45 of the 66 genes were characterized by a 
significant difference between cohorts (p < 0.05/66, Bonferroni adjusted). The second reason 
is that some samples showed callability values around 0% over some genes (visible, for 
example, for MYBPC3, MYH7 and TTN in Figure 2.6), and keeping these samples would 
spuriously alter the observed burdens of variation, given the approximately null confidence 
of the variant calls for the genes in question. 
I attempted an implementation of the second option, by writing a program based on an 
iterative optimisation procedure to even the overall sequencing quality over all genes in cases 
and controls. The main difficulty here was the necessity to treat each gene in the same way 
(by retaining the same samples for each gene, needed to perform the consequent regression 
analyses on the effects of multi-genic variation), in spite different genes were characterized 
by different callability means and different dispersion around the mean.  
The program was retaining a fixed set of 417 HVOL samples (the three outliers visible in each 
gene in Figure 2.6 were removed), given the higher overall sequencing quality and the lower 
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dispersion of values in controls compared to the DCM patients, and iteratively removing DCM 
samples, starting from those at lowest callability values. At each iteration, a Mann-Whitney U 
test was performed to assess the difference between cohorts, and the program would shift 
to the next gene once comparability was achieved (p > 0.05/66). This procedure was heavily 
influenced by the order in which genes were considered, therefore the program was 
randomizing the order of genes at each iteration, and would stop after 100 iterations with the 
same number of samples excluded (count would restart from 1 only if, with the new gene 
order, more samples than before were retained, in order to minimize the number of excluded 
samples). At the end of the iterations, samples retained in <1 % of the iterations were 
excluded to avoid outlier samples at low sequencing quality to be retained. There were some 
issues which prevented the program to yield an optimal result: 
1) Four genes (FOXD4, CTF1, ABCC9 and SYNM) were characterized by an average higher 
callability in the 505 DCM than in the 417 controls. To render sequencing quality 
comparable between cohorts in these genes, the program would have needed to start 
the iterative sample removal process from the DCM samples at higher callability (thus 
removing the best ones).  
2) DES showed similar average callability between the 505 DCM and the 417 controls 
(mean callability 77.6% and 78.2% in DCM and HVOL respectively), but different SD 
(16.4% in DCM and 5.4% in HVOL). In this case, many samples needed to be excluded 
(from both ends of the distribution, removing also samples of optimal sequencing 
quality) to make the callability distributions not significantly different (Mann-Whitney 
p > 0.05/66). 
3) DCM samples characterized by low or very low callability values in only a small number 
of genes were generally retained. This would have caused burden figures to possibly 
be - although slightly - altered by the inclusion of samples with markedly low (or null) 
callability in testing the burden of variation for the genes in question. 
The algorithm, when run on the whole set of 66 genes, converged to retain between 110 and 
140 DCM samples. Discarding FOXD4, CTF1, ABCC9 and SYNM from the analysis (the 4 genes 
characterized by higher average callability in the DCM patients) the algorithm converged on 
the retention of approximately 170 DCM samples, and the additional exclusion of DES 
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resulted in 190 DCM patients being kept, therefore all approaches excluded a very high 
number of samples, which would be highly suboptimal for downstream experimental power. 
In light of these issues, I chose the third option, by manually excluding outliers and samples 
with a recurrently lower percentage of callable bases over all genes, rather than relying on an 
automatic process. While acknowledging that a manual procedure could introduce biases, in 
this way I was able to obtain comparable callability values in cases and controls without 
excluding as many samples as it would have been needed to obtain a statistically non-
significant difference between cases and controls in terms of callability values, and without 
retaining any outlier at very low or null callability in any gene (Paragraph 2.3.6.2).  
2.3.6.2 Filtering and quality control at the sample level 
The main difficulty in applying the manual exclusion of samples, in order to make the two 
cohorts comparable over the highest possible number of genes was that of finding an 
appropriate balance not discarding an excessive amount of samples, inevitably leading to a 
loss of statistical power, and not discarding many genes, potentially hampering the possibility 
of efficiently surveying the effect of multi-genic variation in DCM. I manually excluded outlier 
samples characterized by markedly low callability in ≥1 genes, and samples with a recurrently 
lower percentage of callable bases over all genes. Eventually, given the overall higher quality 
of the HVOL cohort, I discarded 109 DCM cases (all sequenced on the ICC4 assay version) and 
3 HVOLs (characterized by a markedly lower callability than the rest of the HVOL samples in 
all genes, sequenced on ICC5), which left 392 DCM and 417 HVOLs for subsequent quality 
assessment. Figure 2.7 shows the effects of the filtering procedure on the distribution of 
percent callability scores for LMNA, MYBPC3, MYH7 and TTN. In spite of a marked 
improvement in terms of average per-gene callability difference and of having achieved a 
similar inter-sample variability between cohorts, a subset of the genes was still characterized 
by significantly different intra-gene callability distributions between cases and controls (Table 
2.8). This was expected, as the program that I developed and tested prior the choice of 
applying a manual filtering was discarding more than 200 additional DCM samples before 
reaching a non-significant difference over each gene in terms of callability. For this reason, I 
applied further quality control and filtering steps, both at the gene level, but especially at the 
single variants’ level, in order to ensure full comparability between cohorts (Paragraphs 
2.3.6.3 and 2.3.6.4). However, the manual sample filtering procedure was needed to exclude 
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from further analysis all outlier samples with very low or null callability values in ≥1 genes, in 
order not to consider uninformative samples in the subsequently computed variation burden 
figures. 
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Figure 2.7 - Distribution of percent callability for the samples of the two cohorts before and after the filtering to make cohorts as comparable as 
possible in terms of overall sequencing quality. LMNA, MYBPC3, MYH7 and TTN are shown as example genes.
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Table 2.8 - Summarising figures in terms of callability before and after the manual sample filtering procedure. 
 BEFORE FILTERING 
SAMPLES OUT 
AFTER FILTERING 
SAMPLES OUT 
AVERAGE PER-GENE 
CALLABILITY DIFFERENCE 
BETWEEN CASES AND 
CONTROLS 
3.5% 0.7% 
AVERAGE PER-GENE SD IN 
CASES 
16.9% 1.6% 
AVERAGE PER-GENE SD IN 
CONTROLS 
7.7% 1.4% 
GENES SHOWING A 
SIGNIFICANTLY DIFFERENT 
CALLABILITY DISTRIBUTION 
BETWEEN COHORTS 
(p<0.05/66) : GENES NOT 
SHOWING A SIGNIFICANT 
DIFFERENCE 
45:21 27:39 
 
The following quality control and filtering step at the sample level, to avoid population 
stratification resulting in systematic differences between cases and controls, was that of 
retaining only individuals with the same ethnic background. All individuals had indicated their 
ethnic background at the moment of recruitment, but I validated self-reported ethnicity by 
Principal Component Analysis (PCA), performed with the EIGENSTRAT population 
stratification method (179), part of the EIGENSOFT package. I clustered individuals on the 
basis of their ethnic groups through PCA using their genetic variants with MAF > 1% in 
ESP/1KG within all the 201 genes included in the ICC sequencing panel, in order to obtain the 
finest clustering possible. PCA to ascertain self-declared ethnicity was performed after the 
exclusion of poor quality samples in order to avoid inaccurate clustering of individuals with 
lower overall sequencing quality, despite the exclusion of non-Caucasians being planned from 
the beginning. Following PCA, I retained only individuals of ascertained Caucasian ethnic 
background. I discarded a total 60 DCM and 98 HVOL, of which 3 and 1, respectively, declared 
themselves to be Caucasian but clustered more tightly with individuals of African or Chinese 
background. Figure 2.8 shows how samples were clustered in the PCA analysis. On the basis 
of the PCA result, 651 samples (n=332 DCM, 53±17 years old, 74.1% males and 319 HVOL, 
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42±14 years old, 53.9% females) of Caucasian ethnic background were retained for the 
analysis.  
 
Figure 2.8 – PCA performed using all variants (MAF>1% in ESP/1KG) in the 204 genes included the targeted gene ICC 
sequencing panel. First (PC1, X axis) and second (PC2, Y axis) principal component are displayed, defining the clustering of 
individuals (n=809, 392 DCM and 417 HVOL left after filtering out those at lower sequencing quality), colour coded by self-
declared ethnic group. PC1 reflects the European-African gradient, while PC2 represents the European-Asian gradient. 
Individuals who declared themselves to be Caucasians but clustered with Africans/Chinese, and, alongside those who declared 
to be non-Caucasian, were excluded from further analysis are indicated by the red arrows. The non-optimal separation of 
Caucasians from Asians along PC2 was probably due to the limited amount of variants available for performing the analysis 
(mostly exonic variants in 204 genes). The clearer separation of Caucasians from individuals of African descent instead 
probably reflects the greater genetic diversity of Africans from the other ethnicities. 
After this first PCA, I performed a second one on the 651 Caucasian samples kept for final 
analysis, in order to confirm the absence of systematic batch effects due to the different 
versions of the sequencing assay, which would have translated in systematic differences 
between cases and controls. PCA confirmed the absence of batch effects (Figure 2.9). 
However, as mentioned in Paragraph 2.3.6.2, a subset of the genes was still characterized by 
significantly different distributions of callability values between cases and controls. I applied 
further quality controls on the gene-, but especially on the single variant-level in order to 
ensure full comparability between cohorts (Paragraphs 2.3.6.3 and 2.3.6.4).  
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Figure 2.9 - PCA performed using all variants (MAF>1% in ESP/1KG) in the 204 genes included the targeted gene ICC 
sequencing panel on the samples (n=651, 332 DCM and 319 HVOL of ascertained Caucasian ethnic background retained for 
final analysis). First (PC1, X axis) and second (PC2, Y axis) principal component are displayed. Results of the same analysis are 
shown twice: the colour coding highlights the different versions of the sequencing assay used to sequence samples in Figure 
panel A, and the cohort to which samples belong in Figure panel B. In both cases the different classes of samples are not 
clustered apart, proving the absence of batch effects due to the ICC4/5/6 versions of the sequencing assay, which would 
translate in batch effects between cases and controls.  
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A summary of the composition of the cohorts retained for the final analysis is shown in Table 
2.9. 
Table 2.9 - Overview and breakdown of the DCM samples selected for the final analysis. Caucasian ethnic background of all 
samples was ascertained by principal component analysis. 
COHORT SAMPLE COUNT AGE GENDER 
DCM Prospectives 234 54±14 70.5% males 
DCM Retrospectives 98 39±16 83.7% males 
Total DCMs 332 53±17 74.1% males 
HVOLs 319 42±14 46.1% males 
2.3.6.3 Filtering and quality control at the gene level 
After the filtering on single samples described in Paragraph2.3.6.2, two of the 66 genes 
initially included in the analysis still displayed an absolute difference, in terms of mean 
percent callability, greater than 5% between the two cohorts, which I assumed too large to 
consider the two cohorts comparable over the genes in question. For this reason, FOXD4 
(mean callability 71.2±12.2% DCM, 55.0±14.9% HVOL) and GAA (mean callability 96.5±5.3% 
DCM, 90.5±10.1% HVOL), both of which have very limited evidence for a role in DCM, were 
excluded from further analysis. Following these exclusions, the average difference in terms of 
mean callability between the two cohorts over the remaining 64 genes was 0.41%. Table 2.10 
shows summarizing statistics of percent callability values for the 64 genes and computed over 
the 651 samples retained in the study. 
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Table 2.10 - Summarizing figures in terms of percent callability after the filtering process. Some figures are not shown as 
they are implicit: the most homogeneous callability is observed in the 9 genes characterized by a mean of 100% in both 
cohorts (standard deviation = 0%), and the gene characterized by the lowest mean callability in HVOL is CTF1, as displayed 
for DCM. 
 VALUE 
(%) 
GENE VALUE IN 
DCM (%) 
VALUE IN 
HVOL (%) 
Smallest difference in mean 
callability between DCM and 
HVOL 
0 CASQ2, CAV3, CSRP3, 
DTNA, MYOZ2, PLN, 
RAF1, SGCD, TNNC1 
100.0 100.0 
Largest difference (higher mean 
in DCM) 
4.3 DES 82.5 78.2 
Largest difference (higher mean 
in HVOLs) 
3.3 TPM1 87.7 91.0 
Least homogenous callability in 
DCM (largest standard deviation) 
8.1 TCAP 8.1 2.2 
Least homogenous callability in 
HVOL (largest standard deviation) 
7.0 JPH2 6.3 7.0 
Lowest mean callability in DCM 28.1 CTF1 28.1 28.2 
 
2.3.6.4 Filtering and quality control at the variant level 
Comparing two cohorts over the burden of rare variants means that results, at the very least 
for some of the analysed genes, will be greatly influenced even by very small fluctuations of 
the number of variants prioritised in the study. Mainly for this reason, a strict quality control 
on the single variants, aimed at the exclusion of false positives from the analysis, is necessary 
to guarantee that observed burden differences between cases and controls reflect at best the 
disease-related differences.  
The first hard filter applied was relative to previous assessments performed within our group 
on validation results (by Sanger sequencing) of variants called with Lifescope v2.5.1 on SOLiD 
5500xl sequencing data, shown in Figure 2.10. Table 2.11 shows which classes of variants 
were excluded from analysis on the basis of these results. 
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Figure 2.10 - Sanger validation result for variants sequenced on the SOLiD 5500xl and called with Lifescope v2.5.1. The area 
shaded in green represents the combinations of allele balance (variant reads / read depth) and depth of coverage values 
characterizing variants generally failing to be confirmed (analysis performed by Roddy Walsh). 
 
Table 2.11 - Categories of variants retained (Y) or excluded (N) from the analysis on the basis of the combination of read 
depth and allele balance values. 
 READ DEPTH 
 
ALLELIC  
BALANCE 
<10x 10x-29x 30x-74x >75x 
<0.2 N N N Y 
0.2-0.3 N N Y Y 
>0.3 N Y Y Y 
 
After this first hard filter, I tested each protein-altering variant (regardless of its MAF) in the 
64 genes for: 
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1) Deviation from the Hardy-Weinberg equilibrium, based on genotype frequencies. The 
test was performed with the function HWExactMat(), part of the HardyWeinberg R 
package. 
2) Deviation from the expected allele frequency, based on allele counts in Caucasians in 
the ESP and 1KGP. In doing this, I combined DCMs and HVOLs as a single sample group. 
It is true that rare disease-causing variants would be enriched in DCMs as compared 
to ESP and 1KGP, but the enrichment wouldn’t be high enough to cause the erroneous 
exclusion of true positive disease variants. 
3) Difference between cohorts for samples read depth distribution, in case the average 
read depth for a variant in one or both cohorts was <10x. This test was needed to 
avoid the inclusion of variants characterized by a low overall sequencing quality in one 
or both cohorts, which could result in an artificial difference in the proportion of single 
variants excluded because called with a read depth <10x. 
Bonferroni correction for testing multiple variants (n=1448) was applied to all three tests. An 
overview of how many variants failed these tests is given in Table 2.12. 
Table 2.12 - Overview of the number of protein-altering variants in the 64 analysed genes that failed the tests performed to 
exclude false positive variants. The total number of discarded variants does not correspond to the sum of variants that 
failed single tests because some variants failed more than one test. 
TEST VARIANTS THAT FAILED 
Hardy-Weinberg equilibrium 6 of 1448 
MAF in public cohorts (Fisher test) 22 of 1448 
Comparable read depth (Mann-Whitney test) 32 of 1448 
TOTAL 54 of 1448 
 
2.3.6.5 Assessing equal variant detection between cases and controls 
After the series of preliminary quality controls performed at the samples and genes level 
described in Paragraphs 2.3.6.2 and 2.3.6.3, I applied the same steps for quality control at the 
variant level also on coding synonymous variants, and compared their burden between 
cohorts – assuming they have no disease-causing potential. Considering the entire set of 64 
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genes, and coding synonymous variants observed up to 10 times in the 4679 individuals of 
European descent in the ESP and 1KGP, 56.6% of cases (n=188) and 55.5% of controls (n=177) 
were observed to carry at least one variant (two-tailed Fisher test p=0.81). At the single gene 
level, only RBM20 showed a nominally significant difference between cases and controls 
(3.1% cases, n=10; 7.2% controls, n=23; p=0.019). However, this was caused by a single 
synonymous variant (chr10:112541270:T:G) observed in 16 HVOL, absent in the 379 
Europeans of the 1KGP, and at a base position not sequenced in the ESP samples. As this 
difference for RBM20 was caused by a single variant (not observed for any other gene), I 
retained RBM20 for further analyses. 
2.3.7 DCM variant association testing 
The rationale of making the two cohorts as similar as possible in terms of sample composition 
and sequencing quality was that of enabling the downstream detection of genetic differences 
explanatory of the disease status and not reflecting artificial biases. After the data quality 
control steps, my aim was to compare the frequency of potentially disease-causing variants 
in DCM cases and controls, in order to estimate the contribution of each gene to the burden 
of DCM, and the disease-causing potential of different categories of genetic variants. To do 
so, I developed an automated script called burden_test, using the R programming language 
(180), that allows the user to choose over which gene(s) and variant class(es) to compare two 
cohorts in terms of functional effect, MAF in ESP and/or 1KGP and several other features. 
Given the complexity of the program, I will discuss its development and functionality in detail 
in the Appendices (Paragraph 6.1) and show some example blocks of code in Paragraph 6.4.1. 
In short, the script determines the proportion of cases and controls carrying at least one 
variant of the category defined by the user in the genomic region or gene(s) of interest, and 
can be classified as a region-based aggregation burden test (Paragraph 1.6.3.2). I have 
developed two versions of the script: a first one taking as input the table of variants previously 
annotated through the pipeline used in-house for all research samples, and a second one 
(used for the replication described in Paragraph 2.4.5.2) working directly on VCF files and 
annotating variants automatically before performing association testing.  
Separately for each gene, I filtered variants for those annotated in Ensembl canonical 
transcripts (often those with the longest translation with no stop codons, ideally CCDS 
annotated (Paragraph 1.5.1.1) as protein-altering, further categorised as protein-truncating 
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(non-sense, stop-loss, frame-shift, or canonical splice site) and non-truncating variants 
(missense or inframe insertion or deletion). As reference population to define the MAF of 
variants, I used the samples of European descent in ESP and 1KGP combined (379 Europeans 
in 1KGP + 4300 European-Americans in ESP, total n=4679, to which I will refer as 
EurESP/1KGP). The filtered variation was subsequently trimmed to that with a MAF between 
0% (novel variants, not observed in EurESP/1KGP) and 11 consecutive cut-offs in the form 0-
X alleles in EurESP/1KGP to an upper limit of X=10 observations, corresponding to a 
MAF≤0.107%.  
Genes not showing an enrichment of rare protein-altering variants in cases versus controls at 
any of the 11 frequency cut-offs were excluded from further analysis.  
We used the excess frequency in DCM cases to estimate the proportion of disease cases 
potentially explained 
 
𝐸𝑥𝑐𝑒𝑠𝑠 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 =
𝑁. 𝑜𝑓𝐷𝐶𝑀𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠𝑤𝑖𝑡ℎ ⩾ 1𝑣𝑎𝑟𝑖𝑎𝑛𝑡
𝑇𝑜𝑡𝑎𝑙𝐷𝐶𝑀𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠
−
𝑁. 𝑜𝑓𝐻𝑉𝑂𝐿𝑤𝑖𝑡ℎ ⩾ 1𝑣𝑎𝑟𝑖𝑎𝑛𝑡
𝑇𝑜𝑡𝑎𝑙𝐻𝑉𝑂𝐿𝑠
 
 
and calculated the proportion of variants observed in patients that would be DCM-causing 
under the assumption of complete penetrance, and called this parameter “aetiological 
fraction”: 
 
 𝐴𝑒𝑡𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =
𝐸𝑥𝑐𝑒𝑠𝑠 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦
(
𝑁.𝑜𝑓𝐷𝐶𝑀𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠𝑤𝑖𝑡ℎ⩾1𝑣𝑎𝑟𝑖𝑎𝑛𝑡
𝑇𝑜𝑡𝑎𝑙𝐷𝐶𝑀𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠
)
 
 
Considerations on the derivation and definition of the aetiological fraction are made in the 
next paragraph. Statistical comparisons of frequency in cases and controls have been done by 
means of one-tailed Fisher's exact tests, in order to test specifically whether the enrichment 
of variation in DCM was significant as compared to controls. 
2.3.7.1 Derivation of aetiological fraction 
Attributable risk percent among exposed (ARP), provides an estimate of the proportion of the 
risk in an exposed population that can be attributed to the exposure. In case-control studies, 
ARP can be conveniently calculated using odds ratios (OR), which provide accurate estimates 
of the underlying relative risk (181), leading to: 
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𝐴𝑅𝑃(%) =
𝑂𝑅 − 1
𝑂𝑅
× 100% 
 
The same value has been defined as aetiological fraction when expressed as a decimal 
fraction:  
 
𝐴𝑒𝑡𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =
𝑂𝑅 − 1
𝑂𝑅
 
 
and I refer to aetiological fraction hence with.  
 The aetiological fraction is closely related to an alternative measure which has been 
previously used to estimate the importance of rare variation in known disease genes, the 
estimated probability of pathogenicity (EPP) (182) or estimated predictive value (183) where: 
 
𝐸𝑃𝑃 =
𝑅𝑎𝑟𝑒 𝑝𝑎𝑡ℎ𝑜𝑔𝑒𝑛𝑖𝑐 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑎𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑎𝑠𝑒𝑠
 
 
Since the frequency of rare pathogenic variants in cases can’t be measured directly, it is 
estimated by assuming that rare variants found in controls are benign, and that the 
frequency of benign rare variants is the same in cases and controls: 
  
𝐸𝑃𝑃
=
𝑇𝑜𝑡𝑎𝑙 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑎𝑠𝑒𝑠 − 𝑅𝑎𝑟𝑒 𝑏𝑒𝑛𝑖𝑔𝑛 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑎𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑎𝑠𝑒𝑠
 
   
=
𝑇𝑜𝑡𝑎𝑙 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑎𝑠𝑒𝑠 − 𝑇𝑜𝑡𝑎𝑙 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑖𝑛 𝑐𝑎𝑠𝑒𝑠
 
 
 
This EPP formula can be transformed in: 
  
𝐸𝑃𝑃 = 1 −
𝑎𝑐 + 𝑏𝑐
𝑎𝑐 + 𝑎𝑑
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Where: 
 𝑎 = 𝑛 𝑐𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 
 𝑏 = 𝑛 𝑐𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 
 𝑐 = 𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑤𝑖𝑡ℎ 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 
 𝑑 = 𝑛 𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑟𝑎𝑟𝑒 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 
When considering rare variants - although the derivation is distinct from aetiological fraction 
(calculated as in (181)) - the values obtained are extremely close, and the result is 
approximately equal to: 
 
𝐴𝑒𝑡𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑎𝑙 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  1 −
𝑏𝑐
𝑎𝑑
=  
𝑂𝑅 − 1
𝑂𝑅
 
 
2.3.8 Sample size and power calculations 
I needed to establish whether the size of the cohorts was adequately powered for testing the 
burden of disease-causing variants in TTN, in the other main DCM genes and at the gene-set 
level. On the basis of frequencies reported in literature or estimated from the ESP, I 
performed power calculations taking into account our sample size.  
Given the observed background variation in controls, I also retrospectively calculated the 
minimum sample size needed to ensure adequate power (80%) in testing the burden over 
each gene excluding TTN, which was observed to harbour a markedly higher burden of rare 
variants in the general population and considered as an outlier. The latter calculation was 
done assuming a ~1% background variation rate in the general population for each gene 
(based on our results, excluding TTN) and a ~1% average excess rate of variation rate in cases 
with respect to controls (based on the approximate figure of ~40 DCM genes reported to 
explain 30-50% of all cases (24), in this case making the important assumption of all genes 
apart from TTN to contribute equally to DCM). To perform the sample size calculation, and to 
calculate the statistical power I had in detecting a true enrichment of variation for some of 
the main genes, I used the functions power.prop.test() and pwr.2p2n.test() of the R package 
pwr, respectively. 
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2.3.9 Logistic regression for modelling DCM risk 
I used regression models to survey the importance of genetic variation in the 38 genes 
enriched for rare variants in patients in determining DCM and to shed light on their effects on 
the cardiac phenotype of DCM patients. In all the logistic models, the Status of our samples 
(case or control) was the only dependent variable. I developed a first model to assess whether 
the presence of truncations and non-truncating variants in TTN, and in the rest of the gene 
set was significant in determining disease. I tested whether the number of variant genes was 
an important determinant of disease risk through the comparison of two nested models by 
means of the Likelihood Ratio Test (LRT): one resembling a mono-genic disease (Status ~ 
presence_of_variation, where rare genetic variation increases the risk of disease regardless 
of how many genes are hit) and a second accounting for the number of genes altered by 
potentially disruptive variants (Status ~ presence_of_variation + n_genes). 
2.3.10 Linear regression to investigate the effects of variation on cardiac 
morphology and function 
I adopted linear regression models to measure the influence of rare variants in the set of 38 
genes on prognostically important and DCM-defining cardiac phenotypic parameters of 226 
DCM patients and 304 HVOL for which detailed CMR data were available: left-ventricular end-
diastolic volume (LVEDV), ejection fraction (LVEF) and wall thickness (LVWT). LVEDV of each 
patient was indexed to the BSA. An association between the presence of TTNtv and reduced 
LVWT was previously documented in a DCM cohort largely overlapping with the one I 
analysed (26). For each cardiac parameter I built first a model including only age and sex as 
independent variables (e.g. LVEDV~age+sex) to check whether they were significant in 
influencing the phenotype and determine if correcting for their effect was necessary. I then 
added each of the 38 genes to this model – referred to as “baseline model” – in the form of 
binary variables describing the presence/absence of variation (e.g. in case both age and sex 
were kept LVEDV~age+sex+gene1+...+gene38) and ran stepwise backward variable selection 
based on the Bayesian Information Criterion (BIC) to determine which genes were the most 
important in influencing the phenotype. Finally, I assessed the effect on the phenotype of 
every gene retained by checking its coefficient and significance in the optimal model. I also 
assessed the last genes excluded by the BIC-based stepwise selection method, given that 
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some might be excluded because of the low number of carrier samples rather than a lack of 
association with the phenotype. I investigated also the additive effect of multiple variant 
genes with LRT nested models comparison, comparing the baseline model to one also 
including the number of genes altered by variation (e.g. LVEDV~age+sex+n_genes). I repeated 
these analyses modelling an interaction between the samples’ gender and the presence of 
variation in genes on the X chromosome, since the disease phenotype is generally expected 
to be more severe in males in case of X-linked disease. 
2.3.11 Permutation testing to identify gene-gene interactions in DCM 
I used permutation testing to assess whether variation in specific gene pairs was co-occurring 
significantly more often than expected in DCM patients, in order to identify relevant gene-
gene interactions in the context of DCM. I tested all gene pairs for which statistical power was 
sufficient (TTN + other gene) and randomly re-assigned 100,000 times the disease status 
(DCM or HVOL) to the 651 samples of the discovery cohorts, keeping cohort sizes constant. 
Doing so, I obtained an empirical p-value reflecting whether the rate of co-occurrence of 
variants in the two genes in DCM was significantly higher than expected by chance. I repeated 
the same procedure on replication cohorts, and combined p-values of the two analyses using 
the combine.test() function of the R package survcomp, using cohort sizes as relative weights 
and using the Fisher method. 
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2.4 Results 
2.4.1 Overview of the history and cardiac phenotype of the selected samples 
As outlined in the thesis aims (Paragraph 1.7) and explained in Paragraph 2.3.10, one of the 
objectives of this study was to investigate the effect of genetic variation on DCM severity. This 
was done by means of linear regression models considering three prognostically important 
and DCM-defining cardiac phenotypic parameters: LV ejection fraction (LVEF), LV end-
diastolic volume (LVEDV, indexed to the body surface area (BSA) calculated with the Du Bois 
formula (184) (LVEDVi)) and LV wall thickness (LVWT), beside age and sex as covariates. For 
this reason, I explored and compared the characteristics of DCM patients and HVOL retained 
for final analysis (n=332 and n=319, respectively) on these parameters prior to the analysis, 
with regards to age and sex of cases and controls for which phenotype data were available 
and complete (n=226 DCM and n=304 HVOL) (Figure 2.11).  
Two of the three parameters I analysed (LVEF and LVEDVi) were also analysed in healthy 
subjects by Maceira et al. in 2006 (168), and, accordingly, I observed LVEF to increase with 
age in HVOL and LVEDV to decrease with increasing age (in both males and females). As far 
as LVWT is concerned, I observed an increase of LVWT with increasing age in HVOL, as 
outlined by previous studies on healthy subjects conducted using echocardiographic 
measurements (185) or CMR (186). As I explained in Paragraph 2.3.2, CMR LVWT 
measurements were different in DCM and HVOL. I analysed the maximum LVWT in DCM 
subjects, and the anteroseptal LVWT in controls. This would introduce a bias if measurements 
were used to analyse differences between cases and controls, and direct statistical 
comparison cannot be made. However, I performed genotype-phenotype analyses in the two 
cohorts separately, thus not introducing biases.  
As far as DCM patients are concerned, LVEF follows an opposing trend compared to HVOL: as 
age increases, LVEF decreases in both males and females. LVEDVi in DCM remains 
approximately unchanged in males, while it increases slightly in females, as age increases. In 
spite of LVWT having been measured at different positions in DCM and HVOL, it follows the 
same trend in the two cohorts, increasing with increasing age in both male and female DCM 
patients, as in healthy controls. 
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Figure 2.11 -Effects of age and sex on LVEF, indexed LVEDVi and LVWT in HVOL DCM patients. Each CMR parameter is plotted 
against age at time of scan. Plots show individual samples as points (light blue=males, dark pink=females) with linear 
regression lines and 95% confidence intervals. 
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Whilst not making a direct statistical comparison of LVWT measures in cases and controls for 
the reasons outlined above, I compared the two cohorts over LVEF and LVEDVi. As shown in 
Table 2.13 and in Figure 2.12,the distribution of both parameters was substantially distinct in 
DCM and HVOL, and the spread of both parameters was greater in the DCM cohort, likely 
reflecting the broad spectrum of disease.  
Table 2.14 shows how the proportions in terms of categorical variables - as well as the 
distributions of the three cardiac parameters on which I performed the genotype-phenotype 
analysis – changed with the prior exclusion of samples on the basis of their ethnicities and 
sequencing quality in the two cohorts. As displayed in the table, the only significant difference 
was detected in terms of LVEDVi in the excluded HVOL samples (77.2±12.7 mL/mm2) 
compared to those retained for final analysis (82.4±13.2 mL/mm2). However, results were not 
suggestive of systematic biases introduced by the prior exclusion of samples on the basis of 
ethnic background and/or sequencing quality. 
Table 2.13 - Direct comparison of the distributions of LVEF and LVEDVi measurements to assess the difference between DCM 
patients and HVOL. Statistical comparison was performed by means of Mann-Whitney U tests, and p-values have been 
Bonferroni-corrected for the testing of two parameters. 
 DCM HVOL 
P-VALUE 
MEAN SD MEAN SD 
LVEF (%) 38.9 12.7 64.8 5.3 1.5x10-82 
LVEDVi (mL/mm2) 129.4 42.5 82.4 13.2 4.8x10-60 
 
Figure 2.12 - Boxplots providing an overview comparison of LVEF and LVEDVi in DCM patients and healthy volunteers, 
stratified by gender. 
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Table 2.14 -Overview and comparison of samples’ proportions relating to categorical variables and distributions of cardiac 
phenotype parameters between the samples retained for final analysis and those excluded beforehand on the basis of non-
Caucasian ethnicity and sequencing quality. Fisher exact tests have been adopted to compare proportions, while Mann-
Whitney U tests have been used to compare distributions. In cases in which the nominal p value was significant, I also 
displayed in brackets the p value following adjustment for performing 21 tests. Values were computed on those samples for 
which data were available, therefore different proportions and means might have been computed on different number of 
samples.  
 
VARIABLE / CLASS 
PERCENTAGE 
OR MEAN±SD 
IN SAMPLES 
EXCLUDED 
FROM FINAL 
ANALYSIS 
(n=173 DCM, 
101 HVOL) 
PERCENTAGE 
OR MEAN±SD 
IN SAMPLES 
RETAINED FOR 
FINAL 
ANALYSIS 
(n=332 DCM, 
319 HVOL) 
NOMINAL P-
VALUE (ADJ 
P)  
DCM 
prospectives 
only 
Family history of DCM 14.6% 14.4% 1 
History of myocarditis 7.1% 3.4% 0.17 
History of alcohol excess 16.5% 12.2% 0.31 
History of chemotherapy 0.9% 7.5% 0.01 (0.21) 
History of iron overload 1.7% 1.1% 0.64 
Conduction disease 32.7% 31.5% 0.90 
Peripartum 4.1% 1.5% 0.16 
Bystander CAD 6.8% 6.2% 0.83 
LVEF 37.5±12.9 38.9±12.7 0.27 
LVEDVi 128.4±32.0 129.4±42.5 0.34 
LVWT 8.5±2.1 8.2±1.7 0.40 
DCM all Sex: Male 74.1% 74.1% 1 
HVOL 
LVEF 65.0±5.3 64.9±5.3 0.85 
LVEDVi 77.2±12.7 82.4±13.2 
1.5x10-4 
(3.2x10-3) 
LVWT 6.9±1.7 7.3±1.7 0.11 
 
2.4.2 Statistical power in comparing 332 cases and 319 controls 
Truncating variants in TTN were reported in literature to cause 24% of familial DCM cases (25) 
(with observed frequencies of 27% in DCM and 3% in healthy controls). Considering our 
sample size, the comparison of 332 cases with 319 controls provides full statistical power 
(100%) to replicate this finding with a significance level α=0.05. The second gene most 
commonly causing DCM is reported to be LMNA, with 6% of cases explained (15). I estimated 
from the ESP data the background frequency for potentially disease causing variation in LMNA 
in ~0.5% (23 protein-altering variants with MAF≤0.107% in 4300 European-American samples 
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sequenced (187). Assuming these estimates to reflect the true burden of variation in cases 
and controls, our sample size provided adequate power (99.4%) to test the burden of 
potentially disease-causing variants in the main disease genes such as LMNA. As far as the 
gene set level is concerned and excluding TTN, which accounts for a much greater proportion 
of cases than the rest of the genes, variants in other susceptibility genes are reported to cause 
~30% of DCM cases (12). The background burden in the control population is unknown, but 
with our cohorts power would be adequate (≥80%) with up to 21.5% of controls carrying 
disease-causing variation in the gene set.  
2.4.3 Prevalence of rare, protein-altering variants in DCM cases and controls 
Preliminary burden testing on each of the 64 genes was performed for novel variants (absent 
from EurESP/1KGP) and for variants at ten sequentially increasing allele frequencies (from 
novel, to an upper limit of X=10 alleles (1:X alleles) in EurESP/1KGP), to obtain a more inclusive 
assessment of the contribution of rare (not just novel) genetic variation underlying DCM. In 
Table 2.15, I report what was the highest rare-allele frequency enrichment value in DCM vs 
HVOLs, observed over the 11 ranges of allele frequencies tested (novel variants only + 10 
additional and increasingly inclusive frequency ranges).  
Twenty-six genes did not show any enrichment of rare variation in DCM as compared to 
controls, at any frequency cut-off, and these genes were discarded from further analyses. 
Targeting novel coding variation in the retained 38-gene set, burden testing revealed the 
highest enrichment observed over all allele frequencies in the disease cohort (56.3%, DCM; 
37.6%, controls; one-tailed Fisher test p=1.21x10-6). After correcting for multiple testing of 66 
genes, TTN truncating variants (TTNtv) were significantly enriched in DCM (12.7%, DCM; 1.9%, 
controls, adj. p=2.5x10-6), but none of the other genes or variant types showed a significant 
enrichment of rare coding variation in disease cases. In contrast with TTNtv, I did not detect 
an enrichment of non-truncating variation in TTN (TTNnt), for which the highest observed 
excess in DCM was 0.7% (38.9% DCM, 38.2% HVOL considering variants with MAF≤0.052%, 
nominal p-value = 0.47), and I did not detect an enrichment >3% in any of the other 
genes, which could also reflect low statistical power for single genes, but certainly highlights 
how the high background variation rate in controls may lead to a re-estimation of the 
contribution of each gene to DCM. Given the increasingly inclusive nature of the targeted 
variant frequency ranges (with novel variants being included in the tested variation all 11 
110 
 
times, and, at the opposite end of the spectrum, variants observed 10 times in EurESP/1KG 
being tested only once, in the widest frequency range), I chose not to formally correct for the 
multiple testing of 11 frequency ranges, but to limit the multiple testing correction to the 66 
genes analysed. However, as can be inferred from Table 2.15, an additional multiple testing 
correction for 11 frequency ranges would have led to the same result, with TTN truncating 
variants being the only variant class characterized by a significant enrichment in DCM. TTN 
truncating variants were the only variants on which systematic confirmation of NGS findings 
was performed by Sanger sequencing, in the context of the study on TTNtv performed by the 
group (26) while this work was produced. 
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Table 2.15 - Prevalence of rare, protein-altering variation in the 64 cardiomyopathy genes included in the study, in DCM cases and controls. The 
proportion of DCM cases and controls (in %, represented by blue bars, bars out of scale are represented in light blue and with breaks) carrying at 
least one rare, protein-altering variant in each gene is displayed. The corresponding number of cases and controls is indicated. For each gene, I 
report the highest enrichment observed over all cut-offs analysed, the cut-off relating to each observation is displayed in terms of maximum 
number of alleles observed in EurESP/1KG (in case of consecutive cut-offs characterized by the same figure, I reported the most inclusive (e.g. if 
frequency did not change between “novel” and “Max 10 alleles”, I report “Max 10”). Displayed P values are obtained with one-tailed Fisher exact 
tests and colour-coded by significance (RED=nominally significant and significant after multiple-testing correction, ORANGE=nominally 
significant, GREEN=not significant). Genes written in italic have been excluded from further analysis due to a lack of variation enrichment in DCM.  
GENE
PROPORTION OF
DCM CASES (n=332)
PROPORTION OF
HVOL (n=319)
N 
DCM
N 
HVOL
NOMINAL 
P-VALUE
FDR-ADJ 
P-VALUE
EXCESS 
FREQ
IN DCM
FREQ 
CUTOFF 
(MAX 
ALLELES
 IN EURESP
/1KG) 
TTN (truncations) 12.7% 1.9% 42 6 3.81x10-8 2.48x10-6 10.8% 10
LMNA 3.3% 0.3% 11 1 3.62x10-3 0.095 3.0% 10
RBM20 4.5% 1.9% 15 6 0.045 0.471 2.6% 5
LAMA2 6.0% 3.4% 20 11 0.087 0.471 2.6% 6
MYPN 2.4% 0.0% 8 0 4.39x10-3 0.095 2.4% 10
DSP 3.6% 1.3% 12 4 0.044 0.471 2.3% 0
MYBPC3 3.9% 1.6% 13 5 0.055 0.471 2.3% 1
LDB3 2.1% 0.0% 7 0 8.70x10-3 0.141 2.1% 5
MYH7 3.6% 1.6% 12 5 0.081 0.471 2.0% 1
PKP2 2.7% 0.9% 9 3 0.081 0.471 1.8% 2
TNNT2 1.2% 0.0% 4 0 0.067 0.471 1.2% 4
CALR3 1.2% 0.0% 4 0 0.067 0.471 1.2% 10
FKTN 1.5% 0.3% 5 1 0.118 0.505 1.2% 10
LAMA4 3.0% 1.9% 10 6 0.25 0.855 1.1% 10
DES 0.9% 0.0% 3 0 0.132 0.505 0.9% 0
RAF1 0.9% 0.0% 3 0 0.132 0.505 0.9% 10
TCAP 0.9% 0.0% 3 0 0.132 0.505 0.9% 1
MYL2 0.9% 0.0% 3 0 0.132 0.505 0.9% 10
BAG3 1.2% 0.3% 4 1 0.199 0.719 0.9% 5
SCN5A 3.9% 3.1% 13 10 0.372 0.87 0.8% 10
TTN (non-truncating) 38.9% 38.2% 129 122 0.468 0.87 0.6% 5
NEXN 0.9% 0.3% 3 1 0.327 0.87 0.6% 0
CRYAB 0.9% 0.3% 3 1 0.327 0.87 0.6% 10
VCL 0.9% 0.3% 3 1 0.327 0.87 0.6% 3
TNNC1 0.3% 0.0% 1 0 0.51 0.87 0.3% 10
PLN 0.3% 0.0% 1 0 0.51 0.87 0.3% 10
ACTC1 0.3% 0.0% 1 0 0.51 0.87 0.3% 10
MYL3 0.3% 0.0% 1 0 0.51 0.87 0.3% 10
TAZ 0.3% 0.0% 1 0 0.51 0.87 0.3% 10
SGCD 0.3% 0.0% 1 0 0.51 0.87 0.3% 10
LAMP2 0.3% 0.0% 1 0 0.51 0.87 0.3% 10
TRIM63 0.6% 0.3% 2 1 0.515 0.87 0.3% 4
TP63 0.6% 0.3% 2 1 0.515 0.87 0.3% 10
PTPN11 0.6% 0.3% 2 1 0.515 0.87 0.3% 10
MYOZ2 0.6% 0.3% 2 1 0.515 0.87 0.3% 10
112 
 
GENE
PROPORTION OF
DCM CASES (n=332)
PROPORTION OF
HVOL (n=319)
N 
DCM
N 
HVOL
NOMINAL 
P-VALUE
FDR-ADJ 
P-VALUE
EXCESS 
FREQ
IN DCM
FREQ 
CUTOFF 
(MAX 
ALLELES
 IN EURESP
/1KG) 
TNNI3 0.6% 0.3% 2 1 0.515 0.87 0.3% 10
CASQ2 0.9% 0.6% 3 2 0.519 0.87 0.3% 1
DTNA 0.9% 0.6% 3 2 0.519 0.87 0.3% 10
PRKAG2 1.2% 0.9% 4 3 0.522 0.87 0.3% 10
CSRP3 0.0% 0.0% 0 0 1 1 0.0% 10
DNAJC19 0.0% 0.0% 0 0 1 1 0.0% 10
TPM1 0.0% 0.0% 0 0 1 1 0.0% 10
CAV3 0.0% 0.0% 0 0 1 1 0.0% 10
PDLIM3 0.0% 0.0% 0 0 1 1 0.0% 10
ILK 0.9% 0.9% 3 3 0.676 0.994 0.0% 7
SDHA 0.9% 0.9% 3 3 0.676 0.999 0.0% 1
TMEM43 0.3% 0.3% 1 1 0.76 1 0.0% 10
SYNM 3.3% 3.4% 11 11 0.623 1 -0.1% 10
ACTN2 1.5% 1.6% 5 5 0.648 1 -0.1% 8
EMD 0.0% 0.3% 0 1 1 1 -0.3% 10
FXN 0.0% 0.3% 0 1 1 1 -0.3% 10
GLA 0.0% 0.3% 0 1 1 1 -0.3% 3
CTF1 0.0% 0.3% 0 1 1 1 -0.3% 10
GATA4 0.6% 0.9% 2 3 0.826 0.994 -0.3% 10
DSG2 1.8% 2.2% 6 7 0.736 1 -0.4% 10
RYR2 3.0% 3.4% 10 11 0.704 1 -0.4% 0
JPH2 0.0% 0.6% 0 2 0.627 1 -0.6% 7
JUP 0.3% 0.9% 1 3 0.943 1 -0.6% 0
ABCC9 0.3% 0.9% 1 3 0.943 1 -0.6% 10
ANKRD1 0.6% 1.3% 2 4 0.901 1 -0.7% 10
DSC2 2.4% 3.1% 8 10 0.789 1 -0.7% 6
SOS1 0.6% 1.6% 2 5 0.945 1 -1.0% 10
MYH6 1.2% 2.2% 4 7 0.901 1 -1.0% 2
DMD 2.4% 3.8% 8 12 0.89 1 -1.4% 10
SYNE1 4.5% 7.2% 15 23 0.949 1 -2.7% 0
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TTN harbours a markedly higher burden of rare variants in the general population as 
compared to the other 37 genes retained in the analysis: more than 45% of controls had at 
least one protein-altering variant with MAF≤0.107% in TTN as opposed to an average of 0.9% 
of controls for the other 37 genes. I performed a sample size calculation to ascertain the 
numbers needed to detect enrichment of variants not caused by sampling errors in each of 
the other genes and found that, on average, ~1750 samples per group would be needed to 
ensure 80% power in testing the burden over each single gene, excluding TTN. 
In light of this result, I kept TTN separate from the other 37 genes altogether in downstream 
analyses, discerning between truncations and non-truncating variants. Figure 2.13 shows 
excess frequency and aetiological fraction for the 4 categories of variation alongside each 
single gene retained in the analysis, reflecting their estimated contribution to disease and 
interpretability in the clinical context. I built logistic regression models to assess the 
importance of these classes of genetic variants in determining DCM, and results confirmed 
the determinant role of both non-truncating variants and truncations in the 37-gene set, as 
well as that of truncations in TTN, in increasing the risk of DCM (Figure 2.14). 
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Figure 2.13 – Interpreting genetic variation in DCM genes. The Excess frequency (%) of rare variation in DCM genes (in cases 
vs controls) is plotted against the aetiological fraction (as explained in Paragraph 2.3.5; an estimate of the proportion of 
variants that are penetrant and pathogenic).  Y captures the importance of each gene (contribution to disease or clinical 
sensitivity), and X captures interpretability (clinical applicability when a variant is found). Black dots summarise results for 
the three main categories of variants: protein-truncating variants in TTN (TTNtv), protein-truncating variants in other genes 
combined (n=37, Other_tv), non-truncating variants in TTN (TTNnt) and non-truncating variants in other genes combined 
(n=37, Other_nt). Grey dots show the same information for each of the 38 genes analysed. The size of circles is representative 
of the number of genes represented by the data point. Confidence intervals are not shown for single genes. For each category 
and gene, I report the figure observed at the frequency cut-off characterized by the highest variation excess frequency in 
DCM.  
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Figure 2.14 - Forest plot showing the odds ratio (inferred from logistic regression) of having DCM for carriers of truncating 
and non-truncating variants in TTN (TTNtv and TTNnt, respectively) and in other genes (n=37, Other_tv and Other_nt, 
respectively). Bars represent 95% confidence intervals for the odds ratio. For each category, I report the figure observed at 
the frequency cut-off characterized by the highest variation excess frequency in DCM. 
2.4.3.1 Impact of the release of ExAC data on this study’s results 
ExAC data (described in Paragraph 1.5.2.3) were released and made publicly accessible in 
October 2014, while this study was in process and using EurESP/1KGP as reference cohorts 
for variants’ frequencies in the general population. Although not all healthy, the 60,706 
individuals included in the ExAC constitute an enormous reference cohort, about 7 times 
larger than the ESP and 1KGP cohorts combined. Several variants that are considered to be 
novel in this study (as absent in EurESP+1KGP, that I used as reference cohort) are instead 
observed recurrently in the 33,370 samples of European ethnic background (excluding the 
Finns) comprised by the ExAC cohort. While the MAF of the same variant is likely to be similar 
in both cohorts, using such a large cohort as reference population may allow a finer dissection 
of variants based on their MAF. Due to time constraints, I could not repeat the whole analysis 
substituting EurESP+1KGP with the ExAC samples of European descent (EurExAC), but I 
compared the burden of protein-altering variants absent in EurExAC in DCM cases and HVOL. 
As compared to the previous analysis, when I considered absence in EurESP/1KGP to define 
novelty, 35.9% of genes (n=23) were characterized by a higher excess frequency in DCM than 
in the previous analysis, while 31.3% (n=20) showed a lower excess frequency in disease. The 
remaining genes showed no difference (Table 2.16). The difference in terms of novel variation 
excess frequency in DCM observed between using EurExAC and EurESP/1KGP as reference 
cohort was not significant overall (Mann-Whitney U test for paired data p=0.58 considering 
all 64 genes, with a mean difference at the single gene level of +0.03% when using EurExAC). 
This suggests that, at least at the gene set level, EurESP/1KGP is a “proxy” for the general 
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population large enough to provide reliable estimates of variants’ frequencies. However, this 
doesn’t take away the fact that, the larger the reference cohort, the more precise the 
measures of variation frequencies, and indeed for some single genes the observed difference 
was marked (e.g. MYH6, +1.6% excess frequency in DCM when using EurExAC), and it would 
be warranted to re-perform the whole analysis using EurExAC as reference group for variant 
frequencies. Table 2.16 shows the frequencies of variants absent in EurExAC samples in DCM 
and HVOL, and the comparison in terms of excess frequencies in DCM between using 
EurESP/1KGP and EurExAC to define novelty. 
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Table 2.16 - Prevalence of novel variation (absent from the reference cohort used – EurExAC on the left hand side, 
EurESP/1KGP on the right) in the 64 cardiomyopathy genes included in the study, in DCM cases and controls. The proportion 
of DCM cases and controls (in %) carrying at least one variant in each gene is displayed. The corresponding number of cases 
and controls is indicated in brackets. For each gene, I report the frequencies of novel variants obtained using EurExAC and 
EurESP/1KGP as reference cohorts, and the net difference in excess variation frequency observed in DCM compared to 
controls. Displayed P values are obtained with one-tailed Fisher exact tests and not corrected for multiple testing. TTN variants 
are shown altogether, as well as divided between truncating and non-truncating variants (the sum of the number of samples 
with TTNtv and TTNnt is not equal to the number of samples with any of the two since some samples carry both types of TTN 
variation). 
 Variation absent in EurExAC samples (n=33,370) 
Variation 
absent 
in EurESP/1KGP 
samples 
(n=4,679) 
Net difference in 
excess frequency in 
DCM using 
EurExAC to define 
novelty 
GENE 
DCM cases 
(n=332) 
Controls 
(n=319) 
Nominal 
p-value 
Excess 
frequen
cy 
in DCM 
Excess 
frequency 
in DCM 
TTN (truncations) 11.7% (39) 1.6% (5) 5.71x10-8 10.2% 10.2% 0.0% 
TTN (any) 24.7% (82) 16% (51) 0.004 8.7% 7.7% 1.0% 
RBM20 3.3% (11) 0.6% (2) 0.013 2.7% 2.3% 0.4% 
DSP 2.7% (9) 0.6% (2) 0.037 2.1% 2.4% -0.3% 
MYH7 2.4% (8) 0.3% (1) 0.022 2.1% 2.0% 0.1% 
LMNA 1.8% (6) 0% (0) 0.017 1.8% 2.4% -0.6% 
CALR3 1.2% (4) 0% (0) 0.067 1.2% 1.2% 0.0% 
PKP2 1.8% (6) 0.6% (2) 0.156 1.2% 1.8% -0.6% 
TNNT2 1.2% (4) 0% (0) 0.067 1.2% 1.2% 0.0% 
RAF1 0.9% (3) 0% (0) 0.132 0.9% 0.9% 0.0% 
BAG3 0.6% (2) 0% (0) 0.260 0.6% 0.3% 0.3% 
DES 0.6% (2) 0% (0) 0.260 0.6% 0.9% -0.3% 
DTNA 0.6% (2) 0% (0) 0.260 0.6% 0.0% 0.6% 
MYBPC3 1.8% (6) 1.3% (4) 0.401 0.6% 1.1% -0.5% 
MYPN 0.6% (2) 0% (0) 0.260 0.6% 1.2% -0.6% 
TCAP 0.6% (2) 0% (0) 0.260 0.6% 0.9% -0.3% 
TTN (non-truncating) 14.8% (49) 14.4% (46) 0.496 0.3% -0.1% 0.4% 
ACTC1 0.3% (1) 0% (0) 0.510 0.3% 0.3% 0.0% 
LDB3 0.3% (1) 0% (0) 0.510 0.3% 1.2% -0.9% 
MYH6 0.6% (2) 0.3% (1) 0.515 0.3% -1.3% 1.6% 
MYOZ2 0.3% (1) 0% (0) 0.510 0.3% 0.0% 0.3% 
NEXN 0.6% (2) 0.3% (1) 0.515 0.3% 0.6% -0.3% 
PLN 0.3% (1) 0% (0) 0.510 0.3% 0.3% 0.0% 
TNNC1 0.3% (1) 0% (0) 0.510 0.3% 0.3% 0.0% 
SCN5A 1.8% (6) 1.6% (5) 0.527 0.2% -0.7% 0.9% 
ACTN2 0% (0) 0% (0) 1.000 0.0% -0.6% 0.6% 
CAV3 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
CRYAB 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
CSRP3 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
DNAJC19 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
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DSG2 0.3% (1) 0.3% (1) 0.760 0.0% -0.7% 0.7% 
FKTN 0.3% (1) 0.3% (1) 0.760 0.0% 0.6% -0.6% 
LAMP2 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
MYL2 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
MYL3 0% (0) 0% (0) 1.000 0.0% 0.3% -0.3% 
PDLIM3 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
PTPN11 0.3% (1) 0.3% (1) 0.760 0.0% 0.0% 0.0% 
SGCD 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
TAZ 0% (0) 0% (0) 1.000 0.0% 0.3% -0.3% 
TNNI3 0.3% (1) 0.3% (1) 0.760 0.0% -0.3% 0.3% 
TPM1 0% (0) 0% (0) 1.000 0.0% 0.0% 0.0% 
TRIM63 0.3% (1) 0.3% (1) 0.760 0.0% 0.3% -0.3% 
VCL 0% (0) 0% (0) 1.000 0.0% -0.3% 0.3% 
ABCC9 0% (0) 0.3% (1) 1.000 -0.3% -0.9% 0.6% 
CASQ2 0.3% (1) 0.6% (2) 0.883 -0.3% 0.3% -0.6% 
CTF1 0% (0) 0.3% (1) 1.000 -0.3% -0.3% 0.0% 
EMD 0% (0) 0.3% (1) 1.000 -0.3% -0.3% 0.0% 
FXN 0% (0) 0.3% (1) 1.000 -0.3% -0.3% 0.0% 
GLA 0% (0) 0.3% (1) 1.000 -0.3% -0.3% 0.0% 
ILK 0% (0) 0.3% (1) 1.000 -0.3% -0.6% 0.3% 
JUP 0% (0) 0.3% (1) 1.000 -0.3% -0.6% 0.3% 
LAMA4 0.6% (2) 0.9% (3) 0.826 -0.3% 0.6% -0.9% 
SDHA 0.3% (1) 0.6% (2) 0.883 -0.3% -0.6% 0.3% 
SOS1 0.3% (1) 0.6% (2) 0.883 -0.3% -1.3% 1.0% 
TMEM43 0% (0) 0.3% (1) 1.000 -0.3% 0.0% -0.3% 
TP63 0% (0) 0.3% (1) 1.000 -0.3% 0.3% -0.6% 
SYNM 0% (0) 0.6% (2) 1.000 -0.6% -1.3% 0.7% 
ANKRD1 0% (0) 0.6% (2) 1.000 -0.6% -0.9% 0.3% 
JPH2 0% (0) 0.6% (2) 1.000 -0.6% -0.6% 0.0% 
PRKAG2 0% (0) 0.6% (2) 1.000 -0.6% -0.6% 0.0% 
DSC2 1.5% (5) 2.2% (7) 0.827 -0.7% -1.0% 0.3% 
GATA4 0% (0) 0.9% (3) 1.000 -0.9% -0.6% -0.3% 
DMD 0.9% (3) 1.9% (6) 0.921 -1.0% -1.9% 0.9% 
LAMA2 1.2% (4) 2.2% (7) 0.901 -1.0% 1.1% -2.1% 
RYR2 2.1% (7) 3.1% (10) 0.857 -1.0% -0.4% -0.6% 
SYNE1 1.8% (6) 3.4% (11) 0.941 -1.6% -2.7% 1.1% 
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2.4.4 Evidence for multi-genic variation underlying DCM 
The excess frequency of any category of variation (in this case: protein-altering and at 
different frequency ranges up to ≤10 alleles observed in EurESP/1KGP) can be split in two 
components: the excess of samples with monogenic variation, and that of individuals with 
variants in multiple genes (multigenic). Table 2.17 shows the total number of variants and 
carrier samples per cohort with the corresponding frequency enrichment in DCM, as well as 
the breakdown between samples with monogenic and multigenic variation, over each of the 
11 frequency cut-offs analysed. Performing this analysis, TTNnt variants were included in all 
counts. The highest enrichment of DCM samples with mono-genic rare, coding variation was 
observed for novel variants (41.3% DCM (n=137) versus 31.7% HVOLs (n=101), excess 
frequency in DCM = 9.6%; p=6.9x10-3). However, for a given disease prevalence, individual 
variants contributing instead to a multigenic model of genetic disease, whether recessive 
mono-genic or multi-genic, may have a higher allele frequency than variants that cause 
dominant disease, as the frequency at which two alleles are found in combination is 
proportional to the product of their individual frequencies (under Hardy-Weinberg 
equilibrium). I therefore considered again all the 11 frequency ranges of allele frequencies (0-
11 alleles) when assessing potential multi-genic disease. In these analyses I detected the 
highest excess frequency of multi-genic variation for variants observed up to 5 times in 
EurESP/1KGP (MAF≤0.052%; 26.8% DCM (n=89) and 12.9% HVOL (n=41), excess frequency in 
DCM 13.9%, p=5.5x10-6). Figure 2.15 graphically recapitulates the excess frequency in DCM of 
monogenic and multigenic variation, over the 11 frequency cut-offs analysed, while Figure 
2.16 shows the proportion of samples with no variation, monogenic variation and multigenic 
variation in the two cohorts, considering variants observed up to 5 times in EurESP/1KG. 
Focusing on this frequency range, I used nested logistic regression models to assess the 
effective importance of the number of variant genes in determining DCM. I compared through 
LRT a first model predicting the status (DCM or control) of samples solely on the basis of the 
presence/absence of rare variants in the gene set (Status ~ presence_of_variation), to a 
second taking also into account the number of variant genes (Status ~ presence_of_variation 
+ number_of_genes). While the simple presence of variation, in the first model was 
significantly linked to disease (OR 2.05, 95% CI 1.49-2.82, p=1.1x10-5), the additional 
information of the number of genes harbouring a variant, added as an independent variable, 
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markedly improved the model (LRT p=5.9x10-4), demonstrating an additive effect of multiple 
variant genes on DCM risk. Controlling for the presence of variation, the OR for an additional 
gene being altered in DCM was 1.74 (95% CI 1.26-2.46, p=1.1x10-3). These data demonstrate 
an important role of multigenic variation underlying DCM risk.
121 
 
Table 2.17 -Number of variants, carrier samples (divided in those with monogenic and multigenic variation) and corresponding proportions of individuals carrying rare, protein-altering variation 
at each of the 11 frequency cut-offs analysed, on the whole set of 38 genes retained in the analysis after the exclusion of those showing no excess at any of the cut-offs. TTNnt variants were 
included in all counts. 
MAX N 
OBS IN 
EURESP
/ 
1KG 
N 
VARS 
IN 
332 
DCM 
N 
VARS 
IN 
319 
HVOL 
N DCM 
SAMPLES 
WITH 
VARS 
OF 
WHICH 
MONO 
GENIC 
OF WHICH 
MULTI 
GENIC 
N HVOL 
SAMPLES 
WITH 
VARS 
OF 
WHICH 
MONO 
GENIC 
OF 
WHICH 
MULTI 
GENIC 
PROP 
DCM 
WITH 
VARS 
PROP 
HVOL 
WITH 
VARS 
EXCESS 
FREQ 
IN DCM 
OF 
WHICH 
MONO 
GENIC 
OF 
WHICH 
MULTI 
GENIC 
0 277 161 187 137 50 120 101 19 56.3% 37.6% 18.7% 9.6% 9.1% 
1 315 192 205 142 63 141 116 25 61.7% 44.2% 17.5% 6.4% 11.1% 
2 343 215 215 148 67 151 117 34 64.8% 47.3% 17.4% 7.9% 9.5% 
3 363 224 223 148 75 157 122 35 67.2% 49.2% 18.0% 6.3% 11.6% 
4 378 238 226 143 83 165 128 37 68.1% 51.7% 16.3% 2.9% 13.4% 
5 399 248 229 140 89 166 125 41 69.0% 52.0% 16.9% 3.0% 13.9% 
6 407 254 232 142 90 171 126 45 69.9% 53.6% 16.3% 3.3% 13.0% 
7 413 263 235 144 91 176 129 47 70.8% 55.2% 15.6% 2.9% 12.7% 
8 420 269 237 146 91 181 132 49 71.4% 56.7% 14.6% 2.6% 12.0% 
9 427 276 239 145 94 185 134 51 72.0% 58.0% 14.0% 1.7% 12.3% 
10 434 284 239 142 97 186 131 55 72.0% 58.3% 13.7% 1.7% 12.0% 
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Figure 2.15 - Excess frequency of protein-altering variation in the 38-gene set, at the 11 analysed frequency cut-offs. The dark 
green bar indicated the strongest excess observed for samples with mono-genic variation, while the dark purple bar shows 
the strongest excess given by samples with multi-genic variation. 
 
Figure 2.16 -Proportion of samples, in the two cohorts, with no variation, monogenic, or multigenic variation considering 
variants observed up to 5 times in EurESP/1KG (the frequency range characterized by the greatest excess of multi-genic 
variation in DCM, as shown in Table 2.17 and Figure 2.15.  
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2.4.5 Evidence of a specific di-genic interaction between TTN and RBM20 in 
DCM 
2.4.5.1 Evidence in the discovery cohorts 
Having detected a signature of an important multigenic effect underlying DCM, I wanted to 
investigate whether particular combinations of variant genes were more commonly 
encountered in DCM patients, examining rare variation with MAF≤0.052%. I used Monte Carlo 
permutation sampling to randomize cases and controls (100,000 iterations) and assessed 
whether the co-occurrence of variation in any gene-gene combination among those for which 
I was sufficiently powered (the 37 gene pairs TTN+X, since TTN is the only gene for which we 
were fully powered with our sample size, as explained in Paragraph 2.4.2) was significantly 
more common than expected in patients, based on the variation frequencies of the two single 
genes. The only gene-gene combination characterized by an enrichment significantly higher 
than expected, after correcting for multiple testing with the Bonferroni method was 
TTN+RBM20 (10 of 332 DCM and none of the controls, empirical p-value derived from 
permutations 3.7x10-2). Dividing TTN variants in truncating and non-truncating, permutation 
testing showed that enrichment of variants was significant for TTNnt+RBM20 (9 of 332 DCM 
and none of the controls, p=2.4x10-3), also when excluding patients with both TTNnt and 
TTNtv (7 of 332 DCM and none of the controls, p=9.2x10-3) but not for TTNtv+RBM20 (3 of 
332 DCM and none of the controls, p=0.13). 
2.4.5.2 Replication in independent cohorts 
As described in Paragraph 2.4.2, I attempted to replicate burden testing and permutation 
testing for variants in TTN and RBM20 in DCM in independent cohorts (n=386 DCM and n=514 
HVOL, described in Paragraph 2.3.4). In replication cohorts, I could test only the TTN:RBM20 
interaction (the only significant interaction in the primary analysis) as only sequencing data 
on these two genes were available from collaborators. After the application of the same 
quality controls on the variant level as done for data from the study cohorts, I filtered variants 
for those annotated as protein-altering in Ensembl canonical transcripts by the Ensembl VEP 
(94). Since the ethnicity of the replication samples was mixed (<20% non-Caucasians), I used 
the whole ESP/1KGP cohorts (6503 samples from ESP + 1092 from Phase 1 of 1KGP) as 
reference population in this case, and tested variants observed up to 16 times in ESP/1KGP 
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(MAF≤0.105%, the closest possible MAF cut-off to the one applied for the study cohorts), once 
more dissecting variation in different frequency ranges in the form 0-X alleles. The very similar 
frequency of coding synonymous variants (with MAF≤0.105%) in the two cohorts ensured 
equal variant detection in cases and controls (24.1% in DCM, n=93; 25.1% in HVOL, n=129; 
two-tailed Fisher p=0.76). Permutation testing detected variants in TTN and RBM20 to co-
occur significantly more often than expected in DCM when considering variation observed up 
to 4 times in ESP/1KGP (corresponding to MAF≤0.027%, 8 of 386 DCM and 2 of 514 HVOLs, 
empirical p-value derived from permutation testing = 1.9x10-2). The slightly different variation 
frequency range at which I detected a significant co-occurrence of variation in TTN and 
RBM20 in DCM in discovery and replication cohorts (MAF≤0.052% and MAF≤0.027%, 
respectively) might be due to the slightly different ethnic composition of discovery and 
replication samples, and/or to sampling effects caused by the small size of the cohorts to 
provide optimal power in the detection of multi-genic interactions. 
As in the discovery cohorts, the enrichment of the double gene alteration considering only 
TTNnt variants (TTNnt+RBM20) was significant (8 of 386 DCM and 2 of 514 HVOL, p=2.0x10-
2), also when excluding samples carrying a TTNtv (7 of 386 DCM and 2 of 514 HVOL, p=3.7x10-
2), while it was not for TTNtv+RBM20 variation (1 of 386 DCM and 2 of 514 HVOL, p=0.43). By 
combining the results for both the discovery and replication cohorts there was significant 
enrichment in coincident variation for TTN+RBM20 (p=5.8x10-3), TTNnt+RBM20 (p=5.1x10-4), 
TTNnt+RBM20 excluding TTNtv carriers (p=3.1x10-3) but not for TTNtv+RBM20 (p=0.21). 
2.4.6 Effects of genetic variation on cardiac morphology and function 
2.4.6.1 Effects on the cardiac morphology and function of DCM patients 
I used linear regression models to assess the effect of rare coding variation in the 38 genes 
retained in the analysis on cardiac morphology and function of DCM patients, as described in 
Paragraph 2.3.10. Both age and sex were kept in the models predicting LVWT and LVEF, while 
only sex was retained in the model for LVEDVi, since age was not a significant predictor for 
LVEDVi in the “baseline” model (LVEDV~Age+Sex). All the p values reported were not 
corrected for multiple testing, as the three parameters I analysed are not independent of each 
other. However, I mark p-values with an asterisk in Figures Figure 2.17, Figure 2.18 and Figure 
2.19 if they would still be significant after Bonferroni correction for multiple testing of three 
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cardiac parameters. At the single gene level, a more severely thinned LV wall was associated 
with truncating variants in TTN (31 TTNtv +ve vs 195 TTNtv -ve: 7.5±1.2 mm vs 8.3±1.7 mm; 
p=5.0x10-3), variants in MYH7 (6 MYH7 +ve vs 220 MYH7 -ve: 6.1±1.3 mm vs 8.3±1.6 mm; 
p=6.9x10-3) and variants in TNNT2 (3 TNNT2 +ve vs 223 TNNT2 -ve: 5.8±0.8 mm vs 8.3±1.6 
mm; p=3.5x10-2), also when controlling for LVEDV, by adding in as a covariate to the 
regression model (LVEDV itself was a significant predictor of LVWT, p=2.9x10-4).  
Variants in LAMA2 were associated with lower EF (12 LAMA2 +ve vs 214 LAMA2 -ve: 31±14% 
vs 39±12%; p=1.7x10-2), while variants in LMNA were associated with a lower LVEDV (4 LMNA 
+ve vs 222 LMNA –ve: 92±10mL vs 130±42mL, p=3.9x10-2). An additive effect of the number 
of variant genes was observed for LVWT (p=9.3x10-3), and such association was stronger when 
considering only genes encoding proteins forming the sarcomere (p=1.3x10-3). Figure 2.17 
recapitulates the significant effects of genetic variation in single genes on the cardiac 
morphology and function of DCM patients, while Figure 2.18 shows the association between 
the number of variant genes and the degree of LV wall thinning in DCM. All reported p values 
were corrected for testing 3 cardiac parameters with the Bonferroni method. I obtained the 
same results by modelling an interaction between the gender of DCM patients and the 
presence of variation in genes on the X chromosome (namely, LAMP2 and TAZ).
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Figure 2.17 - Effects of single variant genes on the cardiac morphology and function of DCM patients. P-values marked with an asterisk would 
have remained significant after Bonferroni correction for testing 3 cardiac parameters.
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Figure 2.18 - Association between the number of variant genes and maximum left-ventricular wall thickness considering all analysed genes (n=38, on the left) and limiting the count to genes encoding sarcomeric 
proteins (n=17, on the right hand side). The association was observed only without including TTNnt variants, using 226 DCM samples. P-values marked with an asterisk would have remained significant after 
Bonferroni correction for testing 3 cardiac parameters.
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2.4.6.2 Effects on the cardiac morphology and function of healthy subjects 
Separately I assessed with the same procedure the effects of rare coding variation on the 
cardiac phenotype of healthy subjects (n=304, for which CMR data were complete). As 
indicated in Paragraph 2.4.6.1 for DCM patients, reported p-values were not corrected for 
multiple testing, as LVEF, LVEDVi and LVWT are not independent of each other. In the case of 
HVOL, both age and sex were kept as covariates in all three models (for LVEF, LVWT and 
LVEDVi), as they were both significant predictors in the “baseline” model for each parameter 
(LVEF/LVEDVi/LVWT ~ Age+Sex). I did not detect any association between genetic variants 
and LVWT, but truncating variants in TTN were associated with a lower LVEF (6 TTNtv +ve vs 
298 TTNtv -ve: 59.3±4.1 % vs 64.9±5.2 %; p=2.7x10-3) as well as variants in DSP (9 DSP +ve vs 
295 DSP -ve: 60.4±6.0 % vs 64.9±5.2 %; p=2.9x10-2) and in TP63 (1 TP63 +ve with LVEF=52 % 
vs 303 TP63 –ve with LVEF=64.8±5.2%; p=4.8x10-2). Variants in LAMA4 were instead 
significantly associated with a higher LVEF (6 LAMA4 +ve vs 298 LAMA4 -ve: 69.3±4.5 % vs 
64.7±5.2 %; p=1.3x10-2) Variation in SCN5A was associated with a larger LVEDV (10 SCN5A +ve 
vs 294 SCN5A -ve: 88.7±9.1 mL vs 82.3±13.4 mm; p=2.4x10-2), as displayed in Figure 2.19. 
No HVOLs had variants in the two genes located on the X chromosome and retained in the 
analysis after burden testing (LAMP2 and TAZ), therefore I could not model interactions 
between variation on chromosome X and the samples’ gender. 
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Figure 2.19 - Effects of single variant genes on the cardiac morphology and function of healthy subjects. P-values marked with 
an asterisk would have remained significant after Bonferroni correction for testing 3 cardiac parameters. 
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2.5 Discussion 
The general landscape of genetic causes of DCM is that of a highly genetically heterogeneous 
disease, with many genes each contributing to only a small proportion of the disease burden. 
In the past, this has hampered the efforts towards comprehensive genetic testing for DCM, 
given the need to screen such a large number of genes. Next-generation sequencing 
technologies have overcome this technical limitation, making finally possible to sequence 
large cohorts on increasingly larger genetic regions (188,189). Furthermore, the discovery of 
the leading role of titin variation in DCM helped in filling the gap of inconclusive genetic tests 
(20,25). However, a great obstacle in measuring each gene's contribution to the disease 
burden remained the necessity of well phenotyped healthy controls, needed to estimate the 
cumulative background rate of rare variants in the general population, and I addressed this 
limitation comparing DCM cases to a well-defined cohort of healthy volunteers, redrawing 
the contribution to the burden of DCM of genes previously associated with cardiomyopathies. 
Previously published studies, mostly using controls from publicly accessible populations, only 
reported the background frequency of single variants but did not assess the cumulative 
background frequency of potentially disease-causing variation for example on a gene-by-gene 
basis. 
2.5.1 Demographics and phenotypic parameters of cases and controls 
The DCM cohort available for study, composed of both unselected DCM patients 
prospectively recruited (representing the typical “through-the-door” patients), and end-stage 
DCM patients recruited retrospectively from a tissue biobank (representing highly selected 
severe cases considered for transplant), represents, as a whole, DCM patients in South East 
England, with the majority of individuals being males (74.3%) and Caucasians (86.5%). 
In order to minimise population stratification biases, I excluded by means of PCA all non-
Caucasian samples, and compared ethnically matched cases and controls. I retained the 
difference between DCM patients and HVOL samples in terms of gender (DCM retained for 
final analysis: 74.1% males, HVOL retained for final analysis: 46.1% males) acceptable for the 
purposes of this study. This for two reasons: in the first place, this is most likely to impact only 
burden figures for genes on the X chromosome (namely LAMP2, TAZ, DMD and EMD), due to 
variants in X-linked genes unlikely causing overt DCM in males, or variant genes leading to 
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DCM only in combination with sex-specific factors (e.g. hormonal). In the second place, 
matching the DCM cohort to the control cohort in terms of gender stratification would have 
required discarding 169 additional DCM male patients, leading to a dramatic loss of statistical 
power. The considerable difference in age between the cohort included in the final analysis 
(DCM: 53±17 years old, HVOL: 42±14 years old) probably did not introduce any bias, since the 
only risk would be that of some HVOL being latent DCM cases, and possibly developing DCM 
in the future. This event is, in the first place, unlikely to occur in more than one or two 
individuals, given the prevalence of DCM in the general population, and in the second place 
discarding older DCM patients or younger HVOL to age-match the two cohorts would not 
ensure the absence of this possibility, while instead leading to a further loss of statistical 
power. 
Due to the high difficulty in determining whether exposure to a particular risk factor is the 
primary cause of disease in any given case, and in absence of certainty regarding aetiology, 
patients with history of alcohol excess, iron overload, myocarditis, peripartum disease 
presentation, chemotherapy and bystander CAD were not excluded. While the presence of 
relative risk factors does not exclude a primary genetic cause of DCM, it must be kept in mind 
that, if exposures to these risk factors were the primary cause of disease, the nature of DCM 
in the analysed cohort would not be homogeneously idiopathic, therefore lowering the power 
of the study. Conversely, patients with a clear non-genetic primary cause of DCM were 
excluded. 
I detected a significant difference (p=3.2x10-3) in terms of LVEDVi between HVOL samples 
retained for final analysis (n=319, LVEDVi 82.4±13.2 mL/mm2) and those discarded prior to 
final analysis on the basis of their non-Caucasian ethnic background and sequencing quality 
(n=101, LVEDVi 77.2±12.7 mL/mm2). This may be due to Caucasian samples being 
characterized by higher average LVEDVi, compared to normal individuals from other ethnic 
groups, as recently reported in literature in comparison with South Asians (190) and especially 
with Indians (191), which constituted the largest ethnic group after Caucasians prior to the 
removal of non-Caucasian samples. 
2.5.2 Contribution of single genes to the burden of DCM 
I measured the prevalence of rare, protein-altering variation in cases and controls, and used 
the excess variation frequency in DCM patients as an estimated contribution to disease of 
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variants in the targeted region. Combining the excess frequency with the amount of 
background variation observed in controls, I could also estimate the disease-causing potential 
of variants in each gene, through their aetiological fraction (representing the proportion of 
variants in cases regarded penetrant and pathogenic). In this context, results on single gene 
burden tests back the disease association of several genes previously associated with DCM in 
literature, such as TTN, LMNA, RBM20, MYPN and MYH7, all observed within the top 10 genes 
in terms of enrichment of rare coding variants in DCM. Among the main DCM genes, 
truncating variants in TTN, as well as variation in LMNA, MYPN and TNNT2 seem markedly 
pathogenic, as characterized by an estimated aetiological fraction higher than 80%. 
2.5.2.1 Non-truncating variants in TTN are not interpretable in the context of DCM 
Results of this work confirm TTN to be the top gene with regards to the proportion of DCM 
cases potentially caused, albeit its key role as disease-causing gene is clear only considering 
variants causing a truncation of the full-length protein product. Indeed, I did not detect any 
appreciable excess of non-truncating variants in DCM patients: this does not dismiss coding 
SNVs and short indels in titin from causing DCM (co-segregation of non-truncating TTN 
variation and DCM has been previously reported (192)), but it does prove that, at least if taken 
as a whole, this category of variation is not interpretable in the context of genetic screening 
and in the clinical setting for DCM. A hypothetical explanation might lie in the enormous size 
of full-length titin (34,350 residues (Uniprot, Titin: entry Q8WZ42. 
http://www.uniprot.org/uniprot/Q8WZ42 (accessed 09/10/15))): such a giant protein would 
have most likely not survived thousands of years of purifying selection if not with a marked 
degree of resistance to variation. Petrovski et al. (90) scored >16000 genes in terms of 
intolerance to functional variation in the human population (Residual Variation Intolerance 
Score, RVIS), and TTN ranked in the 98th percentile, therefore among the genes most tolerant 
to coding variants. Consistently, the only human gene encoding a protein of a size comparable 
to titin (mucin-16, 22,152 residues (Uniprot, Mucin-16: entry Q8WXI7. 
http://www.uniprot.org/uniprot/Q8WXI7 (accessed 09/10/15))) ranked in the last position 
among all genes scored in the study. However, I also considered the metric published by 
Samocha et al. (193), who identified genes under selective constraint as those deficient in 
functional variation, based on the expected rate of de novo coding variants. Although 
reasonably correlated with the RVIS, this metric ranked TTN in the 29th percentile in terms of 
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degree of constraint.  Undoubtedly, further work is needed to shed light on the disease-
causing potential of non-truncating variants in TTN, and to identify which sub-classes of non-
truncating variants in in the TTN gene may be particularly deleterious in hampering the 
physiological function of the protein and causing disease. 
2.5.2.2 Burden of variation in DCM patients in some ARVC genes supports the idea of a 
genetic overlap between cardiomyopathies 
Besides MYH7, which is well known to play a major role in familial HCM and has been 
described for decades as one of the main DCM genes as well, I observed DCM patients to be 
enriched also for rare coding variants in some genes primarily linked to ARVC: plakophillin-2 
(PKP2) and desmoplakin (DSP), both primarily associated with ARVC. Elliott et al. (194) 
screened 100 unrelated DCM patients for variation in the same desmosomal protein genes 
that I included in the analysis (DSP, DSC2, DSG2, JUP and PKP2), and detected pathogenic 
variants in DSP and PKP2 in patients (with a burden of 3% in DCM patients for both genes, in 
line with the 3.6% for DSP and 2.7% for PKP2 I observed), but did not find disease-causing 
evidence for DSC2, DSG2 and JUP. These findings, on one hand may substantiate the idea of 
an existing – although partial – genetic overlap between different cardiomyopathies, at least 
with regards to some of the genes analysed. On the other hand, they have to be interpreted 
with caution, as neither DSP nor PKP2 were characterized by a significant excess of rare coding 
variants in DCM, after correction for multiple testing for testing 64 genes (although DSP was 
characterised by a nominally significant enrichment). 
However, work recently accepted for publication produced by our group, and to which I 
collaborated as a co-author (195) (biorXiv pre-print available, accepted for publication by 
Genetics in Medicine in May 2016) points towards the genetic overlap between different 
cardiomyopathies being over-estimated in the literature. Our new study was based on the 
comparison of the frequency of rare, coding variation in 7,855 cardiomyopathy cases to that 
in the 60,706 controls constituting the ExAC cohort with the aim of examining for potential 
enrichment of putative disease-causing variants in cardiomyopathy cases. Within the study, 
we performed a more specific frequency comparison between other HCM cases from a 
previously published study (n=874 from Lopes et al. in 2014 (196)) and ExAC samples. Results 
showed a substantial excess frequency of variation in disease cases only in well characterised 
HCM genes (especially MYH7 and MYBPC3), but conversely only little, if any, excess burden 
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of variants in genes primarily associated with DCM and ARVC, with a discrepancy between the 
number of variants predicted to be pathogenic by our comparative approach, and that of 
variants reported to be disease-causing in literature (Figure 2.20). Although this result is 
specific to HCM, these findings suggest that the majority of variants in these genes, although 
rare and protein-altering, are probably bystanders with no deleterious effect, and suggest 
that a substantial genetic overlap between cardiomyopathies (with the exception of a few 
genes such as MYH7) is unlikely, pointing out that previous studies likely relied on data from 
incompletely annotated disease-centred databases and have not used segregation. Also in 
other recent studies, the DCM-causing potential of some genes previously retained of key 
importance for more than one cardiomyopathy has been questioned (for example, that of 
MYBPC3 (24)). 
 
Figure 2.20 - Comparison of the number of variants reported as putatively pathogenic in HCM by Lopes at al. in 2014 (196) 
(using generic analysis criteria such as variant class, missense effect predictions and variant population frequency in ESP) with 
those predicted as pathogenic by the excess of variation in cases over ExAC controls in each gene. Genes are coloured by the 
cardiac disease for which they are primarily associated, as defined by Lopes et al (196). While there is good concordance 
between the research findings and the ExAC predictions for established HCM genes, for genes primarily associated with DCM, 
ARVC and arrhythmias, the variation in cases is similar to that in controls. [Adapted from Walsh et al, 2016 (195)]. 
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2.5.2.3 Considerations on SCN5A and MYH6 
Two genes reported for many years in literature as among the top contributors to DCM, for 
which I did not detect a correspondingly evident excess burden were SCN5A (12,35,41) and 
MYH6 (12,36,41), both previously estimated to cause up to 4% of cases (15). In line with a 
more recent study, which reported the absence of pathogenic variants in MYH6 in 766 DCM 
patients (24), results of this work suggest, at least on the basis of variant frequencies, that 
MYH6 might not be an important contributor to DCM, although the size of our cohorts is not 
large enough to completely rule it out as a DCM gene. 
The lack of an important enrichment of SCN5A variation in DCM patients instead enlightened 
a potential limitation of this study: the recruitment strategy for DCM patients might tend to 
exclude patients suffering from arrhythmic DCM, given that a CMR is contraindicated in 
patients with a pacemaker or ICD. To investigate this, I repeated burden testing comparing 
separately to the HVOL the 234 prospective DCM patients (who had CMR) and the 98 
retrospectives who did not undergo CMR. For the sake of simplicity, I chose to target novel 
variation in each gene, instead of re-running the analysis on all frequency cut-offs. 
Consistently with the hypothesis, SCN5A was the gene characterized by the highest increase 
in excess burden when using the 98 retrospectives with respect to the comparison made using 
the 234 prospectives (+4.2%, against an average change of +0.18% over the 64 genes tested). 
LMNA, also implied in arrhythmic DCM (197), ranked second (+3.8%). The difference in 
frequency of variants in SCN5A and LMNA between the 234 prospective and the 98 
retrospective DCM patients was statistically significant for SCN5A (Fisher test p=0.026) but 
not for LMNA (Fisher test p=0.052).Table 2.18 shows how the variation frequency changed 
for these two genes when considering only the 98 retrospectives as opposed to the 234 
prospective DCM patients, while a full table with results for all genes is shown in the thesis 
Appendices (Paragraph 6.3). 
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Table 2.18 - Comparison of frequency of novel variation for SCN5A and LMNA between the prospective DCM patients 
(n=234) and retrospective DCM patients (n=98, who did not undergo CMR). 
GENE FREQUEN
CY OF 
NOVEL 
VARIANTS 
IN HVOL 
FREQ IN 234 
PROSPECTIV
E DCM (CMR 
REQUIRED) 
FREQ IN 98 
RETROSPECTIVE 
DCM (NO CMR 
REQUIRED) 
DIFFERENCE 
IN EXCESS 
FREQUENCY 
P-VALUE FOR 
DIFFERENCE 
BETWEEN THE 
TWO DCM SUB-
COHORTS 
SCN5A 2.8% (n=9) 0.9% (n=2) 5.1% (n=5) +4.2% 0.026 
LMNA 0.0% (n=0) 1.3% (n=3) 5.1% (n=5) +2.7% 0.052 
 
2.5.3 Evidence of multi-genic interactions underlying DCM 
The work described in this thesis to the best of our knowledge constitutes the first attempt 
to robustly evaluate the impact of variant gene-gene interactions in a large cohort of dilated 
cardiomyopathy patients over a large gene panel. It might be intuitive, as results show, that 
the simultaneous alteration of more than one gene is more likely to cause DCM compared to 
a single variant gene. However, the significance of the number of variant genes in predicting 
disease risk was observed controlling for the presence of a “first” disease variant in the 
regression model, and this should guarantee that a “second” variant is, at least in a proportion 
of cases, a determinant of disease and not a “by-stander” with no disease-causing potential. 
These results, altogether, suggest an additive effect of multiple variant genes on the risk of 
DCM. As to the population frequency of variants involved in mono-genic and poly-genic DCM, 
the enrichment in patients of mono-genic, novel variation suggests that very rare variants are 
those most often involved in Mendelian forms of disease, while slightly less rare variants (MAF 
between ~0.01 and ~0.05%) are primarily involved in multi-genic forms of DCM. Including 
variants at frequencies higher than 0.05% by widening the variants’ frequency range, I 
observed a constant decrease of both mono-genic and multi-genic excess burden in patients, 
dismissing the majority of such variants to be disease-causing. 
2.5.3.1 Evidence for a specific di-genic interaction between TTN and RBM20 in DCM 
Permutation tests highlighted enrichment of co-incident TTN and RBM20 variants in DCM in 
the discovery cohorts (p=3.7x10-2) and also in the replication samples (p=1.9x10-2). The 
functional link between TTN and RBM20 is intriguing, since RBM20 has been described as a 
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direct regulator of titin splicing (198), more specifically as a splicing repressor, promoting a 
gradual increase of exon skipping events between TTN exons 50 and 219, through a direct 
interaction with titin pre-mRNA (199,200). A significant enrichment of TTN+RBM20 gene 
variation was observed in both discovery and replication cohorts for TTNnt+RBM20, but not 
for TTNtv+RBM20 variants. As discussed in Paragraph 2.5.2.1, there was no global enrichment 
of TTNnt variation in DCM patients, and this class of variants, at least if considered as a whole, 
is not interpretable in the context of DCM. This supports the hypothesis of the TTN+RBM20 
double alteration to consist, from the biological point of view, in a double ‘hit’ on TTN. Under 
this scenario, TTNnt variation - which on its own generally does not seem to cause disease - 
causes instead a first, minor impairment of the structure and biological function of titin. Under 
this hypothesis, this first “hit” would acquire disease-causing potential if combined with a 
second alteration impairing the splicing patterns through variation in RBM20 – possibly 
causing the inclusion of TTN exons otherwise skipped – which would affect processing of both 
the TTNnt allele and the wild-type allele. Truncating variants in TTN are well known to be 
disease-causing on their own, and the presence of a “second” alteration in RBM20 in carriers 
of TTNtv would likely not have any additional pathogenic effect, explaining the lack of 
enrichment of TTNtv+RBM20 double alterations in DCM. Similarly, variants in the RBM20 
mutational hotspot for DCM in residues Arg634 and Pro638 are known to be associated with 
DCM (201,202), and they likely possess the potential to cause disease on their own. None of 
the RBM20 variants in discovery DCM samples, and only one in replication DCMs with 
TTN+RBM20 mutations was in the disease-associated 5-residue window.  
It must be kept in mind, however, that the dimensions of both discovery and replication 
cohorts do not provide satisfactory statistical power to test the enrichment of double rare 
TTNtv+RBM20 variants – even more so for variants falling in the Arg634-Pro638 window in 
RBM20 – and repeating the test on larger cohorts is warranted. 
2.5.3.2 Considerations on the different sequencing targets and sub-versions of BWA 
and GATK used for replication cases and controls  
As outlined in Table 2.4 and explained in Paragraph 2.3.4, BWA v0.7.9 and GATK Haplotype 
Caller v3.1-1 were used to align and call variants in replication HVOL (sequenced with WES), 
respectively, while BWA v0.7.12 and GATK Haplotype Caller v3-3.0 were used for replication 
DCM cases (sequenced on a targeted DCM gene panel). As outlined by the release history of 
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BWA (https://github.com/lh3/bwa/blob/master/NEWS.md) and GATK 
(https://www.broadinstitute.org/gatk/guide/version-history), no changes that could have a 
considerable impact on the study results were implemented across the different software 
sub-versions in question. The most important change as far as BWA was concerned occurred 
between BWA v0.7.10 and BWA v0.7.11, with a partial inclusion in the alignment algorithm 
of features supporting the mapping reads to ALT contigs, which essentially represent a 
collection of diverged alleles present in some individuals but not others (therefore having a 
possible impact only on particular genomic regions and in a small subset of the general 
population). As far as GATK was concerned, the changes from Haplotype Caller v3.1-1 to v3.3-
0 were mainly consisting in minor bug fixes and incremental improvements, with the most 
highlighted new feature impacting the analysis of non-diploid genomes. Overall, the different 
sub-versions of BWA and GATK used to align and call variants in cases and controls did most 
likely not introduce any systematic bias between replication cases and controls. The main 
technical difference between sequencing data of replication DCM and HVOL samples 
probably consisted in the different sequencing targets characterising the two cohorts 
(targeted DCM gene panel for replication DCM patients, and WES for replication controls). 
While acknowledging that the usage of different panels might introduce potential biases, both 
approaches relied on the same exon capture method. Systematic differences in read depth 
between the two cohorts over specific regions would have been resolved by the quality 
control steps that I applied at the single variant-level (the same tests described in Paragraph 
2.3.6.4 for the discovery cohorts), including a Mann-Whitney U test-based step to discard 
variants poorly covered in one of the two (or both) cohorts. 
2.5.4 Effects of genetic variation on cardiac morphology and function of DCM 
patients 
2.5.4.1 Sarcomere gene mutations cause a more severe degree of LV wall thinning with 
an additive effect 
Within the subset of 226 DCM-affected individuals, for which high-resolution CMR data were 
available, I observed truncating variants in TTN (p=5.0x10-3) alongside variation in MYH7 
(p=6.9x10-3) and TNNT2 (p=3.5x10-2) to be significantly associated with a more severely 
thinned LV wall, independently of LVEDV, age and sex (included as covariates in the regression 
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models, as described in Paragraphs 2.3.10 and 2.4.6.1). These three genes encode key 
components of the sarcomere, and a prominent sarcomeric basis has previously been 
documented for DCM (203,204). Furthermore, rare, coding variation in sarcomere protein 
genes has been described to significantly increase LVWT in the context of HCM (196,205) 
which, although representing an effect in the opposite direction in a different disease state, 
supports the hypothesis of a relevant role of sarcomeric proteins in regulating LVWT. This 
might justify the significant additive effect of the number of variant genes observed on the 
degree of left-ventricular wall thinning (p=2.8x10-2) to be more evident when limiting the 
analysis to the 17 genes encoding sarcomeric proteins (p=3.8x10-3). This was observed only 
when excluding TTNnt variation from the analysis, which is likely reflective of the 
uninterpretabiliy of TTNnt variants in the context of DCM, when analysed as a whole. These 
result suggest TTNtv, and variants in MYH7 and TNNT2, as well as the number of 
cardiomyopathy genes altered by rare coding variation as possible disease severity markers, 
as far as the degree of thinning of the LV wall is concerned. 
2.5.4.2 Variants in LAMA2 are associated with a lower LVEF  
Variants in LAMA2 were significantly associated with a lower LVEF within DCM patients 
(p=5.0x10-2). An early study, performed on individuals affected with congenital muscular 
dystrophy (MD), reported a significantly lower LVEF in those characterized by deficiency of 
the LAMA2-encoded laminin alpha2 (206), although later reports dismiss cardiac involvement 
as a major complication in LAMA2-related MD (207). Laminin alpha2 indirectly interacts with 
dystrophin (encoded by DMD, within the 64 genes included in our study) through a group of 
dystrophin-associated glycoproteins (208), and DCM is an almost inevitable complication of 
Duchenne muscular dystrophy (209), caused by mutations in DMD. In spite of the previous 
exclusion of DMD from the analysis following burden testing, I checked whether variants in 
DMD were associated with a lower LVEF in patients, and I did not detect an association (5 
DMD +ve vs 217 DMD -ve: 44±13% vs 39±13%; p=0.45). DMD lies on the X chromosome, 
therefore one would expect males to be more often and more severely affected with a disease 
caused by variants in it than females, as it is for Duchenne MD. Of the 5 DMD +ve DCM 
patients, 3 were males but their LVEF was not different from that observed in HVOLs (3 DMD 
+ve males vs 217 DMD -ve patients:  45±18% vs 39±13%; p=0.33). 
140 
 
2.5.4.3 Variants in LMNA are associated with a lower LVEDV and a less severe phenotype 
Variants in LMNA were observed to be associated with a lower indexed LVEDV (p=3.9x10-2), 
and the 4 LMNA +ve patients among the 226 included in the genotype-phenotype analysis, 
were observed to have a less severe DCM phenotype as compared to the average of the 222 
LMNA -ve patients (lower LVEDV, higher EF and higher LVWT, as displayed in Table 2.19). This 
unexpected finding might be caused by the same bias, introduced by the usage of CMR to 
generate phenotype data, discussed in Paragraph 2.5.2.3. LMNA-related DCM is very often 
characterized by conduction disease causing arrhythmias or conduction disturbances (197), 
and LMNA patients often have a pacemaker or an ICD that preclude a CMR scan. This might 
mean that we only had LMNA +ve patients who were characterized by a less severe 
phenotype and without arrhythmic features, actually allowing them to undergo CMR. 
However, this remains a speculation as it would imply a correlation between the severity of 
arrhythmic events and cardiac morphological/functional parameters of which I didn’t find any 
evidence in literature. Another possible explanation for the milder phenotype of LMNA +ves 
could be their age: on average, they are about a decade younger than LMNA –ves, and in 
younger patients DCM is generally less severe, being a progressive disease. As explained in 
Paragraph 2.4.6.1, age was not a covariate in models predicting LVEDVi, as it was not a 
significant predictor of LVEDVi in the baseline model (LVEDVi~Age+Sex) for DCM patients. 
Since arrhythmia/conduction disease generally presents before LMNA-related DCM patients 
develop HF (197), it may be that arrhythmia/conduction disease lead to detection (and hence 
study enrolment) of DCM earlier in the disease process, and before the onset of overt DCM. 
However, in this case the average younger age of the 4 LMNA +ves was caused by a single 
patient aged 21, and this explanation was not plausible (details on the cardiac phenotype and 
age of the 4 LMNA +ve patients are shown in Table 2.19). On top of all these considerations, 
it must be taken into account that, given the low number of LMNA +ves, these differences 
might be also due to random sampling effects. 
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Table 2.19 - LVEF, LVEDV and LVWT and age of the four LMNA +ve DCM patients, characterized on average by a less severe 
cardiac DCM phenotype as compared to the average of the 222 LMNA -ves. Groups’ standard deviations are shows with the 
average values. 
PATIENT(S) LVEF LVEDV LVWT Age 
10LW02013 52 % 96.3 mL 7 mm 21 years 
12JL00046 46 % 82.2 mL 8.5 mm 66 years 
12PH00095 45 % 104.2 mL 10 mm 57 years 
14SD01620 40 % 86.9 mL 12.5 mm 51 years 
Average (4 LMNA +ve) 45.8±4.9 % 92.4±9.8 mL 9.5±2.3 mm 48.8±19.5 y 
Average (222 LMNA -ve) 38.8±12.8 % 130.0±42.7 mL 8.2±1.6 mm 59.1±13.9 y 
 
2.5.5 Effects of genetic variation on cardiac morphology and function of 
healthy subjects 
2.5.5.1 Truncating variants in TTN are associated with a lower LVEF 
Healthy controls carrying TTNtv were characterized by a lower LVEF as compared to TTNtv -
ves (6 TTNtv +ve vs 298 TTNtv -ve: 59.3±4.1 % vs 64.9±5.2 %; p=2.7x10-3). The 5.6 % difference 
in terms of mean LVEF between the two groups, although characterized by statistical 
significance, likely lacks clinical importance in the subjects at this stage. It might be 
hypothesized that TTNtv +ve healthy subjects might develop DCM in the future (which is 
something that cannot be accounted for), and that a slightly lower LVEF could be a first sign 
of the beginning of a deteriorating heart function. However, in this case the 6 TTNtv +ve 
subjects were markedly older, on average, than the 298 TTNtv -ves (6 TTNtv +ves 56±8 years 
old and 298 TTNtv -ves 44±13 years old), and this, while not excluding the possibility of a still 
latent DCM phenotype, renders it more unlikely. As explained in Paragraph 2.4.6.2, age was 
included as a covariate in the regression model, therefore the age difference between TTNtv 
+ve and TTNtv -ve subjects was accounted for by the model. This finding seems to suggest 
that truncating variants in TTN often have an effect also in healthy subjects, causing a very 
mild, yet still measurable, cardiac phenotype. The biological significance of such effect 
remains to be determined. I also detected a significant association of variants in TP63 (1 TP63 
+ve with LVEF=52 % vs 303 TP63 –ve with LVEF=64.8±5.2%; p=4.8x10-2) and DSP (9 DSP +ve 
vs 295 DSP -ve: 60.4±6.0 % vs 64.9±5.2 %; p=2.9x10-2) to a lower LVEF, and of variants in 
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LAMA4 to a higher LVEF (6 LAMA4 +ve vs 298 LAMA4 -ve: 69.3±4.5 % vs 64.7±5.2 %; p=1.3x10-
2). I did not find a plausible explanation for such associations, and any explanatory hypothesis 
would be largely conjectural. Especially for variants in TP63, the significance of their 
association to a lower LVEF was caused by a single TP63-positive subject, therefore the risk of 
a random sampling effect entirely driving the result is very high. 
2.5.5.2 Variants in SCN5A are associated with a higher LVEDV 
Similarly, to the association with a small change in LVEF for TTNtv +ve healthy controls, I 
observed subjects with variants in SCN5A to be characterized by a higher LVEDV (10 SCN5A 
+ve vs 294 TTNtv -ve: 88.7±9.1 mL vs 82.3±13.4 mm; p=2.4x10-2). Variation in SCN5A is mainly 
associated with arrhythmic conditions, such as Brugada syndrome (210), and SCN5A +ve 
Brugada syndrome patients have been observed to have significantly increased cardiac 
dimensions (including LVEDV) as compared to SCN5A -ve patients or healthy controls (211). 
This result might point towards the hypothesis of an indirect role of SCN5A in affecting LVEDV, 
but bigger cohorts and stronger evidence would be required to draw conclusions. 
2.5.6 Limitations of the study 
There are a number of limitations in this study that must be kept in mind when interpreting 
its results. 
2.5.6.1 Technical limitations 
1) Not all variant classes are covered by our approach, being limited to coding regions. 
In coding regions themselves, some variant categories are not well detected (e.g. 
structural variants). Therefore, some classes of disease-causing variants might have 
been missed.  
2) The choice to use samples sequenced on the same platform and processed through 
the same mapping, quality control and variant calling pipeline was necessary to 
guarantee the highest possible comparability between cases and controls. However, 
as highlighted in literature (212) no single sequencing platform/variant caller 
combination achieves 100% accuracy in detecting variants – in particular for indels – 
and some true positive variants would inevitably have been missed.  
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3) The number of samples does not provide sufficient power to draw definite conclusions 
about the burden of rare coding variants in minor DCM genes. Therefore, all results 
pertaining to genes other than TTN can only be considered as preliminary estimates 
of the contribution of each gene to DCM. A multicentre analysis performed by our 
group in collaboration with others involving a higher number of samples is ongoing, 
and it will at least partially resolve the issue of the low statistical power characterizing 
this analysis with regards to genes different from TTN. 
4) All analysed samples received targeted exon sequencing on a panel of ~200 genes. As 
far as the PCA analysis to determine ethnicities is concerned, this sequencing target 
provides enough variants to perform a rather coarse separation of different 
ethnicities, but a larger target would be required to cluster samples in a finer fashion. 
5) The adoption of a CMR-based patient recruitment strategy for a large proportion of 
the DCM cohort might have introduced a systematic bias against the recruitment of 
patients with arrhythmogenic phenotypes which required prior implantation of an ICD 
or a pacemaker (in which case CMR is contraindicated). This could have deflated the 
burden of observed variation in DCM patients in genes typically causing DCM with 
arrhythmogenic features (e.g. LMNA and SCN5A). 
2.5.6.2 Analytical limitations 
1) The decision to consider different rare frequency ranges and report single gene figures 
at the cut-off characterized by the highest excess frequency was made to provide an 
estimation of the maximum contribution of genetic variation in each gene to DCM. 
However, especially for minor disease genes with low variation frequencies in both 
cohorts, the reported figure might suffer from random sampling effects. 
2) Estimating the contribution of each gene to disease simply on the basis of variant 
frequencies is based on the assumptions that all variants observed in HVOLs are 
benign, and that excess variants observed in DCM are disease-causing, which might 
not be the case. 
3) Disease-causing variants might not necessarily be protein-altering, and therefore 
might be excluded from the reported burden figures. 
4) I analysed variation in entire genes without subdividing, for example by protein 
domain or level of expression of transcripts in the myocardium. This might lead to the 
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inability to detect true disease-causing variants in the case of genes where only a 
subclass of the entire set of prioritised variants can cause disease. 
5) The considerable difference in gender stratification between analysed cases (74.1% 
males) and controls (46.1% males) might have introduced a bias in observed variation 
in X-linked genes (i.e. LAMP2, TAZ, DMD and EMD), since it is unlikely for an X-linked 
rare variant (therefore most likely heterozygous) to cause overt disease in males. 
6) As a general rule of thumb, 10-20 observations (samples, in this case) per variable 
would be needed in a regression model to be able to detect reasonable size-effects 
with reasonable power (213). Although I used variable selection procedures in all 
models leading to only a few variables to be retained, the initial models containing all 
genes were based on 226 observations, and contained >30 variables. Anyway, there 
should not be any over-fitting issue (happening in cases where too many variables, not 
completely independent from each other, are included in a model), as all predictors 
included in the models are independent from each other (age and/or sex, and 
variation in single genes). 
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2.6 Conclusion 
Although genetic variation alone often cannot explain in full familial disease, and further 
mechanisms such as epigenetic modifications and gene expression patterns should be 
investigated, as to today's state of the art, NGS-based genetic tests are becoming the most 
widely used methodology for the routine application of clinical diagnostics of DCM. The work 
described in this chapter provides, for the first time, an estimation of the background rate of 
rare variation in deeply phenotyped healthy controls on a relatively broad panel of 
cardiomyopathy genes, which partially reshapes our understanding of the genetic 
architecture of DCM, although estimates regarding minor disease genes must be taken with 
caution. Non-truncating variants in TTN require further study and the identification of 
disease-causing subclasses of TTNnt variation would be beneficial for a further understanding 
of the genetics of DCM. The evidence for the existence of a specific di-genic interaction in 
DCM – between TTN and its splicing regulator RBM20 – represents a first confirmatory finding 
of multigenic variation in DCM, and studies on larger cohorts will surely contribute to unravel 
other gene-gene interactions contributing to the disease process. Nevertheless, the high 
background variation rate in the general population, the evidence of a multi-genic component 
itself in determining disease and the possibility of a substantial genetic overlap with other 
cardiomyopathies pose new challenges. 
These challenges will inevitably have to be addressed also in the clinic, particularly as far as 
genetic testing is concerned. Although, as said many times during the description of this work, 
the cohorts that I could use for the study were underpowered, in terms of dimensions, to 
allow precise estimations of variation pathogenicity, and burdens in cases and controls for 
several genes, results suggest that, for many genes, there is not an appreciable excess of rare 
coding variation in disease. Such genes, characterised by an essentially equal frequency of 
possibly pathogenic variants in cases and controls should not be included in diagnostic panels, 
especially when adopted on single DCM probands, as applying the panel testing to a patient 
or to a healthy individual would most likely lead to the same result. Cascade screening of 
family members can be a solution in some cases, as observing co-segregation of disease with 
a candidate variant represents strong evidence pointing towards a major causal role. 
However, family screening also poses some issues related, for example, to the psychological 
impact on relatives and cost. An emblematic example for such situation is provided by TTNnt 
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variation, equally (and highly) frequent in cases and controls and for which panel testing on 
single probands would be useless, but with previously associated variants to DCM through 
family studies (192). Such classes of variation would need a much finer sub-classification in 
order to identify pathogenic sub-categories of variants to screen for, also in single probands, 
for example considering which transcript, protein residue or domain is altered, the degree of 
evolutionary conservation of the modified residue and the structural and/or functional 
impairment caused on the protein.  
Another issue is represented by variant classes that, while characterised by a markedly higher 
frequency in cases compared to controls, are also characterised by moderately low values of 
aetiological fraction, such as non-truncating variants in the 37 genes analysed together (non-
TTN). As a whole, this class of variation is characterised by aetiological fraction = 0.45 (Figure 
2.13), indicating that less than 50% of prioritised variants are pathogenic, assuming complete 
penetrance. This implies that any new, potentially pathogenic variant identified in a proband 
cannot be easily interpreted, as many variants are likely not disease-causing, therefore also 
the inclusion of these variant classes in diagnostic panels risks to lead to more uncertainty 
than to a higher success rate, at least if reported assuming a monogenic disease model. This 
said, the only genes/variant classes that effectively guarantee easily interpretable results, 
following a monogenic disease model, are those jointly characterised by excess frequency in 
disease and relative absence in healthy individuals (as is the case, for example, of TTNtv, and 
variants in LMNA).  
Another layer of complexity is added by the cases in which disease is not caused by variation 
in a single gene, but by the joint effect of variants in multiple genes. In this respect, this work 
starts to shed light on a possible di-genic disease model (with co-occurring variation in TTN 
and its splicing regulator RBM20 as a novel cause of disease). In order to be confirmed, this 
finding clearly needs to be substantiated by data on larger cohorts and/or functional evidence 
(functional data on animal models are being produced and will be evaluated in the next 
months), but whenever di-genic inheritance can be demonstrated, then di-genic screening 
can be used for genetic counselling, at least in cases where mono-genic inheritance cannot 
explain disease. Hence, this work represents another small step towards a more 
comprehensive understanding of the genetic architecture of DCM, but it strongly highlights 
that much caution has to be adopted in claiming new gene-disease associations, and, in the 
clinics, in deciding whether to include a gene or not in a diagnostic panel. This study also 
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identified some variant classes as possible disease severity markers, as well as the novel 
signature of an additive effect of multiple variant genes on LV wall thinning in DCM. While 
these results can serve as pilot data that provide insights in what variant classes to target in 
future genotype-phenotype analyses, larger patient and control groups are necessary to draw 
more definitive conclusions about the effects of genetic variants on the cardiac morphology 
and function of cases and controls.  
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3 Identification of new causes of familial DCM through 
whole-exome sequencing in an affected family 
3.1 Introduction 
For a disease of unknown genetic causation that segregates in a family, whole-genome 
sequencing (WGS; Paragraph 1.6.2.1) provides the most comprehensive interrogation of 
genetic variation and may lead to the identification of the variant(s) responsible for disease. 
However, WGS is expensive, and the lack of knowledge and the difficult interpretation of the 
numerous variants it reveals, many in non-coding regions, often preclude its use as a first 
approach. Whole-exome sequencing (WES; described in Paragraph 1.6.2.2) combined with a 
filtering-based approach to identify genetic causes of disease (Paragraph 1.6.4.2) is an 
attractive alternative option, targeting protein-coding regions that are known to harbour the 
majority (~85%) of disease variants responsible for Mendelian disorders identified so far 
(104). After the first successful application in 2009 (214), WES has been applied several times 
to determine the underlying genetic causes of multiple Mendelian diseases in recent years 
(215,216), and estimations suggest that – although biased towards recessive disorders – WES 
approaches applied to family pedigrees have reported to have~50% chance of identifying the 
disease gene for rare but clinically well-defined Mendelian conditions (217). In the absence 
of segregation information, WES can be used to identify the genetic cause of disease using 
unrelated patients. Such approach implies identifying multiple individuals with exactly the 
same phenotype and prioritising a gene harbouring potentially disease-causing variants in all 
the affected. This strategy however is most effective only for diseases characterized by 
variation in a single causative gene rendering it unsuitable for phenotypically diverse and 
genetically heterogeneous diseases such as DCM (136). 
In this chapter, I used filtering approaches to identify the genetic cause of an unexplained 
inherited form of DCM, characterized by early onset and a markedly severe phenotype, with 
arrhythmogenic features, in a family sequenced with WES. 
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3.2 Materials and methods 
3.2.1 Study subjects 
3.2.1.1 Family structure and clinical background 
The proband was a 3-year-old Egyptian female diagnosed with DCM, with the main 
symptoms being dyspnea, palpitations, and tachycardia. Holter monitor revealed premature 
ventricular contractions, and echocardiography highlighted a dilated LV with hypokinesia 
(LVEF of 23%), with mild mitral regurgitation and tricuspid regurgitation. She died of sudden 
death at 4 years of age. Two other siblings (both males) were affected with DCM, while two 
more were unaffected (one male, one female) with echocardiography revealing normal 
cardiac phenotype. One of the affected males died at 6.5 years old post-operatively following 
appendicectomy, with a dilated LV and thickened LV wall by echo. The other affected sibling 
was diagnosed at 4 years of age, and died suddenly at 6. Holter had revealed premature 
ventricular activity. The mother was unaffected and phenotypically normal, while the father 
was affected with coronary heart disease (with onset in the fifth decade), but free from DCM. 
Unfortunately, it was not possible to collect DNA from the two affected brothers of the 
proband, therefore WES was performed on the proband (ID: 20MA00417), the unaffected 
brother (ID: 20MO00420) and sister (ID: 20SO00421), and the unaffected parents (Father: 
20HE00418; Mother: 20IB00419). DNA samples of the family came from Egypt, through a 
collaborative effort with the Faculty of Medicine of the Alexandria University. In spite of the 
high rate of consanguineous marriages occurring in the region of origin of the family in Egypt, 
the parents declared to be unrelated. The pedigree of the family is shown in Figure 3.1. 
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Figure 3.1 - Pedigree of the analysed family. The red arrow indicates the proband, and the green square shows samples for 
which WES data were available. 
3.2.1.2 Sequencing and additional information 
WES was performed in Edinburgh by Edinburgh Genomics, University of Edinburgh, using an 
Illumina HiSeq 2500 platform, producing 135 bases-long paired-end reads, following target 
capture with Nextera 37Mb Rapid Capture Exome kit. Sequencing specifications and post-
sequencing procedures applied were as described in Paragraph 2.3.4.2 for the 514 HVOL 
samples used for replication in the study described in the previous chapter.  
3.2.2 Data output and quality control 
3.2.2.1 Sequencing output and target coverage 
A total of 274,121,410 sequencing reads were obtained for the 5 family members. The 
proband (20MA00417) was intentionally sequenced at higher coverage than parents and 
siblings (there was enough proband DNA for only one sequencing experiment, with the 
proband already deceased), with approximately 40% of the total reads (n=109,878,252) 
mapping to her exome, and a mean read depth over the 37Mbp target region of 88x, as 
opposed to the other family members, with mean depths in the range 20x-50x (Table 3.1). 
Sequencing output and WES metrics depend on the technology of choice for target capture, 
DNA sequencing, and on the definition of target itself. Using the “publications list” search 
engine on the Illumina website (http://www.illumina.com/science/publications/publications-
list.html) and Pubmed (http://www.ncbi.nlm.nih.gov/pubmed) I detected four other studies 
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in which WES was performed using Nextera capture and Illumina HiSeq2500 sequencing 
platform (218–221). The four studies specified 93-99% of the target to be covered at ≥10x, 
suggesting that the coverage of our samples was reasonable. 
3.2.2.2 Variant calling 
Variants were called using GATK Haplotype Caller v3.1.1 in multi-sample mode, for the 5 
family members together with the 514 unrelated HVOL mentioned in Paragraphs 2.3.4.2 and 
3.2.1.2, in order to benefit from additional controls besides those publicly accessible, with 
data produced by the same centre, and with the same instruments.  Variants were called on 
all reads with mapping quality >8 across the 37Mb target, including regions up to 100bp 
downstream and upstream of each exon. Including these exon flanking sequences, variant 
calling was performed on a total target region of approximately 77Mb. A total of 114,662 
variants with quality >20 and which passed all quality filters were identified by GATK across 
the 5 family members, with ~64,000-83,000 variants in each sample (Table 3.2). The number 
of coding nucleotide variations identified was between ~22,000 and ~24,500 per sample, 
which is in line with figures reported in literature (222), depending anyway on target 
definition and – to some extent – also on the ethnicity of the study subjects. The total number 
of unique variants in the multi-sample VCF file with the whole set of 519 samples was 920,212 
(of which 791,802 (86.0%) passed all GATK quality filters).
152 
 
Table 3.1 - Sequencing metrics for the five family members sequenced with WES. 
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20MA00417 109878252 90.7 99.0 99.0 99.6 0.5 99.7 97.9 87.8 95.7 88.4 74 74.0 
20HE00418 42471054 90.3 98.9 98.9 99.6 0.5 99.3 89.2 48.4 93.6 34.0 29 73.0 
20IB00419 24207800 91.0 98.9 98.9 99.6 0.5 98.8 75.7 21.5 90.2 20.4 17 73.0 
20MO00420 61522592 90.6 98.7 98.7 99.6 0.5 99.6 93.3 66.8 94.5 47.2 41 74.4 
20SO00421 36041712 90.8 98.8 98.8 99.6 0.5 99.1 86.7 42.6 92.7 30.4 26 73.5 
 
a reads mapping with an alignment quality score ≥8 
b base pairs 
Data refer to the 37,105,383 bp region targeted by the Nextera Rapid Capture Exome kit. 
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Table 3.2 - Variant calling metrics for the five family members sequenced with WES. 
Sample 
name 
Number of variants 
(114,662 distinct quality filtered variants across the 5 samples) 
Transition / 
Transversion ratio 
Heterozygous / 
Homozygous 
ratio 
Non-synonymous 
/ 
synonymous ratio 
 
Total 
variants 
(% not in 
dbSNP144)  
Total 
coding variants 
(% not in 
dbSNP144) 
SNVs 
(% not in 
ExAC) 
Coding 
SNVs 
(% not in 
ExAC) 
Indels 
(% not in 
ExAC) 
Coding 
Indels 
(% not in 
ExAC) 
Coding 
SNVs 
Coding 
SNVs 
not in 
ExAC 
Coding 
SNVs 
Coding 
Indels 
Coding 
SNVs 
Coding 
SNVs 
not in 
ExAC 
20MA00417 
83235 
(8.1) 
24444 
(4.8) 
70061 
(32.5) 
23561 
(1.7) 
13174 
(70.5) 
883 (40.8) 3.0 1.7 1.8 2.2 0.90 1.90 
20HE00418 
75510 
(6.7) 
23414 
(4.9) 
64762 
(30.6) 
22593 
(1.6) 
10748 
(67.6) 
821 (39.0) 3.1 1.9 1.7 2.0 0.91 2.05 
20IB00419 
64560 
(6.0) 
22395 
(4.8) 
56254 
(26.9) 
21632 
(1.5) 
8306 
(65.0) 
763 (39.1) 3.0 1.5 1.5 1.9 0.91 1.80 
20MO00420 
78168 
(7.0) 
23922 
(4.8) 
66528 
(31.1) 
23064 
(1.0) 
11640 
(68.5) 
858 (22.7) 3.0 1.9 1.7 2.0 0.91 1.78 
20SO00421 
73618 
(6.6) 
23526 
(5.0) 
63271 
(29.5) 
22694 
(1.8) 
10347 
(66.9) 
832 (38.2) 3.1 1.7 1.7 1.9 0.91 1.86 
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3.2.2.3 Variant calling quality control 
I calculated several metrics - based on the number and categories of variants detected by 
GATK- that serve as quality control for our WES sequencing data (Table 3.2). A first measure 
of the quality of WES data is the proportion of novel variants. This obviously depends on the 
definition of novelty, but for comparative purposes I decided to report the proportion of 
variants absent in dbSNP144. Other WES studies generally report between 5% and 10% of 
coding variants to be absent from dbSNP (223), including the first study describing the 
potential application of WES in Mendelian disease gene discovery, reporting values between 
6% and 7% c.f. dbSNP129 (214). Considering coding variants, I observed 4.8%-5.0% of them 
to be absent in dbSNP144. The lower values that I detected reflect, on the one hand, the 
comparison with a more recent and more comprehensive dbSNP build, but on the other hand 
lower values also generally suggest more stringent calling. I decided to report the proportion 
of novel variants according to what is perhaps the most up-to-date definition of novelty: the 
absence from the largest accessible exome control cohort ever released: the ExAC. I have 
been unable to find in the literature the reported proportions of WES variants absent from 
ExAC, but one can infer the expected figures by considering the total number of variants 
present in ExAC and in dbSNP. Approximately 2% of variants in dbSNP135 were reported to 
be in coding regions (224), and dbSNP144 is reported to include ~97.5 million validated 
genomic variants (225). Assuming the proportion of coding variants in dbSNP to have 
remained constant across different builds, one can estimate ~1.95 million coding variants to 
be included by dbSNP144. The ExAC includes a total of ~10.2 million unique variants across 
all samples (96), approximately 5 times the amount of coding variants in dbSNP. Therefore, 
one could roughly expect a 5-fold difference between the number of WES coding variants 
novel c.f. dbSNP144 and novel c.f. ExAC, which is approximately what I observed for our 5 
family samples (values around 5% of novel variants c.f. dbSNP144, and values between 1.0-
1.8% for novel variants c.f. ExAC). As far as indels are concerned, the proportion of novel 
variants (c.f. ExAC) is extremely high as compared to that of SNVs, reflecting the existence of 
fewer common indels, but also probably suggesting a poorer quality call set. 
Other QC measures are provided by the ratios of transitions to transversions (Ti/Tv), non-
synonymous to synonymous SNVs (Ns/S) and heterozygous to homozygous variants 
(Het/Hom). In substitution mutations, transitions are defined as the interchange of the purine 
bases A↔G or pyrimidine bases C↔T. Transversions are defined as the interchange between 
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two-ring purine nucleotides and one-ring pyrimidine bases. The possible transversions are 
A↔C, A↔T, C↔G and G↔T. If the probabilities of every possible nucleotide substitution 
were equal, the Ti/Tv ratio would be 0.5, as there are two possible transversions for each 
nucleotide, as opposed to only one transition. In reality, transitions are more common, and 
the Ti/Tv ratio across the human genome is typically ~2.1. In coding regions, the Ti/Tv ratio 
increases to 2.8-3.0 or higher, principally due to the near exonic enrichment of cytosine in 
CpG dinucleotides, which, when methylated, can easily undergo deamination and transition 
to a thymine. In sequencing data quality control, a higher Ti/Tv ratio generally indicates a 
higher quality variant set (226), and the ratios I observed for coding variants were reassuringly 
high (3.0-3.1). As expected, ratios for novel variants were lower (1.5-1.9), indicating a lower 
quality variant call set (novel SNVs are more likely to be errors than common variants, and a 
variants called at random would have a Ti/Tv ratio of 0.5).  
The Ns/S and Het/Hom ratios are less often reported in literature, but serve as additional 
useful quality controls. The typical Ns/S ratio is generally between 0.8 and 1.0, and around 
1.9 for rare variants (214,227,228), as rare variation is enriched for non-synonymous changes 
as compared to common polymorphisms (229). The values I observed (~0.9 for all coding 
variants, and in the range 1.8-2.0 for rare SNVs) were again in line with expectations. 
The Het/Hom ratio provides another general indication of the quality of sequencing data, as 
heterozygous variants might be missed at low read depths or with too stringent variant calling 
parameters, while too low stringency would increase the number of heterozygous calls. 
Differently from the Ti/Tv ratio, the Het/Hom ratio is independent of genomic regions, but 
depends instead on the ethnicity of samples, with values in the range 1.4-2.0 (230), in keeping 
with our results. 
3.2.3 Relatedness analysis 
Before starting the disease-causing variant prioritisation procedure, I performed a pairwise 
IBD estimation using PLINK (231), to confirm the self-declared unrelatedness of the two 
parents and to confirm that all HVOL controls were unrelated. The proportion of IBD is 
denoted by a value between 0 and 1 (denoted as PI_HAT by PLINK), and it is expected to be 
~1 between identical twins, ~0.5 between first-degree relatives (e.g. parent-son) and ~0 
between completely unrelated individuals. In line with expectations, I observed values in the 
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range 0.44-0.56 between all parent-child and sibling-sibling pairs in the family, but PI_HAT 
was 0 between the two parents, confirming the father and the mother to be unrelated. 
3.2.4 Prioritisation of candidate disease-causing variants 
After having ascertained data quality and its suitability for the study, I developed filtering 
strategies to prioritise candidate variants that may be causative of DCM in the family. Taking 
into account the pedigree structure and the disease segregation pattern, possible inheritance 
models were: 
1) Autosomal recessive inheritance with homozygosity in the proband, where a single 
variant is causing disease only if present in a homozygous state 
2) Autosomal recessive inheritance with compound heterozygosity in the proband, 
where two variants in the same gene are causative only if co-occurring  
3) De novo dominant disease-causing variant in the germ line cells of a parent (as DCM 
is recurrent in the family, a classic de novo model, assuming the variant to have arisen 
in the affected, would not fit) 
4) Mitochondrial inheritance, with the disease-causing variant segregating with the 
maternal mitochondrial DNA (mtDNA). The assumption behind this model is that the 
mtDNA mutational load is low enough in the mother and in the unaffected siblings not 
to cause disease, while it is higher (making the same variant disease-causing) in the 
proband.  
The expected genotypes for the first three models, assuming disease-causing variation to be 
in the nuclear DNA, are shown in Figure 3.2. In all models, I filtered variants hierarchically, on 
the basis of variant class, segregation in the family, and frequency in HVOL, ESP and 1KGP 
(using ExAC later on, for further filtering and supportive evidence). I assumed in all models 
the causative variants to have a protein-altering effect. The order in which I applied filters 
varied slightly across different models, for purposes relating to computational time and 
depending on the number of variants left for prioritisation at any given stage. For this reason, 
and to give a clear overview of each pipeline, I discuss the filtering procedures separately for 
each model in Paragraphs 3.2.4.1, 3.2.4.2, 3.2.4.3, and 3.2.4.4. 
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I used SNPEff (93) and SNPSift (232) to annotate and prioritise candidate disease-causing 
variants, respectively, in all models from the multi-sample VCF file containing exome data of 
the 5 family members and the 514 controls. In addition, for the three models assuming 
inheritance via nuclear DNA, I developed a second version of each pipeline, permissive – to 
some extent – towards genotype errors, to ensure the detection of all potential candidates. 
As far as in silico variant pathogenicity prediction tools are concerned, I used SNPEff to 
retrieve from dbNSFP v2.7 the predictions of SIFT (91), Polyphen-2 (92) and MutationTaster 
(233), which are made relying on partially different variant features. SIFT predicts the effect 
of an amino-acid substitution on the protein function taking into account the degree of 
evolutionary conservation of the mutated residue (inferred from a multiple sequence 
alignment), and the type of amino-acid change. Also Polyphen-2 is also based on protein 
multiple sequence alignments to infer the residue conservation in evolution, but it also takes 
into account structural features of the protein. Of note, there are two Polyphen-2 
classifications: HumDiv and HumVar. The HumDiv score is calibrated to predict whether a 
variant will affect protein function sufficiently to influence a trait, whereas HumVar aims to 
identify variants that alter protein function sufficiently to produce Mendelian disease. 
HumDiv is likely more sensitive but less specific than HumVar for identifying variant 
responsible for Mendelian disease. However, I chose to report HumVar, because I am 
interested in disease-causing variants in the family. MutationTaster computes predictions on 
the disease-causing potential of variants relying on a mix of different variant characteristics, 
ranging from residues’ evolutionary conservation over ten species, nucleotide conservation, 
regulatory features, and MAF in 1KPG and HapMap as well as the presence of the variant in 
ClinVar and HGMD.  
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Figure 3.2 – Pedigrees showing the three modes of inheritance for the disease-causing variant(s) in nuclear DNA in the family. 
A) Autosomal recessive inheritance with a single causative variant; B) Autosomal recessive inheritance with two variants in 
compound heterozygosity; C) De novo dominant variant arisen in the germ line cells of a parent. Family members shown in 
transparency represent samples for which DNA was not available.  
3.2.4.1 Autosomal recessive inheritance with homozygosity 
As shown in Figure 3.2, candidate causative variants following this mode of inheritance would 
be heterozygous in both parents, homozygous in the proband, and either heterozygous or 
absent in the healthy siblings.  
The first pipeline that I developed discarded – in the filtering step based on segregation – all 
variants with genotype calls different from these, or also with no-calls in any family member. 
A second filtering pipeline was applied that was more permissive towards genotype errors for 
variant calls made at low read depths (<10x) both in family members and HVOLs and towards 
no-calls, while still requiring minimum supporting evidence for the variant to be present in 
the trio parents-proband (at least 1 variant read to be detected, and not allowing homozygous 
reference genotype calls), to obtain a still manageable number of candidates.  
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The two pipelines differed also in terms of population frequency filters for candidate variants. 
An autosomal recessive segregation with homozygosity in the proband implies that the 
variant can be present in controls only in heterozygous state, and at relatively uncommon 
frequencies. Frequency in the general population is expected to be particularly low especially 
when the disease caused by the homozygous variant is lethal before reproductive age, like in 
this case. The prior probability of the two parents, being unrelated, sharing exactly the same 
rare variant is very low, but if this happens, then the chances of having 3 or more of 5 children 
being homozygous for the disease variant is ~10.4%, as shown by the following binomial 
formula: 
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Selecting a MAF frequency cut-off is an arbitrary choice, and I chose to be inclusive, in order 
to ensure I would not miss plausible candidates. I filtered out variants >1% of ESP and 1KGP 
in both versions of the pipeline, but I allowed up to 1% of HVOL to be heterozygote carriers 
in the stringent pipeline, and up to 5% and 20% of HVOL to be homozygous and heterozygous 
carriers, respectively, in the relaxed version in order to be robust towards erroneous 
genotype calls, which I could subsequently check more thoroughly. 
3.2.4.2 Autosomal recessive inheritance with compound heterozygosity 
Filtering procedures that can be developed with SNPSift are based on single variants’ 
characteristics. This caused the necessity of two separate filtering steps based on family 
segregation: a first one based on the genotypes of the single variants, and a second one in 
which I retained only variation occurring in genes with ≥2 variants, and manually checked that 
the two variants in question did not occur together also in parents and in the healthy siblings, 
besides co-occurring in the proband. Attempting to develop a relaxed filtering approach 
based on similar assumptions to those made for the homozygosity model (Paragraph 3.2.4.1, 
basically regarding all calls made at <10x as unreliable), would inevitably lead to an 
unmanageable number of candidate variants. However, given the importance of 
reference:alternative reads in determining the reliability of heterozygous genotype calls (as 
partly discussed in Paragraph 2.3.6.4), developed an alternative pipeline using SNPSift and a 
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script written in R (called allelic_balance_filter, of which an example block of code is shown 
in the Appendices, in Paragraph 6.4.2) treating variants on the basis of their 
reference:alternative reads ratio (considering ratios between 15:85 and 85:15 as 
heterozygous sites, and treating as homozygous those outside it). The 15:85 – 85:15 cutoffs 
are default values used to help avoid erroneous variant calls, for example by the variant calling 
software Lifescope. In order to validate the check whether these thresholds could well 
discriminate in terms of variant call quality, I assessed the Ti/Tv ratio of the four categories of 
variation defined by these values in the proband (considering biallelic sites with read depth 
≥10x), and Ti/Tv values confirmed heterozygous calls outside the 15:85-85:15 interval, and 
homozygous calls within this interval to be evidently characterised by lower quality (Table 
3.3). This second pipeline – while not being necessarily more relaxed than the first one – could 
still prioritise candidate variants not retained by the initial approach. The probability of 3 out 
of 5 children to be affected by a disease following this model is the same as for the autosomal 
recessive model with homozygosity (10.4%). 
Table 3.3 -Transition/transversions ratios for heterozygous and homozygous (for the reference allele or for the variant allele) 
quality-filtered variant calls in the proband, at biallelic sites covered by ≥10 sequencing reads). While heterozygous calls 
within and homozygous calls outside the 15:85 – 85:15 interval of reference:variant reads ratio are characterized by Ti/Tv 
values reflective of what would be expected in coding sequences, Ti/Tv values of the other two classes of variants are markedly 
lower, indicating lower quality calls.  
 Heterozygous calls Homozygous calls 
Within 15:85-85:15 ratios 2.7 0.5 
Outside 15:85-85:15 ratios 1.4 2.5 
 
3.2.4.3 Dominant de novo variant arisen in the germ line cells of a parent 
A third possibility is that of a de novo pathogenic variant arisen in the germ line cells of one 
of the two parents. The assumption, in this case, would be that the variant arose in a 
progenitor cell line of oocytes or spermatocytes, making possible for a consistent proportion 
of gametes to carry the disease variant, then passed to 3 of the 5 children. However, published 
data show that, on average, a given individual has ~1 de novo variant in his/her exome (125), 
therefore we would expect a very low number of candidate variants, which would encourage 
the application of a stringent filtering pipeline. For this reason, I developed a first approach 
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only retaining protein-altering variants confidently heterozygous in the proband (covered at 
≥10x), confidently absent in all the other 4 sequenced family members (homozygous 
reference genotype at ≥10x), and not observed in controls (unseen in the HVOL, ESP and 
1KGP). However, in doing so, I observed in intermediate filtering steps several variants called 
as heterozygous only in the proband, but with extremely skewed reference:alternative reads 
ratios, with 15 of 22 candidate variants left before the MAF filter with only <15% variant reads, 
making the real genotypes at least in a subset of these variants likely to be homozygous for 
the reference allele. Furthermore, given the expectation of 1-2 de novo coding variants per 
individual exome (125), it is unrealistic, by any means, that all 22 candidates retained at this 
stage would be true de novo variants, with the most likely source of error being a failure to 
detect a transmitted allele in a parent, so that the variant appears to be de novo. This might 
be caused by the combination of the proband being sequenced at a considerably higher read 
depth compared to all other samples, and GATK being used in multi-sample mode. 
Considering the case of all samples to be without a variant (all 5 family members + 514 HVOL), 
the higher number of reads in the proband might raise the prior probability of a few reads to 
contain a false positive variant allele. In such a case, this might be enough for GATK to call a 
heterozygous genotype in the proband, when considering that all other samples had zero 
variant reads. To overcome this hypothetical scenario, I developed a second filtering approach 
looking at allele balances rather than genotype calls, with stringent requirements. I always 
required a minimum read depth of 5x and considered: 
1) a genotype to be homozygous reference only if ≤3.5% reads carried the variant  
2) the proband to be a true heterozygous only with ≥20% variant reads if at ≥10x, or with 
≥28% variant reads if at <10x 
In order to be somehow robust to possible genotype errors and taking into account that DCM 
cases are also included in ExAC, I also allowed a maximum of 5 observations in ExAC for 
candidate variants in this second filtering pipeline. 
3.2.4.4 Mitochondrial inheritance 
The disease could also be caused by a variant present in the mitochondrial DNA of the 
maternal germline cells, and inherited by the children. In this case, the hypothetical disease 
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mechanism would imply that the disease variant accumulated, through repeated 
mitochondrial mitotic segregation and clonal expansion to reach a pathogenic 
proportion/threshold in the embryos of the three affected children. The feasibility of mtDNA 
variant detection in cardiomyopathies using NGS data has been documented in literature, 
although it is estimated that a minimum read depth of 20x is needed for detecting variants in 
homoplasmy (requirement likely met by our samples), but a minimum of 200x to reliably 
detect levels of heteroplasmy (234).  
As far as this model was concerned, I extracted all mtDNA variants from the VCF file at first, 
and converted their genomic coordinates to the latest genome reference build 
(GRCh38/hg38), using CrossMap [http://crossmap.sourceforge.net/]. This step was necessary 
since the mitochondrial reference sequence included in GRCh38/hg38 assembly is the revised 
Cambridge Reference Sequence (rCRS, which differs from the mtDNA reference included in 
the previous genome build), and the main source of information about mitochondrial DNA 
variation and its population frequencies – MITOMAP (235) – refers to rCRS coordinates. Then, 
I retained only variants observed in the proband, and absent in the father (as it would be 
extremely unlikely for the father to have inherited the same variant from his mother). This 
step was enough to obtain a manageable number of variants, for which I later checked 
genotypes in other family members, and frequencies in HVOL and in the 30,589 GenBank 
mtDNA sequences reported in MITOMAP. 
3.2.5 Sanger validation of prioritised candidate variants 
Given the extremely limited quantity of available DNA from the proband, we decided to 
Sanger-confirm the genotypes of the final candidate variants in parents and in the two healthy 
siblings at first, and then proceed for validation in 20MA00417 only if there was very strong 
supportive evidence for the variant to be causative of disease in the family. 
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3.3 Results 
3.3.1 Autosomal recessive inheritance model with homozygosity 
I obtained 1 candidate variant applying the stringent variant prioritisation pipeline, and 32 
additional candidates by being more relaxed towards possible genotype errors (Figure 3.3). 
 
Figure 3.3 - Overview of the candidate disease-causing variant filtering pipelines for the recessive model with homozygosity. 
3.3.1.1 Candidate variants 
The only candidate variant left after applying the pipeline based on stringent filters was the 
non-synonymous SNV chr22:39814746:G>A. This variant in the TAB1 gene (cDNA change: 
c.560G>A, protein change: p.Arg187His) is predicted to have a deleterious effect by 2 of 3 in 
silico prediction algorithms that I took into consideration (deleterious by SIFT, Polyphen-2 and 
MutationTaster). The predicted effect is the same in two Ensembl transcripts 
(ENST00000331454 and ENST00000216160, 1660 and 3237bp long, respectively), both 
annotated from both Havana manual and Ensembl automatic annotation, with the predicted 
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protein modification being Arg187His in both cases. While both arginine and histidine are 
polar aminoacids, and tend to be on the protein surface, they possess different properties, as 
histidine has a pKa near to that of physiological pH, meaning that the side chain can switch 
easily from neutral to positive charge, and vice versa. Two DNA evolutionary conservation 
measures (GERP++ (87) and PhastCons (88)) scored nucleotide chr22:39814746:G as 
extremely conserved across 29 mammal species (scored 4.89 by GERP++) and 100 species 
(scored 1.0 by PhastCons) respectively. The expression level of TAB1 in human LV is not 
markedly high, but still comparable to levels observed in other tissues 
(http://www.gtexportal.org/home/gene/TAB1). 
TAB1 is ranked in the 6% most intolerant genes to variation in humans by the RVIS score 
developed by Petrovski et al., and is an essential gene in mice, since all gene knock-outs 
caused post-natal death (236), with ventricle wall thinning and septal and aortic defects, as 
reported in the Mouse Genome Database (MGD) (237). I also checked the estimated 
probability of being a recessive disease gene (238) (p=0.3, ranked ~15th percentile of ~14,000 
scored genes). Haploinsufficiency would not suit a recessive mode of inheritance, but the 
variant in question could cause a decrease in the protein functionality, in which case the mode 
of inheritance might be recessive also for a haploinsufficient gene. The probability of 
haploinsufficiency for TAB1 calculated by Huang et al (239) is 0.44 ranking it in the 34th 
percentile of ~17,000 scored genes. Variation in TAB1 is indirectly linked to cardiomyopathy 
in the literature, as the encoded protein (TGF-beta-activated kinase 1 and MAP3K7-binding 
protein 1) mediates the auto-phosphorylation of p38α, which is an early event in the 
pathological response to stress of cardiomyocytes in cardiac amyloidosis. Amyloidogenic 
light-chain proteins provoke oxidative stress, cellular dysfunction and apoptosis in 
cardiomyocytes through the TAB1-dependent activation of p38α, and patients suffering from 
cardiac amyloidosis suffer from progressive cardiomyopathy (240). Two of 514 HVOL samples 
were heterozygous for the variant (MAF 0.39%), which is observed at very low frequencies in 
both 1KGP (MAF ~0.1%, 6 heterozygous samples) and ESP (MAF ~0.02%, 3 heterozygous 
samples). Its frequency in ExAC is comparable to those in ESP and 1KGP (~0.06%), but beside 
68 heterozygous samples there is also 1 homozygous carrier of the variant (discussed in 
Paragraph 3.3.1.2). Sanger sequencing confirmed the genotype calls made in our family. 
Thirty-two additional candidate variants were obtained through the application of the relaxed 
pipeline (32 including the variant in TAB1), allowing genotype-errors at low read depths or 
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no-calls. Rather than prioritising variants that clearly segregated with disease, the relaxed 
pipeline retained all variants that could not be confidently excluded on the basis of genotype 
and segregation information, requiring a minimum degree of evidence that the variant was 
present in the trio parents-proband. Given the relatively high number of candidates, I scored 
them on the basis of a series of quality metrics and biological features, as shown and 
explained in Table 3.4. None of the 31 additional candidates were taken forward for Sanger 
validation, as the variant in TAB1 outscored all of them and they were characterized in general 
by poor genotype qualities and did not have features suggestive of disease-causing potential. 
I performed literature searches to check possible associations between the prioritised genes 
and cardiovascular phenotypes, but I did not find anything particularly relevant. Genotypes 
for the candidate variant in TAB1 were confirmed by Sanger sequencing in parents and the 
two healthy siblings (all heterozygotes). 
3.3.1.2 ExAC sample homozygous for chr22:39814746:G>A 
We followed up the homozygous sample by contacting the principal investigator of the group 
where the sample (ExAC ID: 1732B) was originally recruited. 1732B was recruited in Parma in 
year 2000, as part of a cohort of individuals affected with diabetes. At the time of blood 
sampling, he was 39 years old, and without prior history of any cardiovascular disease. He had 
4 healthy sisters, and two possibly related grandfathers. Researchers kindly agreed to try and 
contact him, to investigate whether any disease had manifested in the last years, but they 
were unable to find him. However, DNA was still available, and at the moment we are waiting 
for Sanger confirmation of the variant being actually present in 1732B, and seeking to exclude 
the possibility of sample swap.
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Table 3.4 - Candidate variants left after the application of the relaxed filtering pipeline, ranked by cumulative score. Cells highlighted in green indicate a +1 or +2 in computing the score in the following columns 
from left to right: GENOTYPES CALLED IN FAMILY and COMPATIBLE GENOTYPES (how many genotype calls were made over the 5 family members, and how many were compatible with the inheritance model: +2 if 
5 calls were made and all were compatible (bright green), +1 if <5 calls were made, but all were compatible (pale green)); CALL RATE OVER ALL SAMPLES (proportion of samples, including HVOL, with a genotype 
call. +1 if >0.9); MEAN READ DEPTH OVER ALL SAMPLES (+1 if >10x); HVOL HOMVAR (how many HVOL were called as homozygous for the variant allele, +1 if nil); ≥1 DELETERIOUS PREDICTION (+1 if at least one of 
SIFT, Polyphen-2 and MutationTaster predicted the variant to have a deleterious effect); PHASTCONS conservation score (+1 if >0.9); GERP++ conservation score (+1 if >2, cut-off generally used in literature to define 
constrained genes [e.g. in 1000 Genomes Project Consortium, 2012]); RVIS PERCENTILE (+1 if in the top 10% intolerant genes); CONSTRAINT Z SCORE (alternative gene-based score measuring selective constraint, 
+1 if >3.09, threshold defined in (193) for constrained genes); PROBABILITY OF HAPLOINSUFFICIENCY (as from Huang et al, 2010. +1 if in the bottom 10%); PROBABILITY RECESSIVE DISEASE GENE (as from MacArthur 
et al, 2012. +1 if in the top 10%); ESSENTIAL GENE (as from Georgi et al, 2013. +1 if the gene is essential in mice); CARDIOVASCULAR PHENOTYPE IN MICE (as from MGD database, +1 if mice with induced mutations/KO 
in the gene show a cardiovascular phenotype); CUMULATIVE SCORE (cumulative sum of the score over all evaluated parameters). In case of multi-allelic variant sites, the reported CONSEQUENCE refers to the allele 
segregating in the family. 
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chr22 39814746 G A Non-synonymous TAB1 5 5 1.00 42.6 0 Y 1 4.89 6 0.65 0.29 0.30 Y Y 11
chr19 41173898 TTGCTGTTGC T Inframe deletion NUMBL 3 3 0.92 36.3 0 N NA NA NA 2.46 0.30 0.19 N N 4
chr1 160057534 C G Non-synonymous KCNJ9 1 0 0.18 2.8 0 N 0.021 4.27 43 3.64 0.44 0.14 N N 3
chr7 156802643 A AGCGGCG Inframe insertion MNX1 1 0 0.05 2.0 5 N NA NA NA 3.39 0.34 NA Y Y 3
chr19 36632024 GGGC G,GGGCGGC Inframe deletion CAPNS1 2 NA 0.50 3.4 NA N NA NA 34 0.85 0.07 0.34 Y Y 3
chr16 29395136 T G Non-synonymous NPIPB11 2 2 0.87 9.0 0 N 0.002 NA NA 3.10 0.30 NA N NA 3
chr19 1275564 C G Non-synonymous C19orf24 2 0 0.35 4.5 0 Y 0.001 -0.756 NA NA 0.06 NA N NA 3
chr7 143270987 T C Non-synonymous CTAGE15 1 1 0.00 2.0 0 N NA NA NA NA NA NA NA NA 2
chr1 50884795 C A Non-synonymous DMRTA2 1 0 0.20 2.0 0 N 0.958 NA NA 3.01 NA 0.12 N N 2
chr10 47769643 C T Non-synonymous AL603965.1 2 2 0.23 4.4 8 Y 0 -3.52 NA NA NA NA N NA 2
chr22 37465385 CTGGGG C Inframe deletion TMPRSS6 4 1 0.53 2.6 10 N NA NA 82 0.67 0.10 0.15 Y Y 2
chr11 2906196 ACCGCGACCGGAG A Inframe deletion CDKN1C 1 1 0.16 2.4 18 N NA NA NA 2.27 0.69 NA Y NA 2
chr10 1405690 C A Non-synonymous ADARB2 3 2 0.87 7.0 0 Y 0 -4.67 22 1.39 0.18 0.15 N NA 2
chr4 191002237 C T Non-synonymous DUX4L4 1 1 0.01 1.3 2 N 0 NA NA NA NA NA N NA 1
chr1 152190382 A C Non-synonymous HRNR 1 1 0.03 2.4 4 N 0 0.73 43 -0.73 0.16 0.11 N NA 1
chr1 145313383 T C Non-synonymous NBPF10 1 0 0.13 2.7 19 Y 0 -0.925 NA NA NA NA N NA 1
chr2 131221692 T C Non-synonymous POTEI 1 0 0.28 2.3 5 Y 0.001 0.993 NA NA NA NA N NA 1
chr7 100647460 C T Non-synonymous MUC12 2 1 0.18 6.5 1 Y 0.01 0.859 NA NA 0.08 NA N NA 1
chr10 89126668 G A Non-synonymous NUTM2D 3 1 0.22 3.5 16 N 0 -2.58 NA NA 0.01 NA N NA 1
chr9 65506145 A G Non-synonymous SPATA31A7 1 1 0.26 5.1 8 N 0 1.58 NA NA NA NA N NA 1
chr19 54726628 C T Non-synonymous LILRB3 2 1 0.41 6.3 2 Y 0 0.662 97 1.25 0.06 0.07 N N 1
chr19 49378180 AT A Frameshift PPP1R15A 1 0 0.13 2.6 6 N NA NA 99 0.47 0.03 0.19 N N 1
chr19 42620990 AGAG A Inframe deletion POU2F2 2 1 0.64 4.5 6 N NA NA 20 2.15 0.40 0.28 Y N 1
chr7 27169931 GGCA G Inframe deletion HOXA4 2 1 0.26 4.0 0 N NA NA NA 0.28 0.36 NA N N 1
chr1 13109143 A G Non-synonymous PRAMEF6 1 0 0.13 3.3 2 N 0.68 0.0275 NA 3.44 0.09 NA N NA 1
chr8 8176387 C CGGGGCG Inframe insertion SGK223 1 1 0.17 2.6 20 N NA NA 54 -0.54 NA NA N NA 1
chr2 131221668 G A Non-synonymous POTEI 1 0 0.29 1.5 1 N 0.001 0.993 NA NA NA NA N NA 0
chr2 131221663 G A Non-synonymous POTEI 1 0 0.29 1.0 1 N 0 -1.99 NA NA NA NA N NA 0
chr7 100645311 C G Non-synonymous MUC12 2 1 0.49 3.0 5 N 0 -1.22 NA NA 0.08 NA N NA 0
chr11 60620166 TGCG T Inframe deletion PTGDR2 2 1 0.44 4.0 3 N NA NA NA 0.31 0.09 0.20 N N 0
chr19 2015540 GGGCGGCGGC GGGC,GGGCGGC,G Inframe deletion BTBD2 1 NA 0.05 1.4 NA N NA NA 17 2.12 0.13 0.11 N NA 0
chr11 640090
GCCGCGCCCAGCCT
CCCCCAGGACCCCT
GCGGCCCCGACTGT
GCGCCCC
G,CCCGCGCCCAGCC
TCCCCCAGGACCCCT
GCGGCCCCGACTGTG
CGCCCC Non-synonymous DRD4 1 NA 0.24 3.8 NA N NA NA NA 0.76 0.10 0.40 N N 0
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3.3.2 Autosomal recessive inheritance model with compound heterozygosity 
A total of 4 candidate variants (in 2 candidate genes) were prioritised using the pipeline 
filtering on high-quality genotype calls, with two additional variants (in a different gene) 
retained by the pipeline filtering on the basis of allelic balance (Figure 3.4). 
 
Figure 3.4  - Overview of the candidate disease-causing variant filtering pipelines for the recessive model with compound 
heterozygosity. 
3.3.2.1 Candidate variants 
Two pairs of candidate variants prioritised by the filtering pipeline were chr6:12934045:C>T 
and chr6:13273088:G>A in PHACTR1 (encoding phosphatase and actin regulator 1), and 
chr7:6661229:C>G and chr7:6661491:AGCAACAGCAGCTGTT>A in ZNF853 (encoding zinc 
finger protein 853). An additional pair was retained by the second version of the filtering 
pipeline, based on reference:alternative reads ratio: chr7:100647126:A>G and 
chr7:100647460:C>T in MUC12 (encoding mucin 12). Table 3.5 reports variants’ main 
characteristics.
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Table 3.5 - Candidate variants following the autosomal recessive mode of inheritance with compound heterozygosity. The last pair (variants in MUC12) are additional candidates prioritised by 
the pipeline based on reference:alternative reads ratio rather than genotype calls, and allowing no-calls.  
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chr6 12934045 C T 5 5 Non-synonymous PHACTR1 ENST00000379348 Thr144Ile 326 (0.3%), all het 
chr6 13273088 G A 5 5 Non-synonymous PHACTR1 ENST00000379335 
ENST00000379329 
Arg27His 493 (0.4%), 5 
homozygotes 
           
chr7 6661229 C G 5 5 Non-synonymous ZNF853 ENST00000457543 Leu203Val Novel 
chr7 6661491 AGCAACAG 
CAGCTGTT 
A 5 5 Inframe deletion ZNF853 ENST00000457543 Gln290_Leu295del 101 (0.5%), 3 
homozygotes 
           
chr7 100647126 A G 3 3 Non-synonymous MUC12 ENST00000379442 
ENST00000536621 
Asn4571Asp 
Asn4428Asp 
1 (5.2x10-5), 
low quality site 
chr7 100647460 C T 2 2 Non-synonymous MUC12 ENST00000379442 
ENST00000536621 
Thr4682Met 
Thr4539Met 
Novel 
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PHACTR1 is one of the most commonly identified hits in GWASs for coronary artery disease 
and myocardial infarction, and it has been recently demonstrated to regulate the switch of 
skeletal and cardiac α-actin contractile protein isoforms (241). In the same study, 
investigators also observed that, while mRNA levels did not differ, PHACTR1 protein levels 
were significantly elevated in patients with cardiomyopathy when compared to control 
hearts. Expression levels of PHACTR1 in human LV are markedly higher than those observed 
in other tissues, whilst being in line with those observed in the brain 
(http://www.gtexportal.org/home/gene/PHACTR1). However, the two candidate variants in 
PHACTR1 fall in different, non-overlapping transcripts (one alters the Ensembl/Havana 
annotated ENST00000379348, the other alters the Ensembl/Havana annotated 
ENST00000379335 and the automatically Ensembl annotated ENST00000379329), in 
mutually exclusive exons. In silico predictions are discordant for both PHACTR1 variants. 
Variant chr6:13273088:G>A is also observed in homozygosity in 5 ExAC samples. 
The inframe deletion chr7:6661491:AGCAACAGCAGCTGTT>A in ZNF853 is observed in 
homozygosity in the ExAC cohort (3 samples), and 4 homozygous samples are present in ESP 
and 1KGP cohorts (although up to 3 of them might be the same individuals accounted for in 
ExAC). The other heterozygous candidate variant in the same gene (chr7:6661229:C>G) is 
completely novel, although it appears to be at a nucleotide position not conserved in 
vertebrates (PhastCons score of 0.09, GERP++ score not available). In silico variant 
pathogenicity predictions are not reported in dbNSFP v2.7. However, at the gene level, not 
much appears to be known about the function of ZNF853, and a Pubmed search with this 
gene’s name yields no results. Its expression levels in the human LV are comparable to those 
observed in nearly all other tissues (http://www.gtexportal.org/home/gene/ZNF853). 
As far as the two non-synonymous SNVs in MUC12 are concerned, they are both called as 
heterozygous in the proband, but at read depths <10x (5x and 8x). Some of the other family 
members have no-calls, with genotype calls made being anyway compatible with the 
hypothesized inheritance model. Both MUC12 variants appear to be rare in the population - 
chr7:100647126:A>G has an allele count of 1 in ExAC, while chr7:100647460:C>T is not 
present - although the former is flagged as a low-quality site (it did not pass all quality filters), 
and the latter is at a position covered at very low read depth (≤5x in all samples). In literature, 
I did not find indications suggesting an association of MUC12 with cardiomyopathies, or CVD 
in general. Only variants in PHACTR1 and ZNF853 were brought forward for Sanger validation: 
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genotypes called for variants in PHACTR1 in parents and siblings were confirmed, while in 
ZNF853 Sanger validation was possible only for chr7: 6661229:C>G (confirmed), as the 
inframe deletion chr7:6661491:AGCAACAGCAGCTGTT>A proved to be in a problematic region 
for Sanger sequencing. 
3.3.3 De novo variant model 
As shown in Figure 3.5, I obtained 2 candidate de novo variants heterozygous in the proband, 
and absent in parents, siblings, HVOLs, 1KGP, ESP and ExAC. The second version of the filtering 
pipeline (based on reference:alternative reads ratio) kept 5 additional candidate variants. All 
7 candidate variants were brought forward for Sanger validation, to confirm their absence in 
parents (and in the two healthy siblings) (Table 3.6).  
 
Figure 3.5 - Overview of the candidate disease-causing variant filtering pipelines for the de novo variant model. 
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Table 3.6 - Overview of the 6 variants prioritised by the pipelines for the de novo variant model, and results of Sanger 
validation of genotypes in parents and healthy siblings. NS=non-synonymous, RD=read depth. 
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chr10 14950858 A G NS DCLRE1C 0 0 YES 
chrX 104478667 G T NS IL1RAPL2 0 0 YES 
chr2 128066336 C T NS MAP3K2 3 heterozygotes 
(2.50x10-5) 
0 NO 
chr7 111540441 C T NS DOCK4 3 heterozygotes 
(2.86x10-5) 
0 NO 
chr19 46025769 G C NS VASP Novel (low 
quality site) 
0 (mean RD 
<10x) 
NO 
chr19 49106980 C T NS FAM83E Novel (low 
quality site) 
0 (mean RD 
<10x) 
NO 
chr19 49559626 C T NS NTF4 0 0 NO 
 
3.3.3.1 Candidate variants 
Following Sanger validation, the two candidate de novo variants prioritised by the stringent 
filtering pipeline were left: chr10:14950858:A>G in DCLRE1C (encoding DNA cross-link repair 
1C), and chrX:104478667:G>T in IL1RAPL2 (encoding interleukin-1 receptor accessory 
protein-like 2). Both variants are novel and at well-covered sites in ExAC, and additional 
variant characteristics are shown in Table 3.7. As shown in the table, all in silico predictors 
scored the DCLRE1C variant as damaging, while predictions were discordant for the variant in 
IL1RAPL2 (only MutationTaster scored it as disease-causing). The variant in DCLRE1C alters 
several transcripts, some with Ensembl/Havana merged annotation, others only 
automatically annotated by Ensembl, as are both transcripts altered by the SNV in IL1RAPL2. 
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Given that the de novo dominant disease model is based on the concept of haploinsufficiency, 
I also considered an additional score measuring the probability of each gene of being 
intolerant to functional variation, called probability of being loss-of-function intolerant (pLi), 
which outperforms the constraint Z score developed by Samocha et al. (193) as an intolerance 
metric (96). Values <0.1 indicate loss-of-function tolerant genes, while values >0.9 classify 
genes as loss-of-function intolerant. 
DCLRE1C is ranked in the 60th percentile of RVIS intolerance score, in the 53rd for the 
constraint Z score, and has a pLi score of ~0.003, all values suggestive of a certain degree of 
tolerance to functional variation. It is also not characterized by a particularly high estimated 
probability of haploinsufficiency computed by Huang et al. (239) (0.21, ranking in the 41st 
percentile). Studies have shown associations of variants in DCLRE1C with immunodeficiencies 
and other immune system disorders (242), but I was unable to find any result suggestive of a 
possible role of DCLRE1C in cardiac disease.  
IL1RAPL2 is estimated to be – yet not markedly – more intolerant to variation by RVIS and the 
constraint Z score, being in the 37th and in the 32nd percentile, respectively. Its probability of 
haploinsufficiency estimated by Huang et al. is also not very high, and similar to that of 
DCLRE1C (0.24, 37th percentile). However, pLi scores IL1RAPL2 as being loss-of-function 
intolerant, with a score of ~0.97. IL1RAPL2 is located at a region on chromosome X associated 
with mental retardation (243,244). Expression levels of both DCLRE1C and IL1RAPL2 in the 
human LV are low in comparison with those observed in other tissues 
(http://www.gtexportal.org/home/gene/DCLRE1C and http://www.gtexportal.org/home 
/gene/IL1RAPL2). 
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Table 3.7 - Additional characteristics of the two novel, non-synonymous variants prioritised by the de novo variant filtering 
approach and confirmed by Sanger sequencing. 
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chr10:14950858:A>G DCLRE1C ENST00000396817,ENST00000378254, 
ENST00000453695,ENST00000378258, 
ENST00000378255 
 
ENST00000378246,ENST00000378249, 
ENST00000357717 
 
ENST00000378278 
 
ENST00000378242 
Ile423Thr 
 
 
 
Ile428Thr 
 
 
Ile543Thr 
 
Ile196Thr 
1.00 5.93 SIFT, Polyphen-2 
and 
MutationTaster: 
 
Deleterious/Disease-
causing 
chrX:104478667:G>T IL1RAPL2 ENST00000344799, ENST00000372582 Glu174Asp 0.98 4.94 SIFT, Polyphen-2: 
Tolerated/Benign 
 
MutationTaster: 
Disease-causing 
3.3.4 Mitochondrial inheritance model 
Of the 16,159 quality-filtered mtDNA variants across all samples, 8 were present in the 
proband and absent in the father (it would be extremely unlikely for the father to have 
inherited via maternal mtDNA the same disease-causing variant provoking DCM in the family, 
but with a proportion of variant mtDNA low enough not to cause a disease phenotype). Of 
the 8 variants retained, only 1 had a non-synonymous effect (chrM:11255:T>C), in locus ND4 
(encoding for NADH dehydrogenase subunit 4). However, the same variant was also observed 
in homoplasmy (genotype call 1/1, with all reads carrying the variant, and all calls at >30x) in 
the mother and in the two healthy siblings, besides being observed in 25 samples among 
those reported in MITOMAP. 
174 
 
3.4 Discussion 
3.4.1 Candidate variants and genes 
Following the application of Prioritisation pipelines and the validation of candidates by Sanger 
sequencing, a total of 7 variants in 5 candidate nuclear genes (TAB1, PHACTR1, ZNF853, 
DCLRE1C and IL1RAPL2) were left for final evaluation. 
3.4.1.1 chr22:39814746:G>A in TAB1 
The only candidate variant prioritised by the pipelines for the autosomal recessive model with 
homozygosity and Sanger-validated deserves further attention and it is a good candidate for 
functional studies. The high degree of evolutionary conservation of the mutated nucleotide, 
the marked level of genic intolerance to variation in humans estimated by the RVIS score, and 
the damaging/deleterious prediction made for the variant effect by three independent in 
silico algorithms are all characteristics suggestive of a high disease-causing potential for this 
non-synonymous variant. Furthermore, the previously demonstrated link between TAB1 and 
cardiomyopathy makes this variant the top candidate for disease causation in the family 
among those prioritised. However, the existence of one unaffected individual in ExAC with a 
homozygous genotype, if proven, would strongly question the pathogenicity of this variant. 
At the moment, we are waiting for definitive results regarding the genotype of sample 1732B, 
and in case of a confirmation of homozygosity for the variant allele, the hypothesis for 
chr22:39814746:G>A to cause DCM would become much weaker.  
Incomplete penetrance would be highly unlikely, given the very severe phenotype of the 
proband and the unusually early onset of DCM in the affected family members. For the same 
reasons, it is unlikely – yet not impossible – that 1732B developed DCM at some point during 
the last 15 years, at >40 years of age. Other possible explanations might involve other 
variants: affected, homozygous carriers in the family might carry a second variant that, in 
combination with homozygosity for chr22:39814746:G>A may cause disease. As an 
alternative, 1732B might benefit from the protective effect of one or more other variants 
restoring the physiological functionality of the pathway regulated by TAB1, or this variant 
might be disease-causing in individuals of certain ethnicities (i.e. Middle-Eastern, in this case) 
and not in others (1732B is from the ex-Yugoslavian area), although this does not seem likely 
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given the severity of the phenotype in the family. However, all these hypotheses are largely 
conjectural, besides being difficult to investigate. 
3.4.1.2 chr6:12934045:C>T and chr6:13273088:G>A in PHACTR1 
The candidates in compound heterozygosity in PHACTR1 alter two different transcripts, falling 
in two mutually exclusive exons. In spite of PHACTR1 showing altered expression levels in 
cardiomyopathy in published studies, this makes the two candidate variants very unlikely to 
cause disease following a model based on compound heterozygosity, as - even assuming they 
were expressed simultaneously - one copy of each of the two protein isoforms would be 
functional. Furthermore, 5 individuals in ExAC are homozygous for the non-synonymous 
variant chr6:13273088:G>A. The assumption behind compound heterozygosity implies that 
each of the two variants inherited together by the proband impairs the functionality of one 
of the two copies of the encoded protein. Therefore, homozygosity for any of the two disease 
mutations would result in disease. Even though ExAC does not only include data from healthy 
subjects, the observation of five individuals carrying one of the two candidate variants in 
homozygosity, besides the two variants falling in mutually exclusive exons make PHACTR1 a 
weak candidate in this case. 
3.4.1.3 chr7:6661229:C>G and chr7:6661491:AGCAACAGCAGCTGTT>A in ZNF853 
Zinc finger proteins are the most abundant class of proteins in the human proteome, with 
some associated with disease (245) and with many still uncharacterized. Zinc-finger protein 
853 contains 5 Cys2-His2 zinc fingers - the largest family of DNA-binding domains - extremely 
common feature of transcription factors. Their DNA-binding specificity remained largely 
unknown in spite of years of research, with only very recent efforts yielding new insights 
allowing more accurate predictions of binding sites (246).  However, functional and biological 
information about ZNF853 is very scarce, and a Pubmed search performed with the gene 
name yielded no results. In any case, the presence of 4 homozygous individuals in ESP and 
1KGP for the inframe deletion chr7:6661491:AGCAACAGCAGCTGTT>A suggests – as for 
chr6:13273088:G>A in PHACTR1 – a disease-causing mechanism based on compound 
heterozygosity to be unlikely. 
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3.4.1.4 chr10:14950858:A>G in DCLRE1C 
Non-synonymous variant chr10:14950858:A>G possesses several characteristics indicative of 
a potential disease-causing effect. The variant is extremely rare (being not observed in 1KGP, 
ESP, ExAC and HVOLs), and it falls at an extremely conserved nucleotide position in evolution. 
Furthermore, SIFT, Polyphen-2 and MutationTaster all predict a deleterious effect. The 
amino-acid change (isoleucine to threonine) can predictably cause dramatic consequences on 
the structure and function of any protein, being a hydrophobic residue (isoleucine, usually 
buried inside the protein core) replaced by a polar amino-acid (threonine, often on the 
protein surface). At the gene level, DCLRE1C does not seem to be particularly intolerant to 
variation, as measured by RVIS, and its estimated probability of haploinsufficiency is low. The 
DCLRE1C gene also apparently does not show biological characteristics pointing towards a 
possible involvement in cardiac disease. The encoded protein (DNA cross-link repair 1C) is 
required for V(D)J recombination, mechanism at the basis of the capability of 
immunoglobulins and T-cell receptors to recognize antigens from nearly all pathogens. Thus, 
the physiological role of DCLRE1C seems strictly related to the immune system, which is 
consistent with the associations of DCLRE1C variants with immune system disorders 
demonstrated in previous studies.  
3.4.1.5 chrX:104478667:G>T in IL1RAPL2 
The variant prioritised in IL1RAPL2 (chrX:104478667:G>T) is characterized, in part, by similar 
features to the one in DCLRE1C. It is a novel variant, unseen in publicly accessible reference 
cohorts and in HVOLs, it causes a non-synonymous amino-acid change, and the modified 
nucleotide shows a high degree of conservation along evolution. However, in silico 
predictions in this case are discordant, with SIFT and Polyphen-2 both predicting a neutral 
effect for the variant, and only MutationTaster classifying the variant as deleterious. 
Differently from the candidate variant in DCLRE1C, chrX:104478667:G>T causes the 
replacement of a polar residue (glutamic acid) with another polar residue (aspartic acid), 
sharing similar physical and chemical characteristics. At the gene level, IL1RAPL2 is neither 
characterized by a high degree of intolerance to variation in humans, nor by a high probability 
of haploinsufficiency, as described in Paragraph 3.3.3.1. However, cytokines of the 
interleukin-1 family play a central role in the regulation of immune and inflammatory 
responses, and a role of IL-1 family proteins to play a role in cardiomyopathy was suggested 
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in humans (247) and observed in animal models (248). Also proteins mediating the IL-1 
signalling, such as those of the interleukin-1 receptor family and IL-1 receptor-accessory 
proteins have been shown to mediate at least a part of the processes involved in the 
progression of cardiomyopathies with marked inflammatory features (249,250). Interestingly,  
IL1RAPL2 was predicted to be a causal disease gene for DCM by a machine-learning approach 
prioritising disease genes on the basis of a diverse group of genomic features (251). In any 
case, the most severely affected member of the family was a female (the proband), and whilst 
not ruling out IL1RAPL2 as a candidate, if the causative variant was on the X chromosome we 
would expect males to generally show more severe phenotypes. This is the case, for example 
of Fabry disease (associated with variants in GLA) (218) and Danon disease (associated with 
variants in LAMP2) (253), characterized by HCM and DCM among their phenotypical 
manifestations, respectively. 
3.4.2 Results in the context of other exome studies in familial DCM 
In the last 5 years, WES has been used several times in studies of familial DCM both in cases 
of dominant and recessive inheritance as a tool for identifying putative disease-causing 
variants. While the overall success rate of this approach remains difficult to measure due to 
the lack of publications reporting negative results, there are some studies of this kind that 
successfully identified disease-causing variants in DCM. Only in a small proportion of the 
studies has WES been used exclusively and it is more often coupled with other strategies (such 
as linkage analysis) to help with variant prioritisation (e.g. by narrowing the candidate region 
through linkage) or combined with with further evidence substantiating evidence for 
pathogenicity (e.g. functional assays, or observation of co-segregation of the same variant in 
a second family affected with DCM).  
Starting from 2011, Theis et al. (254) used linkage analysis and homozygosity mapping, 
coupled with WES to identify the variation causing DCM in 3 siblings, and proposed a shared 
homozygous SNV in GATAD1 absent in HapMap, 1KGP and 474 ethnically matched controls 
as being disease-causing. In the same year, Norton et al. (255) published the study originally 
associating variants in BAG3 to DCM, based on the usage of WES and high-density CNV 
assessment in an affected family with dominant transmission. In this case, WES did not 
identify causative variants, but a deletion in BAG3 was identified as causative by the CNV 
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analysis. Investigators also performed functional studies in vivo, by knocking out BAG3 in 
zebrafish, which caused a DCM phenotype in the animals. In 2014, functional studies 
conducted in vitro utilizing cell models to elucidate the effects of the only WES candidate 
variant in a family with a DCM segregation pattern suggestive of X-linked inheritance 
dismissed the variant from being pathogenic. Investigators went back to reanalyse WES data, 
and Sanger sequenced exons on which NGS failed due to the high GC content, and later 
identified a 14bp frameshift deletion in exon 1 of EMD as pathogenic (256). Collectively, these 
studies’ results suggest how additional strategies coupled with WES variant filtering pipelines 
are often necessary to unambiguously identify pathogenic variants.  
In addition, studies that solely used WES to identify pathogenic variation in pedigrees where 
DCM segregates have also been published. These includes the study performed by Campbell 
et al. in 2013 (257), where the authors prioritised the Arg173Pro missense SNV in TNNT2 as 
causative of DCM in a family sequenced with WES. Also in 2013, Wells et al. (258) identified 
the Arg636His RBM20 variant as causative of DCM in a large pedigree using WES alone. In 
these two cases, although variant filtering from WES was the only strategy adopted, 
corroborating evidence for the causal role of the prioritised variation came from multiple 
observations of co-segregation of the same variants in other affected families. Campbell et al. 
reported the co-segregation of the same TNNT2 variant in a distinct pedigree affected with 
DCM included in the cardiomyopathy registry used for study, and the RBM20 variant 
identified by Wells et al. had previously been associated to DCM in 2010 (201). 
As far as paediatric DCM is concerned, I found a single study published in 2015 by Long et al. 
(259), reporting the successful prioritisation of two compound heterozygote truncating 
variants in ALMS1 causative of Alström syndrome with severe DCM in a 5 week-old proband 
with unaffected parents. The authors used 1KGP and ESP sequence data for control and 
prioritised variation in 7 candidate genes. Variants in ALMS1 were then brought forward as 
final candidates as variation in this gene was an already known rare cause of paediatric DCM. 
The paucity of published WES variant prioritisation analyses in families with paediatric DCM 
is likely due to the late-onset of DCM in general.  
In the case of the family I analysed, there are several factors that rendered the sole use of 
WES sufficiently powerful to obtain a manageably low number of candidate variants to be 
considered for further analysis. In the first place, a sequenced trio (provided the parents are 
not consanguineous) is often sufficiently powerful per se in yielding a manageable number of 
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candidate variants in cases of de novo or recessive disease. In the second place, the release 
of ExAC data, inherently provided a much larger control cohort on which I could filter for 
variants’ frequencies in the general population. Thirdly, I also took advantage of >500 healthy 
controls (besides 2 additional unaffected family members) also sequenced with WES using 
the same platform. Furthermore, downstream from the filtering pipeline, strong evidence 
exists in literature pointing towards a disease-causing role of variation in TAB1, harbouring 
the strongest candidate among variants prioritised for causing DCM by the pipelines that I 
developed. In addition, recessive inheritance was the most likely at the outset given the family 
pedigree. Nonetheless, these results cannot be definitive in absence of supportive evidence 
for the pathogenicity of chr22:39814746:G>A in TAB1, or that of other candidates. In this 
respect, the way forward with regards to this family can essentially be summarised in three 
steps: 
1) Performing a CNV analysis on sequencing data, in order to check whether any CNV 
segregating in the family can be the cause of early-onset DCM in the analysed family 
(as was the case, for example, of the family analysed by Norton et al. in 2011 (255)). 
2) Follow up investigators who originally sequenced ExAC sample 1732B which, to date, 
has to be considered a genotype-positive, phenotype-negative sample. I am now in 
the process of obtaining validation data to ensure whether 1732B is actually a carrier. 
In case of a confirmation, further attention can be put on other candidate variants. 
3) Functional analyses on animal models are in process, and functional data can be 
determined in mice carrying the corresponding homozygous variant. 
If none of these approaches provide final evidence towards a definitive disease-causing role 
of the variant in TAB1 (and/or, in the meantime, additional evidence for one of the other 
candidate variants is not discovered or published), an alternative approach to investigate the 
disease-causing variation in this family could be WGS, provided enough DNA from the 
proband is available. WGS would be inclusive with regards to classes of potential disease-
causing variants not targeted or detected by WES (such as variation outside coding regions, 
e.g. possibly disrupting mechanisms regulating gene expression; or in exons not successfully 
targeted, for example due to high GC content). However, WGS would also yield a much higher 
amount of sequencing data to be analysed, with the risk of ending up with many candidate 
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variants of uncertain clinical significance, with an objective difficulty in annotating and 
retrieving variants’ frequencies for those variants outside the exome. In conclusion, WGS 
would remain the last alternative, in case the other steps mentioned above do not provide 
definitive evidence for pathogenic variation, but with a high risk of yielding an unmanageable 
amount of candidate variants, particularly given the fact that multiple inheritance models are 
possible. 
3.4.3 Limitations of the study 
There are a number of limitations in this study that must be kept in mind when interpreting 
its results. 
3.4.3.1 Technical limitations 
1) The disease-causing variant may be synonymous, non-coding or introduce a de novo 
splice site. In these cases, the disease variant would have been missed by our 
approach. 
2) The causative variant might not be included in the target captured for WES. This 
possibility comprises the variant to be in an unknown gene, or in an exon missed by 
the exon-capture technique used. 
3) The variant might be covered, but missed, filtered out by the variant calling software, 
or incorrectly genotyped. 
4) The sequencing quality of sample 20IB00419 (the proband’s mother) was sub-optimal 
as compared to the other family members, due to lower sequencing output causing 
lower depth of coverage.  
3.4.3.2 Analytical limitations 
1) The disease in the family could be caused by a larger structural variant, such as a CNV, 
which would have been missed by this analysis. A separate analysis would be required 
to prioritise potentially disease-causing CNVs. 
2) This approach is sensitive to incomplete penetrance within the family, since a variant 
would have been discarded if confidently called with the same genotype of the 
proband in an unaffected family member. 
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3) For obtaining a manageable number of candidate variants, the hypothesis of 
mosaicism in one of the two parents has not been considered. However, it is possible 
that the disease-causing variant is present in blood cells of a parent and in his/her 
germline, but absent in the myocardium. In this case, the variant would have been 
discarded. 
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3.5 Conclusion 
Although going to be probably increasingly replaced by WGS in the next years, WES remains 
a powerful and effective technique for identifying disease variants segregating in families, not 
necessarily coupled with additional strategies (e.g. linkage analysis), provided the number of 
candidate variants obtained is appropriate for further analyses. Here, I obtained a 
manageable shortlist of candidate variants solely relying on WES considering four different 
possible modes of inheritance for further evaluation and functional characterisation. Further 
analyses are warranted, and candidate genes will be further characterised. All variants 
prioritised by the more relaxed versions of the filtering pipelines either were not retained 
strong enough candidate to undergo Sanger validation, or actually failed to be confirmed by 
Sanger sequencing. This does not question the need to consider the possibility of genotype 
errors when performing variant discovery, but on the other hand confirms good sequencing 
data quality and good specificity and sensitivity of the variant calling algorithm. 
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4 Prioritisation of pathogenic variants from whole-exome 
sequencing data of families affected with 
arrhythmogenic conditions 
At the beginning of my studies described in this thesis, I prioritised potentially pathogenic 
variation in three families affected with different arrhythmogenic conditions. This was 
intended as preparatory work while waiting for WES data from the family affected with DCM 
described in Chapter 3 to be generated. Individuals in the three families were affected with 
unexplained inherited forms of Brugada syndrome (BRS), catecholaminergic polymorphic 
ventricular tachycardia (CPVT) and a clinically uncategorised condition defined by a 
characteristic depression in the S-T segment of the ECG (STDEP). For completeness, these 
initial studies are presented here. 
4.1 Introduction 
Sudden cardiac arrest (SCA) refers to a cessation of cardiac output which, unless treated with 
immediate resuscitation, naturally progresses into sudden death. Such fatal event is referred 
to as Sudden cardiac death (SCD), indicating natural death from a cardiac cause, in which, 
more precisely, loss of consciousness occurs within one hour of the manifestation of acute 
cardiac symptoms. SCD alone represents 25% of all deaths due to CVD (260), with the risk 
being higher in men than in women, and increasing with age. The rate of SCD is estimated to 
range between 1.4 per 100,000 person-years in women, to 6.7 per 100,000 person-years in 
men (261). Acute arrhythmic events are one of the predominant causes of SCD, and they 
therefore represent one of the biggest contributors to the worldwide burden of CVD. Such 
lethal arrhythmic events, often triggered by acute coronary events, may occur in persons 
without known cardiac disease or in association with structural heart disease. The most 
common pathophysiological cascade involved in fatal arrhythmias is considered to be 
ventricular tachycardia degenerating first to ventricular fibrillation and later to asystole 
(Figure 4.1). Prompt treatment is vital to decrease mortality from SCA, with every minute 
delay without resuscitation causing an increase of 7-10% in mortality (262), and bystander 
resuscitation awaiting the arrival of trained responders allowing to increase survival rates 
twofold to threefold in the UK (263). Arrhythmic SCA can be the final result of several 
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pathological states. Epidemiologic data indicate that structural coronary arterial 
abnormalities and their consequences - resulting in IHD - account for approximately 80% of 
fatal arrhythmias. Non-ischemic myopathies, such as primary DCM and HCM, account for the 
second largest number of SCD, with a contribution of 10-15%. Genetically determined primary 
electrophysiological disorders causing heart rhythm abnormalities such as BRS and CPVT – 
two of the conditions characterising the families analysed in this chapter - are estimated to 
trigger about 5% of fatal arrhythmic events in the general population (Figure 4.1 and 
(264,265)), and up to ~50% if only individuals younger than 35 are considered (266). 
 
 
Figure 4.1 – Pathophysiology and epidemiology of SCD from cardiac causes [Reproduced with permission from Huikuri et al, 
NEJM, 2001, Copyright Massachusetts Medical Society]. 
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4.1.1 Brugada syndrome 
In 1989, the first ECG findings of BRS were reported among six survivors of SCA without 
apparent heart disease (267). Three years later, BRS was identified as a distinct clinical entity 
by the cardiologists Pedro and Josep Brugada (268). The BRS ECG pattern was later classified 
into three types, although the typical, diagnostic pattern shows prolongation of the QRS, 
normal QT interval and ST segment elevation. The prevalence of BRS is currently estimated in 
3-5 in 10,000 people, with men 8-10 times more frequently affected than women, and clinical 
phenotype manifesting at a mean age of 41 (269). Frequently SCD is the first manifestation of 
disease, and most of the arrhythmic events take place during sleep, rest or after large meals 
(270). BRS is generally recognised as a rare, inherited cardiac channelopathy caused by 
alteration of ionic currents that lead to ventricular arrhythmias and SCD. However, in recent 
years, studies highlighted how, besides a reduced sodium channel function, also other factors 
are likely important determinants in causing BRS, since dysfunction of ion channels could not 
explain all the cases (271). 
To date, 18 genes have been reported to be associated with BRS, which  - excluding sporadic 
cases - has an autosomal dominant pattern of inheritance, but with 65-70% of clinically 
diagnosed cases still remaining without an identifiable genetic cause (269). So far, variation 
in SCN5A has been identified as the most commonly variant gene in the disease, being causal 
in up to 25-30% of BRS cases (272). Many other genes have been associated with BRS, most 
of which play a role in the regulation of sodium channel function: SCN10A modulates the 
expression of SCN5A, SCN1B, SCN2B and SCN3B encode subunits of the sodium channel 
Nav1.5, while RANGRF and SLMAP contribute to the regulation of the its intracellular 
trafficking. Also several potassium channels, such as KCNE3, KCNJ8, KCND3, HCN4 and KCNE5 
have been associated with BRS, with KCNE5 being the only BRS gene located on the X 
chromosome. Several BRS genes have also been shown to regulate calcium channels, as is the 
case for CACNA1C, CACNB2B and CACNA2D1. Interestingly, also variants in ABCC9 (inducing 
changes in the ATP-sensitive potassium channels) and variants in PKP2 (correlated with a 
reduced inward sodium current), genes primarily associated with DCM and ARVC respectively, 
have been reported to cause BRS (269).  
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4.1.2 Catecholaminergic polymorphic ventricular tachycardia 
CPVT is one of the most severe of the inherited arrhythmogenic disorders, characterized by 
exercise- or emotional-induced polymorphic ventricular tachycardia and by a mortality rate 
of 50% in untreated individuals up to the age of 20 years (273). Its familial segregation was 
first recognized in 1960 by Berg (original article cited, for example in (274)), when three sisters 
were described with polymorphic ventricular arrhythmias in the absence of structural heart 
disease. The basis for acknowledging CPVT as a distinct disease entity were provided years 
later, for example in 1995 (275), when a series of cases in familial as well as in sporadic forms 
were reported, all characterized by adrenergically mediated bidirectional and/or polymorphic 
ventricular tachycardia. The prevalence of CPVT is estimated to be approximately 1 in 10,000 
people. Although rare, timely recognition is of vital importance given the very high mortality 
rate characterising CPVT in the young. 
CPVT has been associated to the presence of pathogenic variation in genes involved in 
regulating calcium homeostasis. Autosomal dominant CPVT is most commonly associated 
with pathogenic variants in RYR2 (276), which are found in 65% of CPVT patients (20). The 
second gene most commonly associated with CPVT is CASQ2, causing an autosomal recessive 
form of disease and reported in 2-5% of cases (277). Other genes associated with CPVT include 
TRDN, CALM1 and CALM2 (277), but contribute to a very small proportion of CPVT cases. It 
has been proposed that variation in two phenocopy genes may cause an arrhythmogenic 
disorder resembling the classical description of CPVT: the potassium channel KCNJ2 and the 
cytoskeletal protein ANKB (20). To date, approximately 30% of CPVT cases remain without an 
identified genetic cause, it is likely that other genes contribute to the overall disease burden. 
4.1.3 Arrhythmogenic S-T segment depression 
I also investigated a family with a cluster of unexplained SCD suggesting a likely genetic cause. 
Prior clinical evaluation did not detect pathogenic genetic variation in any previously 
described ICC gene. Affected family members had a distinctive ECG pattern segregating in the 
family, characterized by an abnormal depression in the S-T segment. A depression in the S-T 
segment is common and often asymptomatic in the general population (278). However, it can 
be an important electrical biomarker – often accompanied by others - for underlying 
pathological states or life-threatening disorders, such as myocardial ischemia (279), and a 
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significant prognostic indicator of clinical outcomes for example in patients suffering from 
acute coronary syndromes (280). Since underlying CVD was previously excluded in the 
analysed family, I attempted to identify the genetic basis of this ECG phenotype, in the hope 
that it may shed light on the arrhythmic substrate in the affected individuals. 
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4.2 Materials and methods 
4.2.1 Study subjects and family structures 
DNA samples from affected individuals of the three families were obtained, with ethical 
approval, from collaborators at St. George’s University Hospital NHS Foundation Trust (family 
affected with BRS) and at Southampton University Hospital NHS Foundation Trust (families 
affected with CPVT and STDEP), and were selected for WES prior to the beginning of my 
analysis. These comprised 6 individuals affected with BRS, 6 with CPVT and 7 with STDEP: At 
the time in which I performed the analysis. All the three pedigrees were characterised by a 
disease segregation pattern typical of autosomal dominant inheritance, with the causal 
variation in the CPVT family characterised by incomplete penetrance. Pedigrees for BRS and 
STDEP families are shown in Figure 4.2, while the extended pedigree of the CPVT family is 
shown in Figure 4.3. 
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Figure 4.2 -Pedigrees of the families affected with BRS (top) and STDEP (bottom). Affected individuals (on which WES was 
performed prior to my analysis) are coloured in black. Individuals in grey and marked with a letter “U” in the BRS family were 
ascertained unaffected following provocation testing. In both pedigrees, the disease segregation was typical of an autosomal 
dominant inheritance of underlying pathogenic variation.
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Figure 4.3 – Extended pedigree of the family affected with CPVT. At the time of analysis, detailed information relating to which individuals were sequenced with WES were not available. However, the pedigree 
shows autosomal dominant inheritance with incomplete penetrance. Theoretically, also autosomal recessive inheritance would be possible, but it would involve multiple carrier individuals from the family to 
independently marry carriers of the same pathogenic variant which, given the rarity of CPVT (1 in 10,000) is an extremely unlikely hypothesis and can be discarded.
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4.2.2 DNA library preparation, sequencing and variant calling 
The affected samples of all three families underwent the same DNA library preparation and 
NGS protocols. DNA libraries were prepared using the SureSelect system (Agilent), according 
to the manufacturer’s standard protocols. For each sample 3µg of DNA was sheared in 120µl 
of low Tris-EDTA buffer (Covaris S2 – 6 cycles frequency sweeping; duty cycle 10%, intensity 
5, cycles per burst 100; total time 60s), end-repaired (SOLiD fragment library construction kit 
End Polishing Enzymes 1 & 2), and ligated with truncated SOLiD sequencing adaptors (Life 
Technologies T4 ligase). 200-250bp fragments were selected using agarose gel 
electrophoresis (Invitrogen E-Gel system and 2% agarose gel with 50bp ladder), prior to nick-
translation and amplification (Agilent platinum PCR amplification system, 12 cycles). 500ng of 
DNA was then incubated with target-specific biotinylated RNA baits for 24 hours, and the 
target DNA captured using streptavidin-coated magnetic beads (Dynal MyOne Streptavidin 
T1, Invitrogen). Full-length SOLiD indexed sequencing adaptors were added using PCR post-
capture (Agilent Herculase II Fusion DNA Polymerase, 8 cycles), libraries were quantified by 
quantitative PCR (SOLiD library TaqMan quantitation kit) and pooled for emulsion PCR. 
Sequencing initially performed using a SOLiD v4 platform using paired-end sequencing (50bp 
forwards / 35bp reverse). This yielded fewer reads than anticipated, therefore sequencing 
was repeated on the SOLiD 5500xl (75bp forwards, 35bp reverse), as for the discovery DCM 
samples analysed in Chapter 2, and reads from both runs were pooled. Reads were de-
multiplexed and aligned in colour space using SOLiD LifeScope v2.5 (173), and duplicate reads 
were marked using Picard v1.53 (68). Target enrichment factor was calculated as: 
 
𝐸𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡 𝑓𝑎𝑐𝑡𝑜𝑟 =  
(
𝑅𝑒𝑎𝑑𝑠 𝑜𝑛 𝑡𝑎𝑟𝑔𝑒𝑡
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑝𝑝𝑒𝑑 𝑟𝑒𝑎𝑑𝑠)
(
𝑇𝑎𝑟𝑔𝑒𝑡 𝑠𝑖𝑧𝑒
𝐺𝑒𝑛𝑜𝑚𝑒 𝑠𝑖𝑧𝑒)
 
 
Variant calling was originally carried out using GATK v1.4-15 (70) in multi-sample mode 
(separately for the three families and for SNVs and indels) and Lifescope v2.5 (173), and the 
resulting data for the BRS family were analysed by Dr. James Ware (“Genomic dissection of 
arrhythmia and cardiac electromechanics”, thesis submitted to Imperial College London in 
May 2012). Variant calling was re-performed in late 2012 by Shibu John, using GATK v2.3-9 
(70) in multi-sample mode (separately for the three families, and for SNVs and indels), and I 
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analysed the resulting data. LifeScope is a proprietary package produced by Life Technologies 
and designed specifically for the analysis of SOLiD colour-space sequencing data, but does not 
provide a multi-sample mode, in which evidence for a putative variant is considered across 
samples. As mentioned in Paragraph 1.4.2.3, multi-sample calling, a variant that does not pass 
quality filters in a single sample may be identified if the same variant is seen in other samples, 
effectively raising the probability of the borderline findings representing a true positive. This 
is advantageous when jointly called samples represent a coherent set, and it is particularly 
applicable to this analysis, where I was interested in variants shared across samples. 
4.2.3 Data output and quality control 
4.2.3.1 Sequencing output and target coverage 
As I did, later on in my studies, for the DCM family described in Chapter 3, I performed detailed 
quality control also on the sequencing metrics of single individuals in the three families 
presented here. On average, 247,848,286 sequencing reads were produced per samples, 
corresponding to an approximate total of 10 Gb of raw sequencing data per sample. Mean 
sequencing depth showed similar average per-sample values in the three families, with mean 
depths of 46.1x 47.5x and 47.7x for the families with BRS, CPVT and STDEP respectively. 
However, at the level of single samples, mean sequencing depths - as well as several other 
sequencing metrics - were more homogeneous in the family with BRS (range 42.6x-49.6x) 
compared with the STDEP and CPVT families (ranges 39.7x-59.3x and 24.1x-61.3x, 
respectively). At the time of the analysis, using the Life Technologies “publications” section 
(http://www.appliedbiosystems.com/absite/us/en/home/applicationstechnologies/solid-
next-generation-sequencing/publications-literature.html), 6 WES studies reporting the 
identification of a Mendelian disease gene using following SureSelect capture and SOLiD 
sequencing were listed (281–286). These studies reported, collectively, mean read depths 
over single WES samples in the range 36.7x-67.5x, generally confirming mean read depth of 
samples in the three analysed families to be reasonably high to perform variant prioritisation, 
as all samples in the three families were within this range, with the exception of 20so00049 
in the family affected with CPVT (mean depth 24.1x). Table 4.1 summarises sequencing 
metrics of all samples in the three analysed families. 
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Table 4.1 – Sequencing metrics for the 19 affected individuals sequenced with WES in the three families. 
 
4.2.3.2 Variant calling quality control 
I performed a quality control based on variant calling metrics (on SNVs called by GATK v2.3-
9), similar to the one I carried out on the WES data of the family affected with early-onset 
DCM (I previously described the meaning of the different metrics in Paragraph 3.2.2.3). GATK 
identified between approximately 16,000 and 18,000 coding SNVs in each sample, although 
16-17% of them did not pass all its quality filters. An average ~90% of good quality variants 
was genotyped in all samples of a given family. At the time of analysis, I checked the 
proportion of novel variants defining novelty as the absence from dbSNP137. As previously 
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BRUGADA SYNDROME
20sg00082 278393696 55.2 73.5 49.9 56.9 29.5 51.6 0.5 44.2 90.3 82.9 77.4 81.8 49.6 38 4401
20sg00083 239991910 53.8 72.0 62.3 56.4 29.4 51.1 0.5 43.2 90.0 82.3 76.4 81.1 49.3 36 3796
20sg00084 180820908 50.0 79.0 65.6 61.3 28.7 38.5 0.4 47.4 89.6 81.4 74.7 80.6 43.4 31 3458
20sg00085 238314510 62.2 70.3 63.4 48.7 31.1 74.0 0.4 42.2 89.7 81.9 76.0 80.3 47.6 35 4069
20sg00086 218955310 62.9 69.6 65.0 48.6 30.9 73.0 0.5 41.8 89.8 81.7 75.3 79.8 44.1 32 4100
20sg00087 236764398 54.2 72.1 52.0 57.5 29.3 48.8 0.5 43.3 89.6 81.5 75.5 80.3 42.6 35 3802
Average value over samples 232206789 56.4 72.7 59.7 54.9 29.8 56.2 0.4 43.7 89.8 81.9 75.9 80.6 46.1 35 3937.7
CPVT
20so00053 249820330 55.0 83.5 59.2 58.3 29.3 46.3 0.5 50.1 91.4 85.3 80.5 84.3 61.3 46 2328
20so00029 306186612 69.1 81.4 39.9 59.4 33.8 82.3 0.4 48.9 93.2 87.2 82.1 85.7 56.8 40 4664
20so00030 314724654 70.5 78.4 37.0 60.5 33.9 84.8 0.5 47.1 93.0 87.5 82.6 86.5 53.6 40 4346
20so00049 186241572 65.3 66.7 42.7 46.8 32.4 85.9 0.4 20.0 85.9 73.5 64.3 71.6 24.1 18 1770
20so00050 295393690 63.2 58.1 65.1 46.5 32.6 85.6 0.5 17.4 88.1 78.8 72.4 77.3 49.0 34 2295
20so00051 241298348 64.4 64.4 57.1 46.6 32.6 85.7 0.5 19.3 87.3 76.7 69.6 75.1 39.8 28 2313
Average value over samples 265610868 64.6 72.1 50.2 53.0 32.4 78.4 0.5 33.8 89.8 81.5 75.2 80.1 47.5 34 2952.7
ST DEPOLARIZATION
20so00022 292711670 63.2 75.5 57.5 48.2 32.0 75.8 0.4 45.3 90.7 84.0 79.1 82.8 58.0 44 3106
20so00023 290045808 63.0 75.2 48.3 48.7 30.8 71.9 0.5 45.2 90.8 83.8 78.6 81.9 48.2 39 2700
20so00024 246614978 61.6 72.2 55.3 48.0 31.8 75.0 0.4 43.4 89.3 81.9 76.3 80.5 43.7 34 2492
20so00025 223131454 63.7 71.1 56.9 48.4 31.9 76.3 0.4 42.7 89.6 81.6 75.4 80.3 41.6 32 2382
20so00057 238274360 52.8 78.7 67.7 58.6 30.9 45.9 0.4 47.2 91.4 84.7 79.6 84.1 59.3 42 2737
20so00059 193562224 62.6 71.3 70.4 48.3 32.4 78.3 0.4 42.8 89.4 81.2 74.8 80.1 43.7 31 2738
20so00066 237870994 57.8 79.6 38.3 59.8 30.2 47.0 0.4 47.8 90.1 82.7 76.9 82.2 39.7 34 1473
Average value over samples 246030213 60.6 74.8 56.4 51.4 31.4 67.2 0.4 44.9 90.2 82.9 77.2 81.7 47.7 37 2518.3
AVERAGE OVER ALL SAMPLES 247848285.9 60.6 73.3 55.5 53.0 31.2 67.3 0.4 41.0 89.9 82.1 76.2 80.8 47.1 35.2 3103.7
Approx. StDev BrS samples 31837164.0 5.1 3.4 6.9 5.1 1.0 14.2 0.1 2.0 0.3 0.6 1.0 0.7 3.1 2.6 324.6
Approx. StDev CPVT samples 49164003.8 5.5 10.4 11.7 7.0 1.7 15.8 0.0 16.3 3.2 5.9 7.6 6.2 13.6 10.1 1224.8
Approx. StDev ST samples 35404430.3 4.0 3.4 11.0 5.3 0.8 14.3 0.0 2.1 0.8 1.3 1.9 1.5 7.9 5.1 514.2
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mentioned, the first WES study applied to Mendelian disease (214) reported 6-7% variants 
absent from dbSNP132, and I observed up to 5.0% to be absent from dbSNP137, in line with 
expectations given the comparison with a more recent and inclusive version of dbSNP. The 
ratio of transitions to transversions was line with that observed in the family presented in 
Chapter 3 and in previously published studies (Paragraph 3.2.2.3), with values around 2.7 
considering all SNVs in the targeted region, and >3 when considering only exonic variants. 
Also the ratios of non-synonymous to synonymous (around 0.9 for all variants) and 
heterozygous to homozygous SNVs (1.4-1.6) were similar to those observed in the DCM family 
presented in Chapter 3 and to values reported in literature (Paragraph 3.2.2.3). Table 4.2 
summarises the various quality control parameters for SNVs called in the three families. 
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Table 4.2 – Variant calling metrics for the 19 members of the three families. 
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4.2.4 Prioritisation of candidate disease causing variants 
Given that the hypothetical inheritance model was the same in all three families (autosomal 
dominant), I applied the same prioritisation pipeline to all three pedigrees. All the sequenced 
samples were affected, therefore all samples in any given family would be expected to carry 
the causative variant in heterozygosity. At the time of the original analysis, I filtered in all 
three families for protein-altering variants not recorded in dbSNP137, called as heterozygous 
at ≥10x in all samples. However, with the release of ExAC data in October 2014, a much larger 
and more reliable resource is available to define variants’ novelty and retrieve variation 
frequencies, therefore I optimised the prioritisation pipelines in these families using ExAC 
instead of dbSNP. Given the incomplete penetrance characterising disease-causing variation 
in the family affected with CPVT, and the fact that incomplete penetrance cannot be excluded 
also in the other two families, I allowed prioritised variants to be observed up to 3 times in 
the ExAC cohort. The choice of allowing a maximum of 3 observations in the 60,706 individuals 
part of the ExAC cohort was made on similar considerations to those that led me to filter for 
variants up to 0.1% in the general population in the context of the study on DCM described 
in Chapter 2 (Paragraph 2.1): considered the genetic heterogeneity characterising BRS and 
CPVT, and their low prevalence in the general population (estimated in 3-5 and 1 in 10,000, 
respectively) it would be unlikely for a causative variant, in spite of not being fully penetrant, 
to be observed at higher frequencies. For all the three families, given the high number of 
candidate variants remaining after the initial prioritisation based on family genotypes, variant 
quality, rarity and protein-altering effect, I ranked candidate variants using several metrics at 
the variant-level (e.g. evolutionary conservation of the variant nucleotide and in silico 
predictions of pathogenicity) and at the gene-level (e.g. degree of constraint of the gene 
towards functional variation, reported cardiovascular phenotype in animal models with 
impaired gene function etc). This is very similar to what I did to rank candidate variants 
obtained with the relaxed pipeline for autosomal recessive inheritance with homozygosity in 
the DCM family presented in Chapter 3 (ranking displayed in Table 3.4). 
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4.3 Results 
Applying the same pipeline in the three families (described above) I obtained a considerably 
high number of candidate variants in spite of the stringency of the filtering procedure, which 
did not consider the chance of any genotype error, did not allow “no-calls” and required a 
minimum depth of 10x in each sample at the variant position. An overview of the number of 
variants left after each filtering step in the three families is shown in Figure 4.4. 
 
 
Figure 4.4 - Overview of the number of variants before and after each filtering step leading to the final set of disease-causing 
candidates in the three analysed families. 
However, many (n=25) of the prioritised rare protein-altering variants were unexpectedly 
shared by more than one family, and have been excluded from further analysis. In the first 
place, it is highly unlikely that the same variant causes two different disease phenotypes in 
different families, and in the second place these variants most likely represent artefactual 
variant calls due to biases introduced by the reads alignment or sequencing in the genomic 
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regions in question, given the fact that variant calling was performed separately for the three 
pedigrees. A list of the variants shared by more than one family is shown in Table 4.3. 
Table 4.3 -List of the 25 rare protein-altering variants shared by more than one family following the prioritisation pipeline. 
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chr3 75714929 G A Non-synonymous FRG2C BRS,STDEP 
chr3 75714950 C A Non-synonymous FRG2C BRS,STDEP 
chr3 75715118 G A Non-synonymous FRG2C BRS,STDEP 
chr3 75781263 T C Non-synonymous ZNF717 BRS,STDEP,CPVT 
chr6 57398226 T A,G Non-synonymous PRIM2 STDEP,CPVT 
chr7 142206799 C A Non-synonymous TRBV10-2 CPVT,STDEP 
chr12 58220841 C T Non-synonymous CTDSP2 BRS,STDEP,CPVT 
chr12 58220844 C T Non-synonymous CTDSP2 BRS,STDEP,CPVT 
chr16 70884524 C G Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 70894087 T C Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 70902559 C T Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 70902568 C T Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 70917855 A G Non-synonymous HYDIN BRS,STDEP 
chr16 70917931 C G Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 70954513 T C Non-synonymous HYDIN BRS,STDEP 
chr16 70972620 G C Non-synonymous HYDIN BRS,STDEP 
chr16 70975667 T C Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 70989299 C T Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 70989335 G A Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 71026076 C G Non-synonymous HYDIN BRS,STDEP,CPVT 
chr16 71061495 A G Loss of stop codon HYDIN BRS,STDEP,CPVT 
chr16 71098649 T C Non-synonymous HYDIN BRS,STDEP,CPVT 
chr17 45234298 G C Non-synonymous CDC27 BRS,STDEP 
chr17 45234343 T G Non-synonymous CDC27 BRS,STDEP,CPVT 
chr17 45235583 A C Gain of stop codon CDC27 BRS,STDEP 
 
Following the exclusion of the 25 candidate variants shared by 2 or 3 families, 10,5 and 13 
candidate variants were left in the BRS, CPVT and STDEP families, respectively. Considering 
the still high number of candidates, in particular in the BRS and STDEP families, I further 
characterised each variant on the basis of several features both at the variant- and gene-level, 
as I did for the relaxed filtering pipeline applied for autosomal recessive inheritance with 
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homozygosity in the DCM family presented in Chapter 3 (Table 3.4). Many metrics measuring 
the constraint of genes towards functional variation were published after the original 
prioritisation pipeline that I applied in 2012-2013, and I recently added them in order to 
further characterise candidates. 
4.3.1 Candidate variants in the family affected with Brugada syndrome 
As shown in Table 4.4, I obtained 10 candidate disease-causing variants following 
prioritisation in the family affected with BRS. Of these, non-synonymous SNV 
chr12:109052690:C>A in CORO1C was characterised by additional metrics that pointed 
towards a possible disease-causing role: altering a nucleotide scored as highly conserved by 
both GERP++ and Phastcons (5.7 and 1, respectively), and being classified as 
deleterious/damaging by all three prediction algorithms SIFT, Polyphen-2 and 
MutationTaster. The variant alters several well annotated protein-coding transcripts, 
including three annotated by both Ensembl and HAVANA (ENST00000261401, 
ENST00000541050 and ENST00000421578). The gene is classified as being likely 
haploinsufficient (probability of haploinsufficiency (239) >0.9) and loss-of-function intolerant 
(pLi (96) >0.9). Also the RVIS metric (90) scores CORO1C as being – to some extent – intolerant 
to functional variation, ranking it in the 16th percentile of the most intolerant genes. CORO1C 
is – although not markedly – expressed in the heart (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=CORO1C). In literature, CORO1C is not associated to any cardiovascular 
disease, and is generally described as an actin-binding protein which can be used as a 
biomarker for some forms of malignant cancers (287,288), and that, if knocked-down causes 
a decrease in tumorigenic potential of hepatocellular carcinoma cells (289). 
As to the other candidates, characterised by features less indicative of a possible pathogenic 
role, I did not find any evidence supportive of a role in arrhythmias or, more generally, in 
cardiovascular disease. ADH7 encodes for alcohol dehydrogenase 7, inefficient in oxidising 
ethanol but mostly active as a retinol dehydrogenase (290). TTK encodes a tyrosine-kynase 
characterised by a near-null expression in the heart 
(http://www.gtexportal.org/home/gene/TTK), which has been reported to be an important 
mitotic check-point protein that, if mutated, can predispose to various cancers (291,292). 
Very little is known about FRG2C, and it also seems to be uniquely expressed in testis 
(http://www.gtexportal.org/home/gene/FRG2C). I only found a very recent publication 
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describing a possible role of an FRG2C long non-coding RNA at the basis of abnormal 
osteogenesis (293). OR4F4 encodes an olfactory receptor and, as expected, I did not find any 
evidence of association with disease, while I did not find any information about the function 
of proteins encoded by FAM196A and CTB-134H23.2. ZNF429 encodes a zinc-finger protein 
which was associated in 2009 to acute post-surgical pain through a GWAS (294), while KIR 
genes such as KIR2DL3 and KIR3DL1 encode for natural killer cell receptors, and as such play 
an important role in the regulation of the immune response (295). HYDIN (a gene encoding a 
protein possibly involved in cilia motility) was the only candidate gene for which a 
cardiovascular phenotype was reported in mice with gene knock-out or inserted variation in 
the Mouse Genome Database. However, the reported phenotype was haemorrhage, 
observed in some of the mice with mutations in the gene, not involving any forms of 
arrhythmia or conduction defects.
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Table 4.4 - Candidate variants in the family affected with BRS, ranked by cumulative score. Cells highlighted in green indicate a +1 in computing the score in the following columns from left to 
right: ≥1 DELETERIOUS PREDICTION (+1 if at least one of SIFT, Polyphen-2 and MutationTaster predicted the variant to have a deleterious effect); PHASTCONS conservation score (+1 if >0.9); 
GERP++ conservation score (+1 if >2, cut-off generally used in literature to define constrained genes [e.g. in 1000 Genomes Project Consortium, 2012]); RVIS PERCENTILE (+1 if in the top 10% 
intolerant genes); CONSTRAINT Z SCORE (alternative gene-based score measuring selective constraint, +1 if >3.09, threshold defined in (193) for constrained genes); PROBABILITY OF BEING LOF-
INTOLERANT (pLi, as from (96). +1 if the gene was classified as LOF-intolerant (pLi>0.9), as defined in the publication); PROBABILITY OF HAPLOINSUFFICIENCY (as from Huang et al, 2010 (239). 
+1 if in the bottom 10%); ESSENTIAL GENE (as from Georgi et al, 2013 (236). +1 if the gene is essential in mice); CARDIOVASCULAR PHENOTYPE IN MICE (as from MGD database, +1 if mice with 
induced mutations/KO in the gene show a cardiovascular phenotype); CUMULATIVE SCORE (cumulative sum of the score over all evaluated parameters). 
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chr12 109052690 C A Non-synonymous CORO1C 0 1 1 5.7 16 1.49 1.00 0.92 N N 5
chr4 100349669 C G Non-synonymous ADH7 0 1 0.904 3.39 68 -1.08 0.00 0.11 N N 3
chr16 70897039 C G Non-synonymous HYDIN 0 1 0.004 -6 NA NA NA NA Y Y 3
chr6 80750407 T C Non-synonymous TTK 0 0 1 5.58 33 0.62 0.01 0.83 N N 2
chr3 75715124 C T Non-synonymous FRG2C 0 1 0.001 0.665 NA 2.91 NA NA N N 1
chr15 102462586 G T Stop-gained OR4F4 0 1 0 -0.469 NA 2.37 0.55 0.06 N N 1
chr19 55255534 C T Non-synonymous KIR2DL3,KIR3DL1 0 1 0.043 -2.01 99, 93 1.2, -0.8 0.04, 0.19 NA N N 1
chr10 128973671 C G Non-synonymous FAM196A 0 0 0.001 -1.93 38 -0.49 0.85 0.27 N N 0
chr16 29063445 C T Non-synonymous CTB-134H23.2 1 0 0.055 NA NA NA NA NA N N 0
chr19 21719161 A C Non-synonymous ZNF429 1 0 0.001 -0.254 96 0.42 0.00 0.15 N N 0
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4.3.2 Candidate variants in the family affected with CPVT 
Five candidate variants in 4 different genes remained after application of the prioritisation 
pipeline on WES data from the family affected with CPVT. Two non-synonymous variants in 
gene CDC27 (chr17: 45249316:T>C and chr17: 45221273:A>C) were characterised by some 
features suggestive of possible pathogenic effects. CDC27 is considered a gene markedly 
intolerant to functional variation by the constraint Z score developed by Samocha et al. 
(Z>3.09, (193)), and likely haploinsufficient by the metric constructed by Huang et al. 
(probability of haploinsufficiency > 0.9, (239)). For both variants, in silico pathogenicity 
prediction algorithms were contradictive: chr17: 45249316:T>C was scored as deleterious by 
MutationTaster, possibly damaging by Polyphen-2 and tolerated by SIFT, while chr17: 
45221273:A>C was considered deleterious/damaging by MutationTaster and SIFT, and benign 
by Polyphen-2. However, the former variant alters a nucleotide scored as highly conserved by 
both Phastcons and GERP++, whilst the latter is retained to alter a markedly conserved 
nucleotide only by Phastcons. At the molecular level, CDC27 encodes a protein of the 
anaphase promoting complex/cyclosome, an ubiquitin ligase that controls progression 
through mitosis, and diseases associated with CDC27 include, for example, breast cancer 
(296). I didn’t find any published evidence, or plausible biological explanation pointing 
towards a possible role of CDC27 in arrhythmic conditions such as CPVT. 
At the variant level, non-synonymous SNV chr4:190873347:A>G in FRG1 is predicted to be 
deleterious by both MutationTaster and SIFT, while Polyphen-2 (humvar) classified the variant 
as benign. The variant alters a nucleotide scored as highly conserved by both GERP++ and 
Phastcons. On the gene level, FRG1 does not seem to be intolerant to functional variation, 
since none of the metrics that I checked flag it as constrained, intolerant to variation, 
haploinsufficient or essential. Little is known about the physiological roles of FRG1, which may 
play a role in regulating pre-mRNA splicing (297), and has been associated to 
facioscapulohumeral muscular dystrophy (298). Also with regards to FRG1, I did not find 
evidence suggesting a possible role in causing arrhythmogenic phenotypes. 
Variant chr16:70896015:GA>G in HYDIN causes a frameshift, therefore can clearly have a 
disruptive effect on the protein’s functionality. However, as discussed above in Paragraph 
4.3.1, HYDIN does not seem to possess features particularly pointing towards a possible 
involvement in arrhythmias. The last candidate variant in the CPVT family was an inframe 
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insertion in FRG1B (chr20:29625961:G>GTTG), encoding for a protein with high sequence 
identity with FRG1 (95%), and about which little is known in terms of biological function and 
physiological roles. Furthermore, with the update of the human genome reference sequence 
from hg19 to hg38, FRG1B has been renamed to FRG1BP and reclassified as a pseudogene, 
and the existence of the encoded protein is “inferred from homology” as indicated in 
UniProtKB (http://www.uniprot.org/uniprot/Q9BZ01). A Pubmed search with “FRG1B” only 
yielded two publications, one reporting lineage-specific mutation patterns in FRG1B in human 
cancer tissues (299). 
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Table 4.5 - Candidate variants in the family affected with CPVT, ranked by cumulative score. Cells highlighted in green indicate a +1 in computing the score in the following columns from left to 
right: ≥1 DELETERIOUS PREDICTION (+1 if at least one of SIFT, Polyphen-2 and MutationTaster predicted the variant to have a deleterious effect); PHASTCONS conservation score (+1 if >0.9); 
GERP++ conservation score (+1 if >2, cut-off generally used in literature to define constrained genes [e.g. in 1000 Genomes Project Consortium, 2012]); RVIS PERCENTILE (+1 if in the top 10% 
intolerant genes); CONSTRAINT Z SCORE (alternative gene-based score measuring selective constraint, +1 if >3.09, threshold defined in (193) for constrained genes); PROBABILITY OF BEING LOF-
INTOLERANT (pLi, as from (96). +1 if the gene was classified as LOF-intolerant (pLi>0.9), as defined in the publication); PROBABILITY OF HAPLOINSUFFICIENCY (as from Huang et al, 2010 (239). 
+1 if in the bottom 10%); ESSENTIAL GENE (as from Georgi et al, 2013 (236). +1 if the gene is essential in mice); CARDIOVASCULAR PHENOTYPE IN MICE (as from MGD database, +1 if mice with 
induced mutations/KO in the gene show a cardiovascular phenotype); CUMULATIVE SCORE (cumulative sum of the score over all evaluated parameters). 
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chr17 45249316 T C Non-synonymous CDC27 0 1 1 5.69 45 3.41 0.49 0.92 N N 5
chr17 45221273 A C Non-synonymous CDC27 0 1 1 -0.80 45 3.41 0.49 0.92 N N 4
chr4 190873347 A G Non-synonymous FRG1 0 1 1 3.47 35 0.82 0.00 NA N N 3
chr16 70896015 GA G Frameshift HYDIN 0 0 NA NA NA NA NA NA Y Y 2
chr20 29625931 G GTTG Inframe insertion FRG1B 0 0 NA NA NA NA 0.00 0.11 N N 0
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4.3.3 Candidate variants in the family affected with the arrhythmogenic S-T 
depression 
The family affected with STDEP yielded a higher number of candidate variants compared to 
those with BRS and CPVT. The 12 candidates are listed in Table 4.6. Two of the candidates - 
the non-synonymous SNVs in CDC27 and FRG2C - possess very similar features to variants 
prioritised in the other two families (candidate variant in CDC27 in the CPVT family, and in 
FRG2C in the BRS family), and their characteristics have been discussed in Paragraphs 4.3.2 
and 4.3.1, respectively. One of the candidates in the STDEP family is a non-synonymous SNV 
in FRG2B, gene characterised by 97% nucleotide sequence identity with FRG2C (detected 
running BLASTn (https://blast.ncbi.nlm.nih.gov) on the CCDS of FRG2B). I didn’t find any 
information related to its function and/or possible disease associations, but such a high 
sequence similarity with FRG2C is suggestive of a likely similar structure and function of the 
encoded proteins. However, as discussed in Paragraph 4.3.1, very little is known about FRG2C. 
The two candidate variants possessing most characteristics suggesting a possible pathogenic 
role were two non-synonymous SNVs in CTBP2: chr10: 126691634:T>A and chr10: 
126691660:G>A. The former is predicted to be deleterious/damaging by all three 
MutationTaster, SIFT and Polyphen-2, while the latter only by MutationTaster and Polyphen-
2. However, both affect a highly conserved nucleotide, and both altering four 
Ensembl/HAVANA annotated transcripts (ENST00000337195, ENST00000334808, 
ENST00000309035 and ENST00000411419). CTBP2 itself does not appear to be particularly 
intolerant to functional variation in humans or likely haploinsufficient, but it is the only gene 
among the candidates for STDEP to be classified as essential and, with variants producing 
cardiovascular phenotypes in mice as reported in MGD. However, the observed 
cardiovascular phenotypes were not characterised by arrhythmogenic features, and were, 
more precisely, abnormal placental vasculature, absence of vitelline blood vessels, abnormal 
heart tube morphology and distended pericardium. CTBP2 encodes two distinct proteins: a 
transcriptional repressor and a component of specialised synapses known as synaptic ribbons, 
and has been suggestively associated to the degeneration of retinal ganglion cells occurring 
in glaucomas (300) and to some cancers (301,302). The expression of CTBP2 in the heart 
appears to be low compared to that measured in most other tissues 
(http://www.gtexportal.org/home/gene/CTBP2). 
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Similar characteristics are shared among candidate non-synonymous SNVs prioritised in 
SPINK5, SCL41A2, GPR151 and MEIS3. In all these four cases, variants were altering highly 
conserved nucleotides following both Phastcons and GERP++ conservation metrics, and all 
four were predicted to be deleterious/damaging by one or two in silico variant prediction 
algorithm among the three considered (MutationTaster, SIFT and Polyphen-2 (HumVar)). 
Among the four genes, SPINK5 was the only one classified as essential in mice by Georgi et al. 
(236), while SLC41A2 was characterised by a high probability of being loss-of-function-
intolerant (pLi>0.9) as from (96). However, none of this genes was characterised, at the 
biological level, by physiological roles suggestive of a potential involvement in 
arrhythmogenic phenotypes. SPINK5 encodes a serine protease inhibitor that may play a role 
in skin and hair morphogenesis, and protein-altering variants in this gene have been 
associated to Netherton syndrome (303), characterised by defective cornification and atopy. 
SPINK5 does not appear to be expressed in heart tissues 
(http://www.gtexportal.org/home/gene/SPINK5). Variation in SLC41A2 – which acts as a 
plasma membrane magnesium transporter and appears weakly expressed in the heart 
(http://www.gtexportal.org/home/gene/SLC41A2)– has been recently associated to a higher 
risk of developing type 2 diabetes (304), while its altered expression is implicated in a 
particular model of Parkinson disease, affecting neurodegeneration processes (305). GPR151 
encodes a G-protein coupled receptor, specifically expressed in particular areas of the 
vertebrates’ brain as reported in literature (306) and in GTEx 
(http://www.gtexportal.org/home/gene/GPR151), with a null expression in heart tissues. 
MEIS3 instead is a homeobox gene which encodes a transcriptional regulator so far not 
associated to any disease in literature. Interestingly, the loss of MEIS1 (member of the same 
family of transcription factors) in the neural crest has been recently shown to increase 
susceptibility to conduction defects and SCD in mice (307), but the authors specified in the 
publication that MEIS3 was never expressed by the analysed neuronal cells at any stage. 
The candidate non-synonymous SNV in BCL9 was predicted to be deleterious by SIFT, and, 
interestingly, Phastcons and GERP++ are highly discordant in measuring the degree of 
evolutionary conservation of the variant nucleotide, with Phastcons classifying it as markedly 
conserved (P>0.9) and GERP++ instead considering it strikingly far from being constrained in 
evolution (GERP++= -6.42, with scores >3 considered indicative of constraint). However, the 
RVIS metric developed by Petrovski et al. (90) ranks the gene in the 3% most intolerant to 
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functional variation in humans, and BCL9 is also in the top 10% genes most likely to be 
haploinsufficient (P=0.75, as from (239)) and also. In spite of not being formally classified as 
loss-of-function-intolerant by the pLi score (defined as P>0.9 in (96)), BCL9 is also 
characterised by a quite high pLi (pLi = 0.83), indicating a general consensus between gene 
constraint metrics in considering functional variation in BCL9 selected against. BCL9 has been 
associated with B-cell malignancies (308), but its function remains unknown, and its 
expression in heart tissues appears to be moderate 
(http://www.gtexportal.org/home/gene/BCL9).  
Not many considerations can be made on the two last candidate variants: frameshift variant 
chr8:52732972:A>AT in gene PCMTD1 and non-synonymous SNV chr12:11461427:C>T in 
PRB4. PCMTD1 is a methyltransferase, and I found several publications associating variants in 
this gene to primary angle closure, a disease involving glaucoma (309,310) and, apart from 
the variant in question causing a frameshift and being novel, there are no other indications 
suggesting that it may have a disruptive effect sufficient to cause SCD, or disease more in 
general. PRB4 instead encodes a salivary glycoprotein and its expression, at least considering 
what is reported in GTEx, appears to be very low in all analysed tissues 
(http://www.gtexportal.org/home/gene/PRB4). Furthermore, neither the variant nor the 
gene seem to possess characteristics indicating a likely pathogenic effect for the prioritised 
SNV, at least considering the variant- and gene-specific metrics that I reported. 
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Table 4.6 - Candidate variants in the family affected with STDEP, ranked by cumulative score. Cells highlighted in green indicate a +1 in computing the score in the following columns from left to 
right: ≥1 DELETERIOUS PREDICTION (+1 if at least one of SIFT, Polyphen-2 and MutationTaster predicted the variant to have a deleterious effect); PHASTCONS conservation score (+1 if >0.9); 
GERP++ conservation score (+1 if >2, cut-off generally used in literature to define constrained genes [e.g. in 1000 Genomes Project Consortium, 2012]); RVIS PERCENTILE (+1 if in the top 10% 
intolerant genes); CONSTRAINT Z SCORE (alternative gene-based score measuring selective constraint, +1 if >3.09, threshold defined in (193) for constrained genes); PROBABILITY OF BEING LOF-
INTOLERANT (pLi, as from (96). +1 if the gene was classified as LOF-intolerant (pLi>0.9), as defined in the publication); PROBABILITY OF HAPLOINSUFFICIENCY (as from Huang et al, 2010 (239). 
+1 if in the bottom 10%); ESSENTIAL GENE (as from Georgi et al, 2013 (236). +1 if the gene is essential in mice); CARDIOVASCULAR PHENOTYPE IN MICE (as from MGD database, +1 if mice with 
induced mutations/KO in the gene show a cardiovascular phenotype); CUMULATIVE SCORE (cumulative sum of the score over all evaluated parameters). 
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chr10 126691634 T A Non-synonymous CTBP2 0 1 1 3.79 75 1.06 0.66 0.40 Y Y 5
chr10 126691660 G A Non-synonymous CTBP2 0 1 1 4.68 75 1.06 0.66 0.40 Y Y 5
chr17 45249365 C T Non-synonymous CDC27 0 1 1 5.69 45 3.41 0.49 0.92 N N 5
chr1 147095956 T G Non-synonymous BCL9 0 1 0.929 -6.42 3 0.06 0.83 0.75 N N 4
chr5 147469174 G T Non-synonymous SPINK5 0 1 1 4.93 99 1.49 0.00 0.21 Y N 4
chr12 105303524 C G Non-synonymous SLC41A2 0 1 1 4.72 42 1.48 0.91 0.11 N N 4
chr5 145894518 C G Non-synonymous GPR151 3 1 1 6.16 79 -1.18 0.00 0.18 N N 3
chr19 47912402 T C Non-synonymous MEIS3 0 1 1 4.06 44 0.15 0.00 0.15 N N 3
chr10 135438977 G A Non-synonymous FRG2B 0 1 0.001 NA NA 1.67 0.15 NA N N 1
chr3 75714917 G A Non-synonymous FRG2C 0 0 0.005 0.397 NA 2.91 NA NA N N 0
chr8 52732972 A AT Frameshift PCMTD1 0 0 NA NA 65 2.42 0.00 NA N N 0
chr12 11461427 C T Non-synonymous PRB4 0 0 0 -1.83 94 NA 0.00 NA N N 0
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4.4 Discussion 
4.4.1 Considerations on the redundancy of candidate variants and genes in the 
three families 
A high degree of redundancy in terms of candidate variants and genes was evident once the 
original lists of candidate variants were obtained following the application of the prioritisation 
pipeline in the three families (a total of 33, 23 and 39 variants were initially identified for BRS, 
CPVT and STDEP, respectively, with 25 of the variants shared by 2 or 3 families Table 4.3). In 
spite of having removed these variants from the final list of disease-causing candidates, 3 
candidate genes were shared by two families (CDC27 in BRS and STDEP, HYDIN in CPVT and 
STDEP, and FRG2C in BRS and CPVT), and 2 genes harboured >1 candidate variants within the 
same family (CTBP2 in BRS and CDC27 in STDEP). Furthermore, variants in genes with 
suspiciously high sequence identity were prioritised across and within the three families: in 
FRG2B and FRG2C (CCDS sequence identity 97%) in BRS (with variation in FRG2C prioritised 
also in CPVT, as mentioned above); and in FRG1 and FRG1B in CPVT (CCDS sequence identity 
93.4%) While this does not automatically rule out such candidates from being potentially 
disease-causing, the low prior probability for the same candidate genes to be prioritised in 
different families affected with different conditions renders more likely the presence of some 
technical flaw, probably at the level of read alignment to the reference sequence, than an 
actual causal role of these variants in any of the families. For example, functional variants in 
CDC27 have previously been reported in literature as artefactual, due to the erroneous 
mapping of reads from a CDC27 pseudogene to the genomic region corresponding to the 
active copy of the gene (238). Also HYDIN, highly represented in the candidate variants shared 
by >1 families (with 14 of the 25 variants harboured by this gene, Table 4.3) has 3 
pseudogenes on chromosomes 1, 3 and X; while CTBP2, with two prioritised candidates in 
BRS has 8. While WES does not intend to target pseudogenes, it is possible that, at capture, if 
the sequence of a pseudogene (or that of another functional gene) is characterised by high 
identity with the targeted region, the DNA could bind to the capture probe and be eventually 
sequenced. This said, the existence of pseudogenes or highly homologous functional genes is 
not a sufficient reason for excluding prioritised variants from being potentially disease-
causing, but in this case - with many original candidates shared across families, and several 
prioritised genes being highly homologous or characterised by the existence of pseudogenes 
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– it is likely that several candidates are spurious, due to the erroneous capture of non-
functional sequences with consequent alignment to the functional copy of the gene, or to the 
erroneous alignment of reads to highly similar targeted genes. 
4.4.2 Candidate variants and genes 
At the variant level, some disease-causing candidates possess characteristics suggestive of a 
pathogenic effect, particularly chr12:109052690:C>A in CORO1C for BRS, which is predicted 
to be deleterious/damaging by all 3 in silico variant pathogenicity predictors considered, and 
alters a very conserved nucleotide in a gene markedly constrained against functional 
variation. However, at the gene level, neither CORO1C, nor any of the other prioritised 
candidates appear to be involved in biological processes or pathways that, if disrupted, could 
directly cause cardiac conduction defects or SCD. Besides the candidate genes with a known 
function, some genes’ physiological roles are unknown. The only – yet speculative - exception 
might be MEIS3, candidate gene for STDEP, given the recently reported association of MEIS1 
(transcriptional regulator of the same family) with an increased susceptibility of conduction 
defects and SCD in mice. However, any hypothetical explanation about an arrhythmogenic 
effect of variants in MEIS3 leading to SCD in the STDEP family would be highly conjectural. 
Furthermore, the likely artefactual nature of some candidate variants, due to possibly 
erroneous alignment of reads to the reference sequence (as discussed in Paragraph 4.4.1), 
highlights that such variants must be interpreted with caution. 
Unfortunately, DNA from these three families is not available for repeating WES with a 
different capture method and a sequencing platform producing longer reads, which could 
solve the issue of the likely artefactual read alignment, and increase the overall sequencing 
quality. An alternative approach on the available sequencing data could be developing more 
relaxed prioritisation pipelines, also considering calls made at read depths <10x, allowing to 
some extent possible genotype errors and no-calls, as I did, later on, for the DCM family 
analysed in Chapter 3. However, this approach is likely going to prioritise an unmanageable 
number of candidates, given the already high number of prioritised variants obtained applying 
the strict pipeline described in this chapter, and developing further ranking strategies to filter 
candidate variants would be needed. 
In conclusion, any candidate variant, whether prioritised in this analysis or following the 
application of a less stringent pipeline, would need robust replication and most likely 
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functional complementation to establish pathogenicity relevant for the conditions described 
in these families. Supportive evidence could consist of: 
1) Prioritisation of the same variant in a different family affected with the same 
phenotype. This is a very unlikely event, given the rarity of prioritised variation and 
the genetic heterogeneity characterising the analysed conditions. 
2) Statistical evidence in cohorts, with a candidate variant being observed significantly 
more often in cases than controls. However, obtaining large cohorts of individuals 
affected with diseases at such a low prevalence is difficult. 
3) Functional evaluation in a model where a phenotype recapitulating that of the 
affected families is observed in presence of a candidate variant. 
4.4.3 Limitations of the study 
Limitations of this analysis are, broadly speaking, similar to those indicated in Paragraph 
3.4.3 with regards to the prioritisation pipelines applied on the DCM family presented in 
Chapter 3.  
4.4.3.1 Technical limitations 
1) The disease-causing variant may be synonymous, non-coding or introduce a de novo 
splice site. In these cases, the disease variant would have been missed by our 
approach. 
2) The causative variant might not be included in the target captured for WES. This 
possibility comprises the variant to be in an unknown gene, or in an exon missed by 
the exon-capture technique used. 
3) The variant might be covered, but missed, filtered out by the variant calling software, 
or incorrectly genotyped. 
4) Sequencing data might be biased by sub-optimal read alignment to the reference 
sequence at least in some genomic regions, as suggested by the marked overlap across 
the three families in terms of candidate variants and genes. 
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4.4.3.2 Analytical limitations 
1) The disease in any of the families could be caused by a larger structural variant, such 
as a CNV, which would have been missed by this analysis. A separate analysis would 
be required to prioritise potentially disease-causing CNVs. 
2) The prioritisation pipeline applied on all three families is sensitive to genotype errors, 
no-calls and calls made at read depth <10x. Therefore, if the disease-causing variant 
was incorrectly genotyped in one of the samples, not called by the variant calling 
software or the variant site was covered at <10x in any of the samples, it would have 
been missed. On the other hand, developing a pipeline permissive towards genotype 
errors and/or very low read depth calls would have led to an unmanageable amount 
of candidate variants. 
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4.5 Conclusion 
This analysis was intended as preparatory and training dataset while waiting for the WES data 
from the DCM family presented in Chapter 3 to be made available. It demonstrated to me the 
crucial role of sequencing quality in rare variant prioritisation studies like this. From this point 
of view, considering the difficulty in obtaining large cohorts of cases affected with diseases at 
low prevalence like BRS and CPVT, and the very low probability of observing the same rare 
disease-causing variant in a different affected family, the best option would probably be 
repeating WES in order to produce higher quality sequencing data to be analysed. It is possible 
that collaborators that provided us DNA for sequencing in 2010-2011 still have DNA samples 
available, but at the moment we don’t have this information. 
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6 Appendices 
6.1 Questionnaire given to prospectively recruited samples 
The following is a copy of the questionnaire that prospectively recruited DCM patients and healthy 
volunteers (HVOL) were asked to fill. Some of the questions have been added after the 
development of this study (e.g. recreational drug use). 
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6.2 Script for case-control genetic variation burden testing 
As mentioned in Paragraph 2.3.7, I have developed a program – called “burden_test” for the sake 
of simplicity – in the form of a script written in R (180), to automatically perform case-control burden 
testing on user-defined variant classes and genomic regions. Although I modified the program 
several times along the development of this work for variable reasons (release of the ExAC data, 
change of input file formats when analysing different cohorts etc.), I will describe here how the most 
comprehensive version of the script works (namely, the version starting from VCF files and taking 
into account ExAC data).  
The script is structured as a unique R function, taking input files and other information (such as the 
directory paths where the user desires to save output files and summary statistics) as function 
arguments. Figure 6.1 summarizes the functionality of burden_test, and example blocks of code 
from burden_test are shown in Paragraph 6.4.1. 
The required input files of burden_test are two multi-sample VCF files: one for disease cases and 
one for controls.  Optional files that can be given to the script are the tab-delimited base-by-base 
read depth files (one for cases and one for controls), indicating the read depth at each genomic 
position for each sample. In our case, these files were produced separately for each sample with the 
function coverageBed of the Bedtools (v2.11.2) (177) toolset for genomic data analysis. I then 
developed a script in R to gather the files of the analysed samples from the in-house database and 
merge them in together for cases and controls. If provided, these files are used by the program to 
perform the Mann-Whitney U test described in Paragraph 2.3.6.4, to ensure comparability between 
the two cohorts at each variant site, if one or both cohorts are characterized by a low mean read 
depth which could render the sequencing data unreliable. 
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Figure 6.1 - Summary of the functionality of the "burden_test" R script. 
 
Among the first actions that the script performs automatically are the exclusion from the analysis 
of variant sites which did not pass all the variant caller’s quality filters in one or both cohorts, and 
the transformation of multi-allelic variant sites, by default on single rows in VCF files, in multiple bi-
allelic variants with the same genomic coordinate on multiple rows. This step is performed through 
the function vcfbreakmulti of the C++ library for VCF file manipulation “vcflib” 
[https://github.com/ekg/vcflib], executed by burden_test through the system function (Figure 6.2). 
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Figure 6.2 - Example of how the function "vcfbreakmulti" of "vcflib" separates multi-allelic variant rows in a VCF file to multiple bi-
allelic variant rows. Only the first 5 data columns are shown. 
The user can subsequently set several parameters with regards to the analysis and choose: 
1) Genes or genomic regions to analyse (in the form of a comma-separated list of HGNC gene 
names, or of genomic intervals). In the case of genomic regions being indicated (e.g. 
chr12:56416373-56449403) the string is simply used to restrict the section of VCF files to be 
analysed in terms of chromosome and genomic position of variants. If a list of gene names 
is submitted, the chromosome, start and end coordinates of each gene are retrieved through 
the getBM function of the R/Bioconductor package “biomaRt” (311,312). Bioconductor (313) 
is an open source and open development software project that provides a wide range of 
statistical and graphical tools based on R.  
2) Tool to use for variant annotation. The script allows to choose between SNPEff (93) and 
Ensembl VEP (94). Both offer similar capabilities and annotation features, although with 
slightly different options and functions to retrieve specific information. For example, SIFT 
and Polyphen-2-2 variant pathogenicity predictions can be retrieved by Ensembl VEP directly 
by adding the arguments “--sift” and “--Polyphen-2” to the main command, while SNPEff 
gathers them through a separate function retrieving information from dbNSFP (86). In 
general, I observed Ensembl VEP to perform quicker in terms of computational time, thanks 
to the optional argument “--fork”, allowing the simultaneous usage of multiple CPUs. 
3) Class(es) of genetic variants (e.g. all protein-altering, only truncating variants, only inframe 
deletions, only synonymous variants etc.) to consider. Variants are classified on the basis of 
their effect on Ensembl canonical transcripts. 
4) Reference cohorts to be consider for retrieving frequency information (1KGP, ESP, ExAC) and 
which variation MAF range. At its latest version (the one I used for replicating the 
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TTN:RBM20 interaction) burden_test allows to choose between 1KGP+ESP combined or 
ExAC, with the option of restricting the chosen reference cohort to samples of Caucasian 
ethnic background. Frequency information are retrieved directly from the VCF files of the 
three projects, and burden_test extracts the data pertaining the genomic regions/genes of 
interest executing “tabix” (314), which allows to extract specified subsets from VCF files. 
1KGP and ExAC data are retrieved remotely, from the ftp repositories of the two projects, 
while for ESP data, at the moment the user is required to download and copy files locally, 
given the non-existence of an ESP ftp address.  
5) which (if any) minimum read depth to require for all variant calls to be considered and, 
separately, which (if any) mean cohort read depth cut-off to consider as threshold for 
performing the Mann Whitney U test mentioned at the beginning of this paragraph and in 
Paragraph 2.3.6.4 (Table 2.12). 
Beside these user-defined settings, burden_test automatically performs additional quality control 
on all variants targeted for burden testing: 
1) Test on MAF in the general population: performed by means of a two-tailed Fisher test 
comparing the allele frequency in the controls to that observed in the reference cohort(s) 
chosen by the user. Strong deviations from frequencies observed in public reference cohorts 
suggest systematic sequencing errors or false-positive variant calls.  
2) Test on genotype frequencies in the analysed cohorts, performed through a Hardy-Weinberg 
test. A deviation from Hardy-Weinberg equilibrium may indicate systematic sequencing 
errors or erroneous genotype calls. While the Fisher test previously mentioned would pick 
up deviations from the expected allele counts, the Hardy-Weinberg test would flag 
deviations from the expected genotype frequencies, not always implying inconsistent allele 
counts. The effectiveness of applying all three tests is demonstrated by the Venn diagram 
displayed in Figure 6.3, showing that many variants fail only one of the tests. It must be kept 
in mind, however, that a high number of variants failing the Hardy-Weinberg test may also 
reflect phenomena such as population stratification or non-random mating, rather than 
genotype errors. 
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Figure 6.3 - Venn diagram showing in detail how many of the 54 variants indicated in Table 2.7 failed 1, 2 or 3 quality control tests. 
The final outputs of burden_test are: 
1) A table of the annotated targeted variant type(s) observed in cases and controls, with 
genotype frequencies, allele counts, information about the predicted variant effect, in silico 
pathogenicity predictions, frequency in the reference cohort(s), which gene and transcript 
harbour the variant, its effect on the transcript and on the protein, mean read depth of the 
variant site in the analysed cohorts, and results of the tests applied for quality control. 
2) A summary of burden test statistics. Since I structured burden_test as a region-based 
aggregation test based on the framework of CAST (Paragraph 1.6.3.2), final statistics relate 
to the number of samples, in the two cohorts, carrying at least one variant of the targeted 
category. Therefore, the program reports number of carrier cases and controls, the p-value 
for the one-tailed Fisher test checking if there is a significant enrichment of variation in 
disease cases, and the aetiological fraction, mentioned and explained in Chapter 2 (in 
Paragraph 2.3.7). 
The analysis performed on the multi-genic effect underlying DCM was made possible by an 
additional feature of burden_test, allowing the user to select whether to consider samples carrying 
variation only in a pre-specified number of genes among those analysed (e.g. mono-genic only, di-
genic, multi-genic) for the final statistics. This feature is present in the first version of the script, 
taking as inputs the tables produced by our in-house database, instead of VCF files.  
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6.3 Difference in terms of excess frequency of potentially pathogenic 
variation between prospective (who had CMR) and retrospective 
(who did not have CMR) DCM patients 
As mentioned in Paragraph 2.5.2.3, I also ran the gene-by-gene burden tests considering separately 
the 234 prospective DCM patients (who were evaluated by CMR) and the 98 retrospective patients 
(who did not undergo CMR), and comparing them to the whole set of 319 HVOL over the frequency 
of novel (absent in EurESP/1KGP) coding variants. Table 6.1 shows the gene-by-gene results, and 
net difference in terms of excess frequency of potentially pathogenic variants in DCM patients 
between the two subgroups of DCM patients. I observed a slight average increase over all 64 genes 
in terms of variation excess frequency when using the 98 retrospective patients (+0.18%), possibly 
reflecting the more severe disease phenotype characterizing the retrospective patient subgroup (as 
described in Paragraph 2.3.1). However, the variation frequency observed in the two subgroups of 
DCM patients (234 prospectives vs 98 retrospectives) was not significantly different overall (Mann-
Whitney test p=0.42). As discussed in Paragraph 2.5.2.3, SCN5A and LMNA, often implied in 
arrhythmic DCM, were the two genes characterized by the highest increase of variation frequency 
when considering the 98 retrospective DCM patients, highlighting a potential bias against patients 
with arrhythmic forms of DCM, given that CMR is contraindication after pacemaker or ICD 
implantation. It must be kept in mind, however, that results (especially with regards to the 98 
retrospectives) might suffer from random sampling effects, given the reduced cohort size. 
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Table 6.1 – Comparison of prevalence and excess frequency in DCM of novel (not observed in EurESP/1KGP) protein-altering variation 
in the subset of prospective DCM patients used in the study (n=234, who underwent CMR) and in the subset of retrospective DCM 
patients (n=98), who did not undergo CMR. Genes are ranked in terms of difference of excess frequency observed when using the 
retrospectives as compared to when using prospectives. The average difference over all genes was +0.18%. 
  Prospective DCM 
cohort (n=234) (CMR) 
Retrospective DCM 
cohort (n=98) (no CMR) 
 
GENE Frequency 
in controls 
(n=319) 
Frequency in  
DCM cases 
(n=234) 
Excess 
frequency 
in DCM 
Frequency 
in  
DCM cases 
(n=98) 
Excess 
frequency 
in DCM 
Net difference in 
excess frequency  
in DCM using retrospective 
patients (no CMR) as oppose to 
prospectives (CMR) 
SCN5A 2.8% (9) 0.9% (2) -2.0% 5.1% (5) 2.3% 4.2% 
LMNA 0.0% (0) 1.3% (3) 1.3% 5.1% (5) 5.1% 3.8% 
MYH7 1.6% (5) 2.6% (6) 1.0% 6.1% (6) 4.6% 3.6% 
CASQ2 0.6% (2) 0.0% (0) -0.6% 3.1% (3) 2.4% 3.1% 
BAG3 0.3% (1) 0.0% (0) -0.3% 2.0% (2) 1.7% 2.0% 
FKTN 0.0% (0) 0.0% (0) 0.0% 2.0% (2) 2.0% 2.0% 
MYBPC3 1.6% (5) 2.1% (5) 0.6% 4.1% (4) 2.5% 1.9% 
PKP2 0.9% (3) 2.1% (5) 1.2% 4.1% (4) 3.1% 1.9% 
CALR3 0.0% (0) 0.9% (2) 0.9% 2.0% (2) 2.0% 1.2% 
ACTC1 0.0% (0) 0.0% (0) 0.0% 1.0% (1) 1.0% 1.0% 
PLN 0.0% (0) 0.0% (0) 0.0% 1.0% (1) 1.0% 1.0% 
TNNC1 0.0% (0) 0.0% (0) 0.0% 1.0% (1) 1.0% 1.0% 
ACTN2 0.9% (3) 0.0% (0) -0.9% 1.0% (1) 0.1% 1.0% 
GATA4 0.9% (3) 0.0% (0) -0.9% 1.0% (1) 0.1% 1.0% 
ILK 0.9% (3) 0.0% (0) -0.9% 1.0% (1) 0.1% 1.0% 
JUP 0.9% (3) 0.0% (0) -0.9% 1.0% (1) 0.1% 1.0% 
PRKAG2 0.9% (3) 0.0% (0) -0.9% 1.0% (1) 0.1% 1.0% 
TP63 0.3% (1) 0.4% (1) 0.1% 1.0% (1) 0.7% 0.6% 
RBM20 1.6% (5) 3.8% (9) 2.3% 4.1% (4) 2.5% 0.2% 
MYH6 2.2% (7) 0.9% (2) -1.3% 1.0% (1) -1.2% 0.2% 
SYNM 2.2% (7) 0.9% (2) -1.3% 1.0% (1) -1.2% 0.2% 
TCAP 0.0% (0) 0.9% (2) 0.9% 1.0% (1) 1.0% 0.2% 
NEXN 0.3% (1) 0.9% (2) 0.5% 1.0% (1) 0.7% 0.2% 
TTN 27.0% (86) 34.6% (81) 7.7% 34.7% (34) 7.7% 0.1% 
ABCC9 0.9% (3) 0.0% (0) -0.9% 0.0% (0) -0.9% 0.0% 
ANKRD1 0.9% (3) 0.0% (0) -0.9% 0.0% (0) -0.9% 0.0% 
CAV3 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
CRYAB 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
CSRP3 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
CTF1 0.3% (1) 0.0% (0) -0.3% 0.0% (0) -0.3% 0.0% 
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DNAJC19 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
EMD 0.3% (1) 0.0% (0) -0.3% 0.0% (0) -0.3% 0.0% 
FXN 0.3% (1) 0.0% (0) -0.3% 0.0% (0) -0.3% 0.0% 
GLA 0.3% (1) 0.0% (0) -0.3% 0.0% (0) -0.3% 0.0% 
JPH2 0.6% (2) 0.0% (0) -0.6% 0.0% (0) -0.6% 0.0% 
LAMP2 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
MYL2 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
PDLIM3 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
SGCD 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
SOS1 1.3% (4) 0.0% (0) -1.3% 0.0% (0) -1.3% 0.0% 
TNNI3 0.3% (1) 0.0% (0) -0.3% 0.0% (0) -0.3% 0.0% 
TPM1 0.0% (0) 0.0% (0) 0.0% 0.0% (0) 0.0% 0.0% 
VCL 0.3% (1) 0.0% (0) -0.3% 0.0% (0) -0.3% 0.0% 
LDB3 0.0% (0) 1.3% (3) 1.3% 1.0% (1) 1.0% -0.3% 
TNNT2 0.0% (0) 1.3% (3) 1.3% 1.0% (1) 1.0% -0.3% 
DSC2 2.2% (7) 1.3% (3) -0.9% 1.0% (1) -1.2% -0.3% 
MYL3 0.0% (0) 0.4% (1) 0.4% 0.0% (0) 0.0% -0.4% 
TAZ 0.0% (0) 0.4% (1) 0.4% 0.0% (0) 0.0% -0.4% 
MYOZ2 0.3% (1) 0.4% (1) 0.1% 0.0% (0) -0.3% -0.4% 
PTPN11 0.3% (1) 0.4% (1) 0.1% 0.0% (0) -0.3% -0.4% 
TMEM43 0.3% (1) 0.4% (1) 0.1% 0.0% (0) -0.3% -0.4% 
SDHA 0.9% (7) 0.4% (1) -0.5% 0.0% (0) -0.9% -0.4% 
SYNE1 7.2% (23) 4.7% (11) -2.5% 4.1% (4) -3.1% -0.6% 
LAMA2 2.5% (8) 3.8% (9) 1.3% 3.1% (3) 0.6% -0.8% 
TRIM63 0.3% (1) 0.9% (2) 0.5% 0.0% (0) -0.3% -0.9% 
DTNA 0.6% (2) 0.9% (2) 0.2% 0.0% (0) -0.6% -0.9% 
DSG2 1.3% (4) 0.9% (2) -0.4% 0.0% (0) -1.3% -0.9% 
DES 0.0% (0) 1.3% (3) 1.3% 0.0% (0) 0.0% -1.3% 
RAF1 0.0% (0) 1.3% (3) 1.3% 0.0% (0) 0.0% -1.3% 
MYPN 0.0% (0) 1.7% (4) 1.7% 0.0% (0) 0.0% -1.7% 
DMD 3.1% (10) 1.7% (4) -1.4% 0.0% (0) -3.1% -1.7% 
LAMA4 1.3% (4) 2.6% (6) 1.3% 0.0% (0) -1.3% -2.6% 
RYR2 3.4% (11) 3.8% (9) 0.4% 1.0% (1) -2.4% -2.8% 
DSP 1.3% (4) 4.7% (11) 3.4% 1.0% (1) -0.2% -3.7% 
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6.4 Analysis scripts 
The complete code of burden_test and of some of the other scripts that I developed and used to 
produce the work described in this thesis are available in a GitHub repository (315). In Paragraphs 
6.4.1 and 6.4.2 I show example blocks of code of burden_test and allelic_balance_filter, respectively, 
as mentioned in Paragraphs 2.3.7 and 3.2.4.2. 
6.4.1 Scripts used for the analysis described in Chapter 2 
 
Figure 6.4 - Example block of code from burden_test. Given the name of a gene to be analysed specified by the user, the program 
retrieves the chromosomal location and genomic coordinates of the gene through the getBM function of the R package biomaRt 
(311,312). Then, calling tabix (314), it retrieves the subset of the 1000 Genomes Project VCF file related to the genomic region to be 
analysed.   
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Figure 6.5 - Example block of code from burden_test. Given a SNV present in the analysed samples, the program checks if the same 
variant is observed in ExAC and, if so, retrieves its frequency. 
 
Figure 6.6 - Example block of code from burden_test. The program computes and outputs the summary burden testing statistics at 
the end of the iterations over cases and controls. 
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Figure 6.7 - Example block of code from burden_test. In case the user chose to annotate the cases and controls VCF files with SNPEff, 
the program uses dbNSFP to retrieve SIFT and Polyphen-2-2 in silico functional predictions, through the SNPEff function “dbnsfp”. 
6.4.2 Scripts used for the analysis described in Chapter 3 
 
Figure 6.8 – Example block of code from allelic_balance_filter. The program, using nested “ifelse” R commands checks (in the 
context of the variant prioritisation for the autosomal recessive model with compound heterozygosity) the reference:alternative 
reads ratio in the proband, and keep only variants with ratios within 85:15 and 15:85. Following blocks of code (not shown) check 
the ratios in the other family members. 
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6.5 Permissions to re-use third-party copyrighted works 
The following is a copy of the permission document to re-use Figure 4 from Hershberger at al. (12), 
that I adapted to produce Figure 1.1 in this thesis. 
 
 
 
